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Abstract 
Multiple myeloma (MM) remains essentially incurable by conventional anti-tumour 
therapy, although the median survival time has increased to 5 years in those who 
respond well to autologous (auto) haematopoietic stem cell transplant (HSCT). In 
a small number of patients with MM, long-term disease-free survival has been 
achieved by harnessing the immune phenomenon, "graft-versus-tumour" effect, 
induced during allogeneic haemopoietic stem cell transplantation. This has 
prompted many investigators to examine ways in which a patient's own immune 
system can be more effectively directed against their disease, with the ultimate 
aim of tumour eradication. However, the MM is associated with a number of 
cytokines and chemokines such as CCL3, IL-6, IL-10, VEGF, and TGFß that have 
immunosuppressive effects on the host, and drive disease progression 
The BDCA antibodies allowed reliable measurement of dendritic cell (DC) subsets 
and B cell numbers in the blood of normal subjects, and patients with MM 
throughout the disease course. The numbers of blood myeloid DC (BmDC) and 
blood plasmacytoid DC (BpDC) are low throughout the course of the disease, and 
only improve for a short period of time following autologous HSCT. Thalidomide 
therapy of patients with relapsed disease was associated with an increase in 
BmDC1 and BpDC numbers. 
Monocytes, mobilised at the time of stem cell collection, were used to produce 
mature DC (matDC) from MM patients and normal donors (ND). The matDC 
produced from MM patients were of poorer quality as compared to those from ND, 
despite using combinations of GM/IL-4, GM/IL-13, X4 and MIMIC in the production 
process. The combinations that contained the X4 maturation cocktail produced the 
best quality matDC. 
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Pre-stimulation of MM T cells with T cell stimulation beads and IL-2 enhanced their 
proliferative response to IL-2 and matDC+IL-2, but blocked proliferation in 
response to matDC alone. Pre-stimulation also blocked T cell cytokine secretion in 
response to DC alone. Despite this, pre-stimulated matDC primed T cells from MM 
patients produced the best killing of MM tumour cell targets, followed by un- 
stimulated matDC primed TC, with un-stimulated matDC primed TC from ND 
producing poor cytolytic effects. 
The fluorescent chemokine uptake assay was a sensitive and specific method for 
detecting chemokine receptor activity, and was able to track changes during DC 
development and maturation. CCL3 uptake was low on MM monocytes. Uniquely, 
mobilised monocytes also demonstrated some CCR7 activity, as indicated by 
CCL19 uptake. This expression was confirmed by RT-PCR. CCR7 activity was 
best on ND matDC matured with the X4 cytokine cocktail, and significantly lower 
on matDC from MM patients. CCR8 expression was significantly higher on MM 
monocytes and matDC than on ND cells, suggesting that they may be more 
sensitive to the immunosuppressive effects of CCL1. 
In summary, the DC/ T cell system is abnormal in MM patients. Despite this, it is 
possible to produce antigen loaded mature MoDC from MM patients. When 
combined with T cell pre-stimulation and IL-2 expansion, these DC are capable of 
inducing anti-MM cytotoxic T cells, which exhibit considerable anti-MM cytolytic 
activity. However, the DC from MM patients still display abnormal chemokine 
receptor expression, which may inhibit their capacity to migrate to lymph nodes in- 
vivo in order to generate these cytotoxic T cell responses. 
These observations will aid in the optimisation of DC based immune therapies for 
MM, and suggest that a combined immunotherapy approach using pre-stimulated 
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T cells, MM Ag primed DC and IL-2 may produced better clinical responses in MM 
patients. 
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1. Introduction and Aims 
1.1 Multiple Myeloma 
Multiple myeloma (MM) is a clonal B-cell malignancy characterised by an excess 
of mature plasma cells in the bone marrow (BM), in association with a monoclonal 
protein in serum and/or urine, decreased normal immunoglobulin (Ig) levels, renal 
failure and lytic bone disease. It has an incidence of around 4/100,000 in 
Caucasians and a median age of onset of 70yrs, with the vast majority of patients 
presenting with fatigue, recurrent infections, bone pain or pathological fractures. 
MM remains essentially incurable by conventional anti-tumour therapy and the 
median survival time is 3yrs. However, this may be extended to 5yrs with modern 
induction therapy and a good response to autologous (auto) haemopoietic stem 
cell transplantation (HSCT) (Attal and Harousseau 1999, Child, et a/ 2003). The 
diagnostic criteria for MM and the other members of the group of disorders known 
as the monoclonal gammopathies were reviewed recently (International Myeloma 
Working 2003). 
Monoclonal gammopathy of uncertain significance (MGUS) is a pre-malignant 
condition affecting 1% of people <50yrs and up to 3% of >70yrs. Patients must 
have a monoclonal protein <30g/l and <10% plasma cells in the bone marrow 
(BM). Patients with MGUS progress to MM or a related disorder at a rate of 1 %/yr. 
Most MGUS patients have detectable clonal abnormalities, and it is thought that 
disease progression is the result of accumulating genetic abnormalities within the 
plasma cell clone. Smouldering MM is defined as the presence of a paraprotein of 
30g/l and/or >10% BM plasma cells, with none of the other diagnostic features of 
MM. Currently there is no evidence that treatment at this stage alters the disease 
course, but a number of on going clinical studies hope to answer this question. 
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MM can be diagnosed by the presence of > 10% infiltrate of plasma cells in the 
BM, in the presence of a monoclonal paraprotein in serum or urine, and evidence 
of end organ damage, such as hypercalcaemia, renal failure, anaemia and bong 
destruction (CRAB). A small number of patients have no detectable paraprotein, 
but meet the other diagnostic criteria, and this is called non-secretory MM. A 
number of disease prognostic markers have been defined; raised serum ß2- 
microglobulin; low serum albumin; deletion of chromosome 13 or it's long arm; 
t(4; 14) and t(14; 16) translocations, and they form the basis of the new 
International Staging System (Greipp, et al 2005). As the disease progresses, the 
neoplastic plasma cell induces a number of changes in the BM microenvironment 
(Figure 1-5); increased angiogenesis; suppression of cell mediated immunity 
(discussed later); paracrine signalling loops with stromal cells which induce tumour 
cell proliferation and resistance to drugs such as Dexamethasone. 
The treatment of MM can be divided into 3 phases, induction, consolidation and 
maintenance. If patients are not eligible for auto HSCT, then a simple induction 
regime of monthly oral Melphalan and Predinisolone until the paraprotein level 
stops falling, despite further therapy i. e. plateau is reached, is the treatment of 
choice because of the low rate of side effects. Unfortunately, Melphalan is toxic to 
stem cells, so younger fitter patients who will go on to have autologous stem cells 
collected need to avoid it and other alkylating agents prior to harvest. A number of 
alternatives have been the subject of clinical trials, such as high dose 
Dexamethasone, VAD (intravenous Vincristine, Dexamethasone and Doxorubicin), 
Z-Dex (oral Idarubicin and Dexamethasone) and CTD (oral Cyclophosphamide, 
Thalidomide and Dexamethasone) (MRC sponsored Myeloma IX study) 
(Alexanian, et al 1992, Cook, et a/ 2004, Garcia-Sanz, et a/ 2002). Although VAD 
and CTD seem to have superior response and complete remission rates, there is 
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currently no evidence that they are associated with improved long-term survival. 
Following 'induction' therapy, patients go on to have auto stem cells collected for 
use in auto HSCT consolidation. 
As already discussed, the role of auto HSCT, conditioned with 200mg/m2 of 
Melphalan, is well established. However, a number of groups have explored the 
use of sequential or tandem auto HSCT, and have shown an improvement in EFS 
and OS (Attal, et a! 2003, Barlogie, et a! 1997). The use of sequential auto and NM 
allogeneic (alto) HSCT is also the subject of clinical trails. The role of maintenance 
therapy following transplant is controversial. At present, there is no convincing 
evidence to support it's use, but a number of studies (including Myeloma IX) are 
exploring the use of thalidomide following auto HSCT. Overall MM patients have a 
relatively poor outlook compared to other low grade lymphoproliferative disorders. 
This has prompted the development of a number of experimental compounds and 
treatment modalities 
1.2 Allogeneic Haematopoietic Stem Cell Transplantation 
The immune system is capable of eradicating malignancies. The first evidence that 
cancer cells were susceptible to immune attack emerged in the early 1960's from 
the animal models used for HSCT (Mathe, et al 1965). This was first demonstrated 
in human HSCT in the late 1980's with the observation that patients who survive T 
cell replete alto HSCT have a lower relapse rate compared to auto, syngeneic or T 
cell depleted alto HSCT (Gale, et al 1989, Hughes, et al 1989). This "graft-versus- 
tumour" effect has also been demonstrated using steady state unprimed donor 
lymphocyte infusions (DLI) to treat relapse following alto HSCT and in the setting 
of minimal residual disease (Kolb, et al 1990). 
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The use of alto HSCT in the treatment, of MM has resulted in a higher rate of 
molecular remission, with lower rates of relapse and disease progression as 
compared to patients treated with auto HSCT (Bensinger, et al 1996, Corradini, et 
a! 1999). Those patients who survive 1 year have significantly improved disease- 
free survival (Bjorkstrand, et a! 1996). This is partly related to the intensity of the 
chemo-radiotherapy conditioning regimen, but it is also a result of the graft-versus- 
myeloma (GVM) effect (Perez-Simon, et al 2003, Tricot, et a11996, Verdonck, et al 
1998). However, these improvements in disease control are achieved at the 
expense of higher treatment-related morbidity/mortality in the first year and have 
prompted the experimental use of potentially less toxic NM HSCT (Crawley, et 'l1 
2005b, Garban, et al 2001, Perez-Simon, et al 2003, Singhai, et a/ 2000). The 
close relationship between Graft-versus-host disease (GvHD) and GVM in 
published studies suggests that donor alto-reactive T cells directed against minor 
histocompatibility antigens (Ags) present on both normal and myeloma cells 
mediates the latter effect. The successful use of DLI in some cases of MM that 
relapse following allo-HSCT has led to increased interest in the possibility that 
other forms of immune therapy might be effective in this disease (Lokhorst, et al 
1997, Lokhorst, et a! 2000). However, the doses of T cells required to induce these 
remissions are higher in MM than in other DLI responsive diseases such as 
chronic myeloid leukaemia (CML) (Verdonck, et al 1998), and are associated with 
an increased incidence of GVHD (Huff and Jones 2002, Salama, et a/2000). This 
may be partly explained by the influence of the malignant clone on the function of 
the immune effector cells resulting from both passive and active suppression, 
although it is possible that MM tumour Ags are less immunogenic compared with 
those on other malignant cells, as MM is associated with several defects in the 
host's immune system (Cook and Campbell 1999). 
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MM tumour cells produce a number of immunologically active agents that can 
modulate the immune response such as transforming growth factor-bete (TGF-ß) 
(Cook, eta! 1999), interleukin-10 (IL-10) (Brown, et a/ 2004), Fas liganc (FasL) 
(Villunger, et al 1997), vascular endothelial growth factor (VEGF) (Oyarpa, et al 
1998) and MUC-1 (Agrawal, et a11998, Gimmi, et a11996, Treon, et a/ 1998). It is 
postulated that by producing these agents the tumour cell modifies both the 
microenvironment to support growth and differentiation of the clone, and the holt 
immune response to prevent tumour rejection. This duality of function is important 
in understanding the possible interactions of the malignant clone with the tumour- 
bearing host, especially if we are to design immunotherapy strategies that will 
achieve their true potential and result in improved survival in MM. 
In an attempt to boost the GVM effect Kwak et al have demonstrated the 
successful transfer of myeloma idiotype-specific immunity from an actively 
immunised bone marrow donor to a recipient with MM, demonstrating MHC class 
I-restricted CD8+ T cell recognition of freshly isolated, recipient myeloma tumour 
cells (Kwak, et al 1995, Yiwen, et al 2000). It still remains to be seen whether the 
GVM effect can be separated from GVHD. However, there is evidence that a 
patients own immune system may play an important role in the control of their 
disease . It has been shown that 
T cells specific for MM associated Ags such as 
Mucin-1 (MUC-1 or CD227) (Beckhove, et ao idiotype protein (Yi, et a11995) and 
NY-ESO-1 (van Rhee, et al 2005b) are present in the peripheral blood of MM 
patients. Joshua's group have shown that the presence of expanded T cell clones 
at any time during the disease course is associated with prolonged overall survival 
(Brown, et al 1997, Raitakari, et a! 2003). 
Immunotherapeutic strategies attempt to utilise the immune system for disease 
control and they have mainly been tested in the setting of relapsed or resistant 
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disease. The use of such strategies in the setting of minimal residual disease 
following conventional chemotherapy or HSCT offers an increased potential for 
tumour cell control by adoptively transferring immune effectors at a timt when they 
are likely to have most impact (Hsu, et al 1997, Stevenson, et a! 2004). 
1.3 Cellular Immunotherapy 
Discovered by Steinman and others in the 1970's (Steinman, et al 1975, Steinmpn 
and Cohn 1973, Steinman and Cohn 1974, Steinman, et al 1974), dendritic cellq 
(DC) have been identified as the sentinels of the immune system. As a result it has 
become theoretically possible to direct the immune response against a specific 
chosen (tumour) Ag towards immunity or tolerance (Matzinger and Guerder 1989). 
It is important to consider how the different components of the immune system 
(DC, T cells and natural killer (NK) cells) develop and interact in-vivo and how this 
may be altered in patients with MM. Subsequently we will consider how cells of the 
immune system may be manipulated ex vivo to overcome any MM tumour cell 
suppressive effects and eradicate the malignant clone. 
1.3.1 In-vivo DC development 
DC precursors are derived from the bone marrow haematopoietic stem cell (HSC), 
differentiating into two phenotypically distinct populations. Myeloid DC (mDC) 
classically arise from the common myeloid progenitor and myelomonocytic 
precursors, are characterised by the surface phenotype of CD11c++/ CD1237/ 
CD1 c+, and tend to induce Th1 responses. Plasmacytoid DC (pDC) arise from the 
common lymphoid progenitor, are CD110 CD123'+, and induce Th2 responses. 
However, factors such as the strength of the T cell receptor/MHC class II 
interaction, Ag density and the microenvironment, are also important in the 
balance between mounting a Thl or Th2 T cell response. Recent studies also 
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suggest that the system for DC generation may exhibit more plasticity than 
previously thought, in that both myeloid and lymphoid DC may arise from either 
myeloid or lymphoid progenitors (Shigematsu, et al 2003). DC precursor and 
circulating blood DC migrate into peripheral tissues, such as skin, portal triads, 
mucosa and lung, driven by their expression of CCR2 and CXCR4 (Figure 1-1 
and 1-3). Here they down regulate CCR2 and up regulate CCR6, which seems to 
be important for (i) DC circulation to lymphoid tissue like Peyer patches via 
constitutive expression of CCL20 and (ii) may play a role in the induction of 
tolerance to self Ags. Immature DC also express CCR1, CCR5 and CXCR2, which 
allows them to migrate towards areas of inflammation via increased levels of 
CCL3, CCL5, CXCL8 and CCL20, which may be inducibly expressed in other 
tissues during an inflammatory response (Austyn and Larsen 1990). The iDC 
actively sample the environment by phagocytosis and process Ag from bacteria, 
viruses and apoptotic bodies (Albert, et al 1998, Hengel, et al 1987, Svensson, et 
al 1997), presenting them in the context of MHC class I and II molecules. To 
mature, iDC require a second `danger' signal such as interferon (IFN) a or y, 
interleukin-1 ß or microbial compounds such as bacterial lipopolysaccharide (LPS) 
(Matzinger 1998). During the ensuing terminal differentiation, DC down regulate 
their phagocytic and Ag processing functions, up regulate expression of MHC 
class I and Il, costimulatory and adhesion molecules (O'Neill and Bhardwaj 2005). 
Dendritic cell maturation also down regulates CCR1, CCR5 and CCR6 and up 
regulates CCR7 and CCR8 expression, thus becoming sensitive to CCL1, CCL19 
and CCL21, which are constitutively expressed in lymph nodes (Qu, et a/ 2004). 
The mature DC (matDC) then rapidly migrate to the secondary lymphoid tissues 
via the afferent lymphatic system, attracted by chemokines such as CCL19 and 
CCL21 (Chan, et al 1999, Dieu, et al 1998), where they efficiently present Ag to T 
cells, and induce an immunogenic response. If iDC encounter Ag in the absence 
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of Inflammation, they partially up regulate CCR7 but do not up regulate co- 
stimulatory molecules, and constitutively migrate to LN to induce/maintain 
tolerance (Matzinger 1998). Naive and central memory T cells also express CCR7, 
thus chemokine expression brings DC and T cells into close proximity for Ag 
presentation to occur. 
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Figure 1-1 In-Vivo DC generation, migration and maturation pathways 
DC arise in the bone marrow and migrate from the BM to peripheral tissues via the 
blood. Here, iDC encounter Ag, mature and migrate to lymph nodes via the 
lymphatics, and present Ag to naive T cells. Effector (cytotoxic) T cells then 
migrate to peripheral tissues via the blood. 
1.3.2 Chemokines and their role in DC trafficking 
Chemokines (CHEMOtatic cytoKINES) were originally defined as proteins 
manufactured by cells and tissues that stimulate movement and activation of 
immune cells to the area where the chemokine is produced and their subsequent 
activation. However, there is now a considerable body of evidence to show that 
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the biological effects mediated by chemokines are far more complex. Virtually all 
cell types, including tumour cells, have the potential to express chemokjnes and 
chemokine receptors and this expression may have a direct impact on tumour cell 
growth, angiogenesis and metastases (Vicari and Caux 2002). At the same time 
the chemokine expression pattern of the tumour may have a direct bearing on the 
host immune system's ability to mobilise monocytes, DC, T cells and NK cells 
against the tumour. The chemokine balance within the patient and the tumour May 
be crucial in determining the type of immune response that is mounted, in that the 
tumour may shift the balance from an immunogenic response in to a tolerogenic 
response by the expression of a different chemokine `signature`. 
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Figure 1-2 General structure of chemokine gene super-family members. 
Schematic representation of the conserved cysteine signature residues present in 
the primary amino acid structure that distinguish members of the chemokine gene 
super-family in to four basic subfamilies, which can be subdivided based on the 
presence or absence of additional cysteine residues and ELR (glutamic acid, 
leucine and arginine) motifs. (Reproduced by kind permission Dr S. McColl, 
Chemokine Biology Lab, University of Adelaide) 
Chemokines are a large family of proteins, with considerable structural homology 
based on conserved cysteine residues and the binding capacity to particular G 
protein-coupled receptors (GPCR) (Zlotnik and Yoshie 2000). They have been 
divided in to 4 major sub-groups based on the relative position of conserved 
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cysteine residues: CC; CXC, XC and CX3C (also known as ß, a, y and 6 
respectively) with CC and CXC being by far the most common. In addition 
Chemokines can be functionally classified into two groups based on whether they 
are expressed in a constitutive/homeostatic or inducible fashion. The 
nomenclature for chemokines is confusing. There are over 40 members of the 
human chemokine family and a large number have several different names, as a 
consequence of being described by different groups at different times. In an 
attempt to rationalise this, a new system to standardise chemokine ligand 
nomenclature, was introduced after the 1998 Gordon Research Conference on 
Chemotactic Cytokines (Zlotnik and Yoshie 2000) (Table 1-1). 
Sytematic name Original names Sytematic name Original names 
CCL1 1-309 CXCL1 Gro a 
CCL2 MCP-1, MCAF CXCL2 Gro P 
CCL3 MIP-la CXCL3 Gro y 
CCL4 MIP-1 ß CXCL4 PF4 
CCL5 RANTES CXCL5 ENA-78 
CCL7 MCP-3 CXCL6 GCP-2 
CCL8 MCP-2 CXCL7 NAP-2 
CCL11 Eotaxin-1 CXCL8 IL-8 
CCL13 MCP-4 CXCL9 MIG 
CCL14 HCC-1 CXCL10 IP-10 
CCL15 HCC-2, Lknl, MIP-16 CXCL11 I TAC 
CCL16 HCC-4, LEC CXCL12 SDF-I 
CCL17 TARC CXCL13 BLC, BCA 1 
CCL18 MIP-4, PARC, DC-CK1 CXCL14 BRAK 
CCL19 MIP-3ß, ELC CXCL16 CXCL16 
CCL20 MIP-3a, LARC 
CCL21 SLC, 6Ckine CX3CL1 Fractalkine 
CCL22 MDC, STCP-1 
CCL23 MPIF-1 XCL1 Lymphotactin 
CCL24 MPIF-2, Eotaxin-2 XCL2 SCM-1 ß 
CCL25 TECK 
CCL26 Eotaxin-3 
CCL27 CTACK, ILC 
CCL28 MEC 
Table 1-1 Human chemokine systematic nomenclatures. 
No human equivalent of mouse CCL6, CCL9, CCL10, CCL12, CXCL15 has been 
identified 
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The function of chemokines on target cells is mediated by binding to their 
corresponding receptors: CCR, CXCR, XCR and CX3CR, which are members of 
the huge G-protein coupled seven transmembrane domain receptor superfamily, 
The complexity of this system is further increased by promiscuity, by wlýich 
chemokines can bind to a number of different receptors and receptors can bind p 
number of different ligands (Table 1-2). The result is that there are many possible 
biological read outs based on the balance of the receptor/chemokine expression 
patterns. 
Chemokine receptors Human chemokine ligands Ligand expression 
CCR1 CCL3- 5,7,14,15,16,23 Inducible 
CCR2 CCL2,5,7,8,13,16 Inducible 
CCR3 CCL3,7,8,11,13,15,24,26,28 Inducible 
CCR4 CCL17,22 Constitutive / Inducible 
CCR5 CCL3- 5,8,16 Inducible 
CCR6 CCL20 Constitutive / Inducible 
CCR7 CCL19,21 Constitutive 
CCR8 CCL1 Inducible 
CCR9 CCL25 Constitutive 
CCR10 CCL27,28 Constitutive / Inducible 
CCR11/CCX CKR CCL19,21,25, CXCL13 ? Decoy 
CXCR1 CXCL1,6,8 Inducible 
CXCR2 CXCL1- 3,5,6,8 Inducible 
CXCR3 CXCL4,9,10,11 Inducible 
CXCR4 CXCL12 Constitutive 
CXCR5 CXCL13 Constitutive 
CXCR6 CXCL16 
CX3CR1 CX3CL1 Inducible 
XCR1 XCL1,2 
D6 CCL2- 5,7,8,11,13,14,17,22 Decoy 
DARC CCL3,5,7,11,13,14,17, CXCLI- 4,7,8, Decoy/ Buffer 
Table 1-2 Summary of the known human chemokine receptors and their 
ligands 
At the International Union of Pharmacology, XXX, 2002, Update on chemokine 
receptor nomenclature meeting, the putative receptor CCR11 was disqualified 
(Murphy 2002) because although high affinity binding to CCL19, CCL21 and 
CCL25 was identified, there was no detectable signalling or induction of 
chemotaxis. This placed it in a group of `silent receptors along with D6 and DARC. 
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By altering the expression of chemokine receptor genes during differentiation and 
maturation, cells such as DC and T cells are able to track from the bone marrow, 
to peripheral tissues and lymph nodes under the influence of homeostatic ligands. 
Inflammatory processes up-regulate inducible CCRs on leukocytes, inducing 
chemotaxis towards pro-inflammatory CCLs, such as CCL3, produced during the 
inflammatory response (Figure 1-3). 
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Figure 1-3 DC migration and chemokine receptor expression 
DC precursors and blood DC migrate into peripheral tissues, driven by their 
expression of CCR2 and CXCR4. Here they down regulate CCR2 and up regulate 
CCR6. Immature DC also express CCR1, CCR5 and CXCR2, allowing them to 
migrate towards areas of inflammation via increased levels of CCL3, CCL5, 
CXCL8 and CCL20, inducibly expressed in other tissues during an inflammatory 
response. Dendritic cell maturation down regulates CCR1, CCR5 and CCR6 and 
up regulates CCR7 and CCR8 expression, becoming sensitive to CCL1, CCL19 
and CCL21, which are constitutively expressed in lymph nodes. If iDC encounter 
Ag in the absence of Inflammation, they partially up regulate CCR7 and 
constitutively migrate to LN to induce/maintain tolerance. Naive and central 
memory T cells also express CCR7, thus chemokine expression brings DC and T 
cells into close proximity for Ag presentation to occur (Gunn 2003, Vicari, et at 
2004). 
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Gene expression, mRNA stability, receptor trafficking and desensitisation regulate 
the expression of chemokine receptors on the cell surface. Desensitisation may 
occur as the result of one of two mechanisms. Either, binding of the ligand to the 
receptor leads to internalisation of the ligand-receptor complex and the cell is 
refractory to subsequent internalisation, despite continued surface receptor 
expression. Alternatively, ligands bind to receptors and induce desensitisation of 
another receptor by transactivation. These processes are known respectively as 
homologous and heterologous desensitisation. As with the cytokine system, the 
chemokine system is further complicated by the expression of a number of atypical 
CCRs (decoy receptors) by the vascular and lymphoid endothelia. The D6 
(Jamieson, et a! 2005) and CCR11/ CCX CKR (personal communication R. J. B. 
Nibbs) receptors bind CCLs with high affinity, which are internalised and 
degraded. However, internalisation is not associated with detectable signalling, 
chemotaxis, receptor desensitisation or reduced re-circulation to the cell surface 
(Weber, et al 2004). In contrast, DARC (Duffy antigen receptor for chemokines) 
may act as a chemokine buffer by binding CCLs present at high concentrations, 
preventing leukocyte desensitisation, but maintaining a background homeostatic 
level (Comerford and Nibbs 2005). 
Until recently, trafficking of matDC to lymph nodes was thought to be mediated via 
expression of CCR7 (Ohl, et al 2004). However, there is recent evidence from a 
transplant model using CCR7 deficient mice to suggest that CCR7 is not essential 
for graft rejection (Beckmann, et al 2004). Interestingly, other groups have 
suggested that CCR8 may also be important for matDC migration (Qu, et al 2004) 
and co-localisation of both effector and regulatory T cells (Sebastiani, et a! 2002). 
Inflammatory cytokines such as TNFa and IL-1 P, and the Pathogen Associated 
Molecular Patterns (PAMPs), which signal through TLRs, are traditionally thought 
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of as the main agents responsible for inducing DC maturation. However, it is 
becoming clear that chemokines may also influence DC maturation. It has been 
shown that T. Gondii derived cyclophilin is able to induce IL-12 production by 
signaling through CCR5 (Aliberti, et a12000, Aliberti, et a! 2003). More recently it 
has been suggested that CCL19 and CCL21 play a role in DC maturation as well 
as migration (Marsland, et a/ 2005). In this study it was shown that the number of 
migrating DC isolated from mice genetically deficient in CCL21 and CCL19 (pit/plt) 
(Paucity of Lymph node T cell mutation) following Ag priming with FITC conjugated 
OVA protein and an LPS maturation signal was significantly reduced. The 
migrating DC expressed a partially mature phenotype, HLA class II was normally 
up regulated, CD40 was slightly reduced, while expression of CD80 and 86 was 
markedly reduced compared to wild type mice. Marsland et al also showed that if 
CCL21 or CCL19 was produced in a eukaryotic system, rather than the normal 
prokaryotic systems used by the majority of commercial suppliers, they were 100 
times more potent at inducing DC migration. They also indicated that these forms 
of CCL21 and CCL19 were able to induce DC maturation, i. e. increased 
expression of CD86, CD80, CD40 and increased production of IL-1 P and IL-12 
(and TNFa in the case of CCL19). These results suggest that small glycosylation, 
structural or conformational changes in CCLs may radically alter their in-vitro 
potency, which may be crucial in the production of DC for clinical use. 
Dendritic cells produce large numbers of different chemokines at the various 
stages of maturation. For example, iDC are able to produce the inflammatory 
chemokines IL8, CXCL10, CCL3, CCL4 and CCL5, which increases the 
recruitment of neutrophils, monocytes and perhaps NK cells to sites of infection 
and inflammation. Whilst matDC produce CCL17, CCL18, CCL19 and CCL22 to 
attract T and B lymphocytes within the lymph node in a paracrine fashion. 
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As already discussed, MM induces a state of immunosuppression by the secretion 
of cytokines such as IL-6, IL-10 and TGF3. It should therefore come as no surprise 
that tumours manipulate the chemokine system as well (Byrne and Halliday 2002, 
Vicari and Caux 2002). The migration of DC into tumours is usually driven by the 
expression of CCL3, CCL4, MCPs and CCL5, which also recruit monocytes and 
macrophages. Once inside the tumour, DC are presented with Ag in the form of 
apoptotic bodies, in the absence of a danger signal. In this type of environment, 
iDC are able to up regulate CCR7 expression, but not co-costimulatory molecules 
(Gallucci, et al 1999, Sauter, et a/ 2000). This effect is enhanced by the 
production of IL-10 and TGF(3 by tumour infiltrating macrophages, 'which block DC 
maturation. Thus partially mature DC migrate to lymph nodes, deliver a tolerogenic 
signal to the immune system and induce the production of TH2 and T regs. 
The effects of the chemokine system are not restricted to the immune system, with 
CCL3 and CCL4 playing predominant roles in driving the increased osteoclast 
activity that causes MM bone disease. CCL3 and CCL4 are present at higher 
concentrations in the serum and bone marrow of MM patients, and correlate with 
the severity of bone disease and prognosis, continuing to rise as the disease 
progresses (Abe, et a/ 2002, Choi, et a/2000, Hashimoto, et a/ 2004, Magrangeas, 
et a12003, Terpos, et a! 2003). Interestingly, CCR1 and CCR5 are also expressed 
by MM plasma cells, where they reportedly mediate cell survival, proliferation and 
migration (Lentzsch, et al 2003, Oyajobi, et a12003), and induce MM cell 
adherence to BM stroma, cellular interactions that lead to the production of 
osteolytic factors by the stroma (Figure 1-5) (Michigami, et a/ 2000). 
It is clear that if we hope to use the immune system to eradicate malignant 
diseases such as MM, a greater understanding will be needed about the influence 
of chemokines on normal DC development and trafficking, and how this can be 
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altered by malignant disease. The results thus far from cellular immuno! herapy 
trials have been disappointing. One of the reasons for this is that mature DC 
administered in these types of studies fail to migrate to secondary lymphoid 
tissues in significant numbers (Blocklet, et a12003, Triozzi, et a! 2000). The 
chemokine system also plays a role in the clinical manifestations of MM, and 
interfering in these pathways may have significant therapeutic potential. 
1.3.3 Antigen Cross Presentation. 
CD8+ T cells require Ag to be presented by MHC class I molecules to elicit a CTL 
response. It was originally thought that only endogenous Ag processed in the 
cytoplasm of the Ag presenting cell (APC) could gain access to this process, 
whereas Ag from both endogenous and exogenous sources can be loaded onto 
MHC class II molecules. It was later found that DC could present Ag acquired from 
phagocytosed apoptotic bodies and present this in the context of HLA class I, thus 
generating CTL responses (Albert, et al 1998, Ronchetti, et al 1999). This process 
has become known as'cross presentation', although the in-vivo phenomenon was 
originally described as 'cross priming' by Bevan over 20 years ago (Bevan 1976). 
Various mechanisms to explain how DC achieve this process have been 
proposed, including recycling of MHC class I molecules exchanging peptide for 
those being newly formed in the endosome, translocation of Ag from the cell 
surface to the cytosol and the passage of Ags from the endosome to the cytosol, 
which seem to be used mostly by DC (Moron, et al 2003). The Ags are then 
processed by the proteosome and transported to the endoplasmic reticulum (ER) 
by transporter associated with Ag processing (TAP) molecules where they can 
bind to MHC class I molecules. However, it has been suggested that rather than 
being released directly into the cytosol, the Ags may remain in the phagosome 
which may either fuse to, or carry elements of, the ER (Guermonprez, et a/ 2003). 
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The required TAP, proteosomes and MHC class I may then be recruited (Houde, 
et a! 2003). Other groups have speculated that there may be a specific transport 
mechanism in DC, which efficiently transports phagocytosed Ag into the cytosol for 
processing (Rodriguez, et al 1999). Using mechanisms such as these, myeloid DC 
are able to induce strong CTL responses to exogenous (tumour) Ag. 
1.3.4 Dendritic cell, T cell interactions 
DC have the unique ability to present Ag to naive T cells. Techniques such as 2- 
photon imaging of lymph nodes have shown that this process follows an orderly 
progression. Within two hours of DC migration T cell behaviour changes from a 
random stochastic nature, to making short-lived contacts with multiple DC 
dendrites. During the next 14 hours T cells form stable clusters around DC before 
breaking down into dynamic swarms, and by 24 hours, T cells proliferate and 
migrate out of the node (Miller, et al 2004). Elegant studies such as these provide 
further evidence that the 'immune synapse' is a dynamic, orderly process. 
Effective priming of naive T- cells induces clonal expansion and differentiation into 
effector and memory cells. This is achieved via the engagement of the T cell 
receptor (TCR)/HLA-I/II/Ag, CD40 / CD40 Ligand (CD40L) and CD28/CD80 
complexes and the secretion of IL-7, IL-12 and perhaps IL-2 (Granucci, et al 
2001). CD4+ T- cell help is required at the time of priming to generate CD8+ 
effector cells, and is mediated by CD40/CD40L engagement, which induces DC 
production of IL-12. This CD40 licensing of DC may also be induced by CD40L on 
some apoptotic bodies (Propato, et a/ 2001). The CD40/CD40L interaction seems 
particularly important in that CD40 ligation alone is sufficient to drive the 
maturation of DC (Caux, et al 1994), and allows matDC to prime CD8' cytotoxic T 
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cells (CTL) without further CD4+ T cell help. Of the many other factors important in 
the T cell response, the maturity of the DC is one of the most important. 
Immature DC induce `abortive proliferation' of T cells, i. e. initial proliferation but 
short-term survival and perhaps clonal deletion. Mature DC induce T cell survival 
and differentiation by displaying Ag in the context of the appropriate co-stimulatory 
molecules (Dhodapkar, et a/ 2001, Jonuleit, et al 2001 b, Liu, et al 2001). Thus it is 
crucial that DC achieve a fully mature state if they are to be used as an anti-cancer 
therapy. This may also partly explain how the tumour is able to evade detection by 
the immune system at an early stage when novel tumour Ags may be encountered 
by APC in the absence of an inflammatory, pro-maturation environment (danger 
signal). Thus APC remain in an immature state and a tolerogenic response may 
be generated (Matzinger 1998). 
1.3.5 How can DC be produced/obtained for clinical use? 
Circulating blood mDC and pDC (Figure 1-4) can be collected using apheresis 
machines and enriched with magnetic cell separation protocols in a similar manner 
to CD34+ stem cells (Fearnley, et al 1997, Lopez, et a! 2003). These cells are 
present at very low concentrations in peripheral blood (Dzionek, et al 2000, 
MacDonald, et a12002) but the number of circulating DC can be dramatically 
increased using FLT-3 (Maraskovsky, et al 1996, Morse, et a/ 2000). 
This is a relatively inexpensive and straight forward process, however, the yield of 
cells is still relatively modest and there is conflicting evidence relating to whether 
circulating DC are functionally normal in patients with MM (Brown, et al 2001, 
Ratta, et a! 2002). Brown et al have previously reported that circulating DC from 
MM patients fail to up regulate CD80 and 86 in response to CD40L, which may be 
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corrected by co-culture with IL-12, IFN-y or anti-TGF-ß antibodies, suggesting that 
TGF-ß1 and IL-10 are implicated in causing this defect (Brown, et a! 2001). 
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Figure 1-4 Potential cell sources for the production DC intended for clinical 
use. 
Alternatively, DC may be generated from either CD34+ HSC (34+DC) (Caux, et al 
1992) or from monocytes (MoDC)(Zhu, et al 2000). 34+DC were first produced 
using a cytokine cocktail containing GM-CSF and TNFa (Reid, et al 1992, 
Santiago-Schwarz, eta! 1992). Many groups have subsequently refined this by 
adding cytokines such as FLT-3, SCF and IL-4 (Evans, et al 2000, Strunk, et al 
1996). The DC generated by these methods have a mature myeloid phenotype, 
low phagocytic activity, and express high levels of co-stimulatory molecules such 
as CD40, CD80, CD83 and CD86 (Ferlazzo, et a! 2000). They are also able to 
induce an Ag specific cytotoxic response from naive T cells (Caux, et al 1995). 
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Unfortunately, patients must first undergo HSC mobilisation with either 3-CSF 
alone, or in combination with chemotherapy. Also, the methods by which 34+DC 
can be loaded with Ag, such as transfection or fusion with tumour cells, are not 
straight forward and are further discussed below. 
DC may be generated from monocytes (MoDC) isolated from peripheral blood 
mononuclear cells (PBMC) separated by either plastic adherence or positive 
selection of CD14+ cells using immunomagnetic beads. In-vitro culture of MoDC 
occurs classically in three stages. Immature DC are produced by culture with IL-4 
and GM-CSF for 5 to 10 days. These cells are CD1a'/CD1c+/CD147/CD86+ and 
HLA-DRand they have a high phagocytic capacity, which facilitates Ag uptake. A 
number of groups have substituted IL-13 for IL-4 at this stage to produce 
functional iDC which may have a more stable phenotype compared to those 
generated with IL-4 (Boyer, et al 1999, Morse, et al 1999a). 
The next stage in the process is to load iDC with Ag. Normal iDC are phagocytic, 
so they can be simply 'fed' Ag as a purified naked form, coated with liposome, 
crude tumour lysate, tumour derived heat shock protein (HSP), whole apoptotic 
tumour cells, antibody coated tumour cells or genetically modified Ag (Mylovenge, 
idiotype-GM-CSF fusion, Dendreon. ), as summarised in Table 1-1 (Galea-Lauri, 
et a! 2004). 
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However, there is some evidence that DC from patients with malignancy (CIVIL and 
MM) have reduced phagocytic capacity due to cytoskeletal abnormalities, reduced 
processing capacity for exogenous Ag and reduced chemokine induced migratign 
(Dong, et al 2003, Ratta, et a! 2002). There are at least three approaches that 
may circumvent this problem. The first is the generation of DC from a malignant 
precursor cell. This is well characterised in myeloid malignancies such as acute 
and chronic myeloid leukaemia (AML and CML), and there have been recent 
reports of the generation of DC-like cells from patients with acute lymphoid 
leukaemia (ALL) (Blair, et al 2001). These cells appear to have the ability to 
stimulate naive T cells, although whether they function as efficiently as normal DC 
is still open to debate. At present there is no evidence that MM plasma cells can 
be converted into more efficient APC. 
The next approach is to generate normal matDC (maturation is discussed below) 
and then fuse them with tumour cells by either electroporation or pegylation 
(Gong, et a12002, Hao, et a12004, Raje, et a/ 2004). These approaches make the 
assumption that the resulting fusion or malignant DC retain normal function. Such 
cells must also express all of the relevant tumour Ags, in a state that the immune 
system is able to recognise as abnormal, so that a cytotoxic response is mounted 
rather than inducing tolerance. The final approach is to again generate normal 
matDC but then transfect them with tumour-associated Ags, such as MM idiotype 
protein (Id) or NY-ESO-1 (van Rhee, et a! 2005b) using viral vectors (i. e. 
adenovirus and lentivirus). It is possible to achieve high rates of transfection but 
these approaches have been hampered by viral effects on DC function and recent 
reports of leukaemic transformation in 2/9 boys undergoing gene therapy for X- 
linked severe combined immunodeficiency due to the activation of the oncogene 
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LMO2 (Hacein-Bey-Abina, et a/ 2003a, Hacein-Bey-Abina, et al 2003b, 
McCormack and Rabbitts 2004). 
Usually, iDC are converted into matDC after Ag loading, using various 
combinations of cytokines and inflammatory stimulants. Classically, tumour 
necrosis factor alpha (TNFa) (Thurnher, et al 1997) or monocyte conditioned 
medium (Romani, eta! 1996) are used, but many other compounds and 
combinations are described including poly (I: C), CD40Ligand , prostaglandin E2, 
IL-1ß and IL-6 to name but a few. Mature DC up regulate surface expression of the 
co-stimulatory molecules CD80, CD83, CD40, HLA class I and II, lose their 
phagocytic ability, increase their migratory capacity to lymph nodes via increased 
CCR-7 and become much more efficient at inducing responses from naive T cells 
(De Vries, et a! 2003a, De Vries, et a! 2003b, Tarte, et a! 2000). 
The production of MoDC (and 34+DC) is costly, labour intensive and requires auto 
cells to be generated for each individual patient. Recently groups have been 
looking at speeding up the process of producing matDC from 1-2 weeks down to 2 
days (Fast DC) (Dauer, et al 2003, Xu, et a/ 2003), which may more closely 
represent what is happening physiologically during the inflammatory response and 
has the added benefits of being quicker and less labour intensive. 
Unfortunately, the MM tumour cells are actively producing cytokines (IL-6, IL-10, 
TGF-ß and VEGF) that interfere with this process at many points, resulting in DC 
being produced in fewer numbers, that are functionally abnormal and fail to mature 
with appropriate stimulation (Brown, et ao (Figure 1-5). When functionally normal 
matDC are generated, it will be critical to choose the correct Ag(s) and adjuvants 
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with which to prime the immune response for clinical use. A number of groups 
have started clinical trials looking at the use of DC as treatment for MM. 
Effector T cells 
0,6 
Figure 1-5 Interaction of MM with the adaptive cellular immune system 
In MM there is a complex interaction between the malignant plasma cell, bone 
marrow stroma and the immune system. The tumour and stromal cells interact via 
adhesion and cytokines, such as IL-6, VEGF and TNFa to induce tumour cell 
proliferation, migration, survival and drug resistance, as well as blood vessel 
proliferation. IL-6 also blocks the conversion of monocytes into iDC, VEGF, IL-10 
and TGFß prevent DC maturation, and TGFß also induces T cell anergy. 
1.3.6 T regulatory cells (TRg cells) 
There is a growing body of evidence that as well as providing immunogenic 'help' 
to the immune system, CD4+ T cell are also important negative regulators of the 
immune response. Many of these effects are mediated by a subset of cells known 
as naturally occurring CD4+/CD25+ regulatory T (TReg) cells, which compose 5- 
Lymph node Peripheral Tissues 
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10% of all circulating CD4+ T cell in adults (Asano, eta! 1996, Sakaguchi, eta! 
1995). Unfortunately, this picture is further complicated by the interaction of iDC 
and naive T cells, which may cause T cell depletion, anergy, and the induction of 
other sub-sets of CD4+ and CD8+ regulatory T cell which secrete IL-10 and TGF-ß 
(Dhodapkar, et a12001, Jonuleit, et a12001 a). 
TReg cells are produced in the thymus by positive selection of CD4*cells with TCR 
that have intermediate affinity for MHC class II-self Ag complexes, and exert their 
immunomodulatory effects in-vitro in a cell contact dependent manner, although 
there is some in-vivo evidence that immuosuppressive cytokines may also be 
involved. TRe9 cells play a role in maternal tolerance to the foetus (Aluvihare, et al 
2004), tolerance following transplantation (Wood and Sakaguchi 2003) and they 
have been implicated in impeding natural anti-tumour immunity and 
immunotherapy (Sakaguchi, et a/2001). One of the proposed mechanisms for 
these observations is the interaction between TReg cell CTLA-4 and iDC B7-1 and 
B7-2 which induces the up-regulation of indolemine 2,3-dioxygenase (IDO) on the 
DC (Mellor, et a/ 2003). These IDO-DC inhibit T cell proliferation, induce T- cell 
apoptosis (Munn, et al 2002) and large numbers of these cells have been found in 
the tumour-draining lymph nodes of patients with malignancies (Munn, et a! 2002). 
The group from Dana Faber recently reported a significant increase in 
CD4+/CD25+ TReg in MM patient samples compared to normal donors (23±4% vs. 
6±3%) (Prabhala, et al 2004). They found that the proliferation of T cells depleted 
of TReg cells was significantly lower in MGUS (n=9, SI=12±2) and MM (n=9, 
SI=28±8) compared with normal donors (n=9, SI=74±9, p<0.01), and LPS was 
unable to overcome suppression of T cell proliferation by TRg cells in MGUS 
(49%) and MM (24%) compared to normal controls (110%). These observations 
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suggest that TRe9 cells may play a role in the immune dysfunction seen in MM 
patients. 
1.3.7 Natural killer (NK) cells 
NK cells are part of the evolutionarily older innate immune system. In contrast to T 
cells, NK cells do not require pre-activation or immunisation in order to recognise 
and kill targets such as tumour cells or virally infected cells. NK cells arise from the 
haematopoietic stem cell (HSC) and develop under the influence of IL-2 and/or IL- 
15, acquiring effector functions such as lytic ability and cytokine production (IFN-y, 
TNF, IL-10, IL-13, Lymphotoxin-ß, and GM-CSF) (Williams, eta! 1997). Mature NK 
cells (CD94+ and KIR+) seed to the periphery where they expand, are recruited to 
tumours or sites of infection (Salazar-Mather, et al 1998, Smyth, et al 2000), where 
they develop into either specialised cytokine producers (CD94+{, CD56++- KIR+, 
CD25+, CCR-7+ and c-KIT+) or cytotoxic cells (CD56+, KIR++, and CD94+). 
NK cells recognise abnormal cells via a number of mechanisms, of which the 
"missing self hypothesis" is the best understood (Ljunggren and Karre 1990). 
Tumour and virus-infected cells may lose or down regulate MHC class I 
expression in an attempt to prevent Ag presentation and evade recognition by 
CD8+ cytotoxic T cells. NK cells detect this via surface receptors, which under 
normal circumstances engage the MHC class I molecules and deliver an inhibitory 
signal to prevent NK cells attacking normal healthy cells. There are at least two 
types of MHC class I inhibitory receptors which either recognise a highly 
conserved element in the HLA class I signal peptide bound by HLA-E molecules 
(CD94: NKG2A heterodimer) (ViIches and Parham 2002), or detect down 
regulation of particular sub-groups via killer Ig like receptors (KIR). KIR binding to 
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HLA class I molecules is similar to T cell receptor binding of HLA-Ag complexes, 
with faster binding and detachment kinetics which may facilitate efficient 
surveillance of the MHC class I repertoire. 
More recently activating receptors have been identified on NK cells (Bauer, et a! 
1999, Diefenbach, et a/ 2002, Gilfillan, et a/ 2002). NKG2D recognises structures 
such as MHC class I chain-related molecule (MIC) A and B, expressed at a 
significant level when cells are stressed or become transformed, promoting the 
rejection of abnormal cells (Groh, et a! 1996). This effect may be circumvented by 
abnormal cells producing soluble MIC, which induces down regulation of NKG2D 
(Groh, et al 1996). The ligands for the Natural Cytotoxicity Receptors (NKp46, 
NKp30 and NKp44) have yet to be identified, but the process appears to be MHC 
independent. 
There are reports of natural NK cytotoxicity to normal (Ferlazzo, et a! 2002) and 
auto Ag-pulsed DC in patients with MM (Zheng, et a! 2002). Immature DC are 
efficiently targeted by NK cells whilst matDC are protected by the up-regulation 
HLA class I (HLA-E). The interaction between NK cells and DC at sites of 
inflammation is complex and was reviewed recently by Ferlazz and Münz 
(Ferlazzo and Munz 2004). DC are able to activate NK cells via IL-12 and perhaps 
IL-18 (Andrews, et a/ 2003) although there is some evidence that cell contact is 
required via engagement of NKG2D/MICA and B. During this interaction DC 
maturation is stimulated by IFN-a released by the NK cell. Why should NK cells kill 
iDC whilst at the same time inducing DC maturation and homing to lymph nodes? 
It has been suggested that this paradox is a control mechanism used during 
infective episodes. Both results of DC/NK cell interaction result in the depletion of 
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DC at sites of inflammation. While this may deprive DC trophic pathogens of their 
host, it may also be an important feed back mechanism to prevent excessive 
production of pro-inflammatory cytokines by limiting recruitment of iDC to the 
matDC pool (Moretta, et al 2003). 
Myeloma cells are susceptible to NK cell lysis (Frohn, et a/ 2002) and there is 
evidence to suggest that the number and state of activation of NK cells is 
increased in MM. These cells have inherent anti-MM-cytotoxic activity and drugs 
such as thalidomide may further augment this effect (EL-Sherbiny, et at 2003, 
Frohn, et a! 2002, Gonzalez, et al 1992, Zheng, et a/ 2002). These observations 
provide evidence that there is an active interface between the innate and adaptive 
arms of the immune response that could be harnessed in future anti-MM NK cell 
and DC based therapies. 
As our understanding of how the immune system regulates itself improves, we 
should be better able to manipulate it to produce more effective immune therapies. 
The next section will review the use of immunotherapeutic strategies in the 
treatment of MM. 
1.4 Anti-tumour vaccines in Multiple Myeloma 
Vaccination is the most effective intervention modern medicine has developed, 
and has almost eradicated diseases such as Small Pox and Poliomyelitis. An ideal 
anti-tumour vaccine would be produced from a tumour-associated Ag (TAA) that is 
only expressed on tumour cells but is shared between different patients and 
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tumour types. It should be highly immunogenic, be able to produce both humoral 
and cellular immune responses and it should be essential for tumour cell survival, 
thus not susceptible to mutation or deletion. As yet, such `ideal' TAA have yet to 
been identified in any malignant disease. In B cell malignancies, the only 
compounds that come close to this ideal are the Id proteins produced by the clope 
of tumour cells. Unfortunately, these molecules are specific to each individual 
patient, requiring the vaccine to be tailor-made for each patient and are thus 
labour intensive and very expensive to produce. Furthermore, Id are weakly 
immunogenic when administered in-vivo and, in the case of MM, expressed at low 
levels on the surface of the tumour cells. However, it has been shown that anti-Id 
antibody and T cells are present in the blood of MM patients (Yi, et al 1995), and 
experimental data shows that the anti-Id immune response is able to kill MM 
tumour cells in-vitro and in animal models (Li, et al 2000, Wen, et a! 2001). A 
number of different strategies have been employed to produce an effective Id 
vaccine. These have employed the use of DNA, purified Id protein or light and 
heavy chain variable regions (VH and VL), which can then be linked to molecules 
such as KLH or cytokines like IL-2, IL-12 or GM-CSF in order to render them more 
immunogenic (King, et al 1998, Osterborg, et al 1998, Rasmussen, et al 2003, 
Stritzke, et a/ 2003). DNA acts as a natural vaccine adjuvant. Bacterial DNA is 
even more potent, due to the 20-fold increase in CpG motifs, recognised by 
molecules such as the Toll-like receptor 9 (TLR-9) present on cells of both the 
innate and adaptive immune system (Hemmi, et al 2000). 
A number of studies in both MM and B cell lymphoma have demonstrated that it is 
possible to use these vaccines to boost the immune system but the clinical results 
so far have been largely disappointing, although most series have been too small 
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to produce statistically significant results. Coscia et al reported that despite 
inducing anti-Id antibodies and skin-prick sensitivity in MM patients in first CR 
following high dose chemotherapy, the residual tumour burden was not eliminated 
(Coscia, et al 2004). This is in contrast to the study reported by Bendanoi, in which 
Id protein vaccination was able to clear circulating tumour cells in 8 of 11 patients 
who were otherwise in remission following chemotherapy for follicular lymphoma 
(FL) (Bendandi, et al 1999). The group in Southampton have developed a DNA 
fusion vaccine which contains the VH and VL genes of the Id protein assembled 
as a single-chain (Fv) sequence. To enhance T cell help, this has been fused to 
either the fragment C (FrC) sequence, a non-toxic part of the Clostridium tetani 
toxin (Spellerberg, et al 1997), or a plant viral protein coat (PVCP) sequence 
(Savelyeva, et al 2001). This scFv-FrC fusion gene vaccine has been used in 
clinical trials in patients with FL and MM (King, et a/ 1998). Antibody responses to 
FrC were seen in 8 of 10 FL patients treated, with 5 patients having detectable T 
cell responses to Id (Stevenson, et a! 2004). The trial in MM patients is in it's very 
early stages, but some immune and clinical responses have been reported 
(Stevenson, et a! 2004). This platform continues to be modified in order to induce 
greater CD8+ mediated immunity by increasing Ag presentation via MHC class I. In 
a similar approach to Kwak et al (Kim, et al 2003), Stephenson is also conducting 
a clinical trial of vaccinating normal donors prior to collection of DLI for use in MM 
patients who relapse following Allo HSCT (Stevenson 2003). 
A novel approach has been taken by Cell Genesys with the GVAX® myeloma 
vaccine. Irradiated, auto MM cells are administered with K562 cells, genetically 
engineered to produce GM-CSF. Twenty two patients have been enrolled in the 
phase I/II trial, and 17 patients have received at least one vaccination. Interim data 
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presented at ASH 2004 demonstrated that chemotherapy followed by ajito HSCT 
and vaccination resulted in six complete responses, five partial responses, threq 
patients with stable disease and two patients with progression (Borrello, et al 
2004). Three patients with early progression after transplantation then 
demonstrated potential antitumor activity following initiation of vaccination, as 
measured by reductions in the myeloma-associated circulating protein (M-spikel of 
92 percent, 37 percent and 25 percent. Treatment with GVAX® myeloma vaccine 
to date has been well tolerated, with only self-limiting skin rashes (2 patients) aqd 
colitis (1 patient) reported. 
1.5 Dendritic Cell vaccination in Multiple Myeloma 
Immunotherapy in MM may be more effective if it is delivered via professional Ag 
presenting cells such as DC. A number of studies have examined the use of DC 
that have been pulsed with tumour-derived Id protein or peptides (Dabadghao, et 
a11998, Reichardt, et a11999, Ridgway 2003, Tarte, et a11997, Titzer, et a12000, 
Zeis, et al 1998). It has been shown that moDC pulsed with purified patient- 
specific Id can serve as cellular vaccine for MM patients after high dose therapy 
and auto PBSCT (Lim and Bailey-Wood 1999, Liso, et al 2000, Reichardt, et al 
1999, Yi, et an. In the study by the Stanford group, 26 patients were immunized 
with Id pulsed DC derived from auto monocytes under serum-free conditions and 
vaccines consisting of mature DCs (HLA-DR+/CD83'/CD80+/CD54+/CD86+, 
median number of 5x106 DC/injection) were administered without serious adverse 
events. Four patients have demonstrated Id-specific T cell proliferative responses 
and 2 patients demonstrated the induction of Id-specific T cell cytotoxicity (Liso, et 
al 2000, Reichardt, et a/ 1999). As all patients received Id/KLH boosters post- 
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vaccination, it is not surprising that 24 of 26 patients developed KLH-specific T Gell 
responses after 2 to 3 ld/KLH booster injections. This protocol has been further 
developed in Tubingen, by the addition of SC GM-CSF, 250ug/m2, as an adjuvant 
to vaccination. Two of twelve patients developed T cell proliferative response and 
one patient formed aT cell cytotoxic response (Reichardt, et al 2003). 
Investigators from Arkansas have also modified this approach by giving Id/KLH 
loaded DC by weekly intranodal injection for 4 weeks, each followed by low dose 
SC IL-2 (5x105 IU/injection) (Yi, et an. 7/8 patients developed T cell responses and 
all enhanced the anti-idiotypic B cell response. The serum paraprotein fell by 30% 
in one patient and five others continue to have stable disease with longer follow-up 
required. This group is also examining the use of MM tumour cells lysates as a 
source of Ag for DC priming (Szmania, et al, Wen, et a12002) whilst Kim et al are 
investigating the use of in-vitro priming of alto donor T cells with tumour Id pulsed 
DC (Kim, et al 2003). 
There is some evidence that the route of DC administration, as well as their state 
of maturation, may influence the ability of DC to migrate and induce an immune 
response. It has been shown than DC given by intra dermal injection (IDI) are 
three times more effective at migrating to lymph nodes than those given by 
subcutaneous injection (SCI), while matDC are eight times better than iDC) 
(Ridolfi, et a/ 2004). Intra tumour injection of DC may result in sequestration of DC 
(Feijoo, et a12005) mediated by CXCL8. 
Dendritic cell based Id vaccination of MM patients is feasible and can induce Id 
specific immune responses in MM patients. However, the clinical effectiveness of 
such vaccinations in MM still needs to be proven. These therapies may need to be 
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'boosted' with adjuvants or other tumour-specific peptides in conjunction with Id- 
pulsed DC. Such an approach has been taken by Dendreon with the Mylovenge 
DC vaccine, which uses Id protein fused with GM-CSF, and is currently in phase II 
trials (Rice and Hart 2002). On-going studies in this area will shed further light op 
the use of DCs as cellular vaccines but clearly this is an area worthy of further 
investigation. 
1.6 T cells and reversal of tumour induced immune 
suppression 
The effects of the tumour cell population and associated microenvironment in MM 
is well described (Cook and Campbell 1999). It has been known for many years 
that patients with MM are immuosuppressed, being more prone to infections 
(Glenchur, et al 1959, Perri, et al 1981, Zinneman and Hall 1954), and MM is less 
responsive to normal T cells when given as DLI to treat relapse post alto HSCT 
compared to other diseases such as CML (Verdonck, et al 1998). This is at least 
partly due to MM tumour cells secreting immunologically active compounds such 
as IL-6, IL-10, VGEF and TGFI among many others. It has been shown that 
multiple myeloma cell lines and freshly isolated myeloma cells from patients 
produce excess TGF-ß, and that this agent is responsible, at least in part, for 
suppressing T cell responses against tumour cells (Campbell, et al 2001, Cook, et 
al 1999). Using the natural inhibitor to TGF-ß, latency associated peptide (LAP), 
the TGF-ß suppressive effect against T cells has been shown to be specific and 
mediated through the inhibition of IL-2 autocrine pathways in the T cells 
(Campbell, et al 2001, Cook, et al 1999). Ex-vivo activation with using anti-CD3 
monoclonal antibody (MoAb) in the presence of exogenous IL-15 is able to 
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overcome this inhibition and, crucially, the IL-2 autocrine pathways are reinstated 
in T cells, rendering them resistant to further TGF-ß suppression (Campbell, et al 
2001). Such a strategy may be employed to reinstate T cell effector function in 
patients with MM, however we have demonstrated that these cells may be 
rendered cytokine dependant and fail to respond to Ag's presented by DC in the 
absence of IL-2/IL-15 (unpublished data). 
Other groups have identified that the T cell Vß TCR diversity in MM patients is 
severely skewed after auto HSCT (Mariani, et al 2001) and that there is a 
significant association between survival and lymphocyte recovery post auto HSCT. 
In the Xcellerate T cell trial (Vij, et al) T cells are activated with anti-CD3 and anti- 
CD28 MoAb coated beads and infused IV three days following stem cell infusion. 
Initial results suggest that this process partially corrects the skewing of the Vß 
TCR repertoire and also rapidly corrects the lymphocyte count following auto 
HSCT. It has been previously shown that patients with MM who have less 
restriction of the T cell receptor Vß repertoire have a better prognosis (Brown, et al 
1997). At present there is little evidence that the cells manipulated by the 
Xcellerate process have any specific anti-tumour activity. However, the presence 
of expanded T- cell clones is associated with prolonged overall survival (Brown, et 
at 1997, Raitakari, et at 2003, Sze, et at 2003), and MM Ag specific T cells 
circulating in the peripheral blood of MM patients have been identified (Beckhove, 
et a/ 2003, van Rhee, et al 2005b, Yi, et a! 1995). These cells could now be 
isolated from the peripheral blood of Myeloma patients using immunomagnetic or 
flowcytometric methods, expanded ex-vivo using some of the methods described 
above and re-infused into the patient. 
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It has been known for some time that immunosuppression with cycloph9sphamide 
may increase the effectiveness of adoptively transferred anti-tumour T cells 
(Rosenberg, et al 1994b), and recently it has been shown that specific depletion of 
CD4+ CD25+ TR cells by anti-CD25 antibodies increases the efficiency of the anti- 
tumour immune response of tumour bearing animals, although the tumours are pot 
completely rejected (Jones, et al 2002, Vela-Ojeda, et al 2005). It is possible to 
enhance this effect by using CD25 depletion along with matDC vaccination 
(Sutmuller, et al 2001). 
1.7 Humoral immunotherapy 
1.7.1 Monoclonal antibodies 
Tumour-directed monoclonal antibody (MoAb) therapy has been the "holy grail" of 
many Haemato-oncologists since the 1970's. With the development of compounds 
such as Rituximab (anti-CD20), Campath-1 H (anti-CD52) and Myelotarg (anti- 
CD33), the potential has developed into a viable treatment for lymphoma and 
leukaemia. This form of immunotherapy is now beginning to be investigated in the 
context of MM. One major hurdle in this area has been the selection of a suitable 
surface Ag that would permit the generation of a MoAb with satisfactory specificity 
and sensitivity for the targeting of the malignant cell resulting in its destruction. 
Potential candidate molecules include CD38, CD138 (syndecan-1), CD54 (ICAM), 
CD40, VEGF (Yang, et a! 2003a) and the un-clustered surface type II 
transmembrane glycoprotein, HMI . 24. The use of anti-CD20 MoAb 
is limited by 
the fact that CD20 is expressed on <20% of fresh myeloma cells. Despite the 
success of anti-CD20 MoAb in follicular lymphoma (McLaughlin, et al 1998, 
Zinzani, et an, diffuse high-grade lymphoma (Coiffier, et al 1998) and 
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Waldenstrom's macroglobulinaemia (Dimopoulos, et a12002, Gertz, et p/ 2003), to 
date the experience in myeloma is limited (Lim, et a12004, Musto, et a! 12003, 
Treon, et a12001), although it may have a role against the MM `stem cell' as 
discussed later. 
The use of anti-CD38 MoAb in clinical trials to date has been limited though sonde 
clinical efficacy has been demonstrated (Ellis, et a/ 1995). Initial difficulties 
associated with human-anti-mouse antibodies (HAMA) have largely been 
temporised with the use of a humanised variant. 
One advance in respect to improving efficacy is the engineering of MoAb as 
carriers of toxin genes. Workers in the Mayo Clinic have generated single-chain 
variable fragments (scFv) that represent the linkage of the carboxyl terminus of 
one variable region (IgH) with the amino terminus of the other (IgL), using 
nucleotides that encode a series of hydrophilic peptides which retain the original 
antibody specificity (Chen, et a/ 1995). The investigators have attached diphtheria 
toxin-A plasmid DNA to a scFv directed against CD38, which is internalised into 
the Ag-expressing cell by receptor-mediated endocytosis. Using this technology, 
in-vitro and animal studies have demonstrated cell suicide by expression of the 
diphtheria toxin-A and the investigators intend to directly target plasma cells using 
tissue-specific transcriptional regulatory elements (e. g. Ig heavy chain enhancer) 
to limit non-specific cell killing. The translation into clinical trials is eagerly awaited 
using this novel technology. 
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1.8 Immunologically active drugs 
1.8.1 Thalidomide and it's analogues 
Thalidomide has been successfully used to treat patients with relapsed/resistant 
myeloma (Singhal, et al 1999). While thalidomide may act as an anti-angiogenic 
factor in myeloma, several other potential mechanisms of action have been 
proposed. Firstly, thalidomide may directly inhibit tumour cell growth and 
differentiation, mediated by reduced cell adhesion interactions and inhibition of 
cytokine secretion (e. g. TNF-a) or through free-radical generation and apoptosis, 
either directly or in response to drugs such as dexamethasone. Secondly, 
thalidomide may inhibit the activity of vascular endothelial growth factor (VEGF) 
and basic fibroblast growth factor (bFGF-2), which act as growth and survival 
factors for myeloma cells. Thirdly, thalidomide may act by promoting a Th1 T cell 
response resulting in the secretion of interferon-y and IL-2. Whether, one or all of 
these mechanisms mediate the clinical effects of thalidomide in myeloma remains 
to be clarified. Several thalidomide analogues are in the early phases of clinical 
development aiming to either inhibit cytokines (phosphodiesterase 4 inhibitors) or 
induce immunomodulation (IMiDs), with fewer side-effects (Corral, eta! 1999). 
There is tremendous future potential in the use of thalidomide or its analogues and 
studies such as the MRC Myeloma IX aim to assess the efficacy of thalidomide in 
combination with induction chemotherapy and as a maintenance strategy following 
Auto HSCT. 
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1.8.2 Interleukin-2 
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IL-2 is a central regulator of immune responses mainly produced by activated 
CD4+1e T cells. However, transformed T cells, B-cells, leukaemia cells, LAK cells 
(lymphokine-activated killer cells) NK-cells and DC may also secrete IL-2. IL-2 iq a 
growth factor for all T cell subpopulations, inducing Ag-unspecific proliferation of T 
cells by inducing cell cycle progression in resting cells, and clonal expansion of 
activated T-lymphocytes. IL-2 also promotes the proliferation of activated NK cells 
and B-cells (but this requires the presence of additional factors, for example, IL-4). 
The observation that leukocytes cultured in IL-2 were able to lyse tumour cells 
(Grimm, et al 1982, Lotze, et al 1981) ultimately led to IL-2 being administered to 
patients with melanoma , renal cell carcinoma and B-cell lymphoma (Lotze, et al 
1986, Rosenberg, et a11987, Rosenberg, et a11985) with a number of complete 
and partial remissions being reported (Yang, et al 2003b). IL-2 has no direct effect 
on tumours, as high concentrations don't inhibit tumour cell growth in-vitro and the 
anti-tumour properties are mediated by the cellular immune system i. e. NK and T 
cells. Investigators such as Rosenberg have combined the use of immune effector 
cells (tumour infiltrating lymphocytes) and IL-2 in the search for more potent 
therapies (Dudley, et a/ 2002). 
Intravenous IL-2 is a toxic therapy. The major side effects include hypotension, 
capillary leak syndrome, organ dysfunction and a treatment related mortality of 
1.5%. This has prompted investigators to reduce the dose and change to the 
subcutaneous route of administration. Although there is debate as to whether this 
reduces the efficacy of IL-2 therapy (Ravaud, et al 1994, Yang, et al 2003b), Kiss 
et al have reported that low dose SC IL-2 (1 Mu BiD for 1 week, 2Mu BiD for 3 
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weeks) induced a complete remission of relapsed Hodgkin's disease following 
sibling alto HSCT complicated by acute skin GVHD (Kiss, et al 2003). Whilst 
Slavin et al have reported long term remissions using in-vitro activation of DLI and 
SC IL-2 for the treatment of relapsed leukaemia following Allo HSCT that was 
unresponsive to DLI alone (Slavin, et al 1996). 
These observations suggest that IL-2 may be a useful adjuvant to cellular 
immunotherapy of MM by providing continuing stimulation of the immune system 
following the administration of immune effector cells. IL-2 could also be given 
following alto HSCT in place of, or in addition to DLI to boost any immune 
mediated effect. 
1.9 Efficacy measurements in immunotherapy trials 
Progress in the understanding of the basic mechanisms involved in generating 
immune responses to tumour Ags has never been greater. However, there is a 
lack of accurate, reproducible and readily transferable measurements of efficacy to 
assess the immune responses generated in the context of tumour immunotherapy. 
The role of efficacy measurements in association with immunotherapy trials is 
fundamental to the full assessment of such novel strategies. It has been assumed 
that current treatment modalities are themselves curative in patients who achieve 
long-term disease-free survival. The role of an auto anti-tumour immune response 
remains to be clarified. It has been shown that it is an auto immune response to 
the residual disease that prevents relapse in acute leukaemias (Lowdell, et al 
1999, Lowdell and Koh 2000, Lowdell, et al 1997) and the data suggests that the 
immune system has some impact on the disease course of MM patients. Knowing 
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whether there is an anti-tumour immune response, albeit inadequate, allows one 
to construct and test hypotheses about how it may be enhanced or indiced when 
absent. Such hypotheses inevitably lead on to the design of appropriate assays of 
immune function during and after administration of the immunological iriterventign 
under trial. 
Measurements of immune function have been notoriously unreliable and poorly 
reflect the true status of the patient. However, recent advances in measurements 
of cell activation, cytokine production and cell-mediated cytotoxicity have radically 
changed the reproducibility of such experiments. The identification of relevant 
peptides from tumour-associated Ags is allowing the construction of peptide/HLA 
tetramers, which can be used to enumerate and analyse the function of Ag- 
specific T cells (Howard, et a/ 1999). In all such assays it remains important that 
the true measure of a relevant immune response is not that the patient or animal 
model can be demonstrated to have responded to the vaccine but rather that the 
response is measurable against the primary tumour. This is plainly easier said 
than done. Nonetheless it should be an aim at the outset of research so that the 
primary tumour is collected and stored in an appropriate manner at presentation 
for use in later experiments. Clearly, robust, reproducible and relevant out come 
measurements of immune function are essential to determine the efficacy of any 
immunotherapy intervention. 
1.10 Combination immunotherapy 
In view of the disappointing clinical response seen thus far in immunotherapy 
trials, a number of groups have looked at whether immune therapies may be more 
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effective if used in combination. Shimizu showed that immune responses to a 
tumour lysate-pulsed DC vaccine could be increased by the addition of IL-2 in a 
murine sarcoma model [146]. Yi et al have reported the use of SC low gose IL-2 
five days following administration of idiotype-pulsed DC. Anti-idiotype T cell 
responses developed in four and B cell responses in all five patients, including 9 
50% reduction in M-protein in one patient (Shimizu, et al 1999, Yi, et a/ 2002). 
Whilst in a murine model, 81 % of animals treated with Id vaccine, plus FLT-3 
ligand (FLT-3L) and IL-2 survived more than 180 days compared to none give the 
individual therapies, and 27% and 41 % given Id plus IL-2 or FLT-3L respectively 
(Zeis, et al 2002). Another approach has been taken by the group in South 
Carolina, who have combined Rituximab and low dose SC IL-2 in NHL. 
Responses correlated with NK cell numbers and the addition of 11-2 resulted in an 
increase in Ag dependant T cell cytotoxicity in responders (Gluck, et an. However, 
some of the most promising results to date have come from the NIH, where the 
combination of vaccination, adoptive transfer of T cells and IL-2 therapy resulted in 
some long term cures in a mouse melanoma model (Overwijk, et a! 2003). 
1.11 Discussion 
The field of cancer immunotherapy stands at a threshold. There have been great 
advances in the understanding of the immune system and how it can be 
manipulated, and in a number of diseases, immune based therapies are 
beginning to realise their potential. The use of antibody therapy, such as 
Rituximab, in combination with conventional chemotherapy for the treatment of 
lymphoma has resulted in improved disease responses and is becoming standard 
practise. Even more impressive results have been achieved using cellular 
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immunotherapy for the treatment of post-transplant lymphoproliferative disorder 
(PTLD) (Bollard, et al 2003). PTLD is a complication of HSCT or solid organ 
transplantation, associated with regimes that contain antibodies such as anti- 
lymphocyte or anti-thymocyte globulin, which generate more profound cellular 
immunodeficiency than those that do not contain such antibodies. This may alloyv 
uncontrolled expansion of Epstein-Barr-virus (EBV)-infected B cells. These 
infected B cells express the full spectrum EBV latent Ags, which are well 
characterised and highly immunogenic, and there appears to be no additional 
immune suppression associated with the malignant clone. Adoptively transferred 
auto or HLA class I matched EBV-specific T cells are able to restore cellular 
immunity, eradicating the disease without the need for conventional 
chemotherapy. However, whilst we can consistently generate auto cellular and 
humoral anti-MM immune responses in-vitro and in-vivo, they have yet to be 
translated into effective clinical tools capable of inducing sustained disease 
responses. We have also yet to show that the anti-MM immune effects seen 
following alto HSCT can be separated from those due to major and minor histo- 
incompatibility. If immunotherapy of MM is to develop into an effective therapy, a 
number of crucial questions still need to be answered: 
What are the most effective anti-MM Ag's, can they be used alone, or are 
they more effective in combination? 
A number of new and old target Ags are currently under investigation. Of these 
molecules, Id protein is the most widely studied. We await with interest the results 
of studies, such as those from Southampton, which look at combining Id with 
adjuvant compounds to increase the potency of the anti-MM immune response. 
Newer molecules such as HM1.24 and NY-ESO-1 are in the early phases of 
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development for the treatment of MM (Chiriva-Internati, et a/ 2003, Rew, et al 
2003). Most MM immunotherapeutic strategies are directed at mature MM cell Ags 
and will thus be effective against the bulk of the tumour cells, however, as with 
other targeted therapies such as Glivec in CML, this approach has the potential to 
leave these tumour stem cells unscathed, resulting in disease relapse (Brick, et al 
2005). MM tumour cells are classically thought of as mature plasma cells 
(CD45+"e/CD19. ve/CD56+"e/CD138+1e/CD38+1e), with a low proliferative index. 
However, as with other leukaemia's, there may be a small population of 'tumour 
stem cells' (CD45+1e/ CD19+1e/ CD22+"e/ CD138""e) that retain the capacity to self- 
renew and proliferate (Matsui, et a! 2004). These cells are able to repopulate 
nod/scid mice and if removed by purging with Rituximab, the MM fails to engraft 
(Jones 2003, Matsui, et a/ 2004). It may be a mistake to select MM Ags that may 
only be present on the non-self-renewing cells in a bid to get good clinical 
responses, when we need to direct our efforts at the cells that contribute to 
relapse, thus improving long term survival. Further studies of the putative MM 
stem cell are warranted. Examining their phenotypic and genotypic characteristics 
may identify novel immunotherapeutic targets. It remains to be seen whether a 
single Ag can effectively eradicate MM in-vitro. Approaches that combine multiple 
Ags, such as tumour lysate or apoptotic tumour cells, have the theoretical 
advantage of being less likely to induce the MM clone to delete the target Ag, a 
phenomenon known as Ag escape. 
Can simple vaccination induce an effective anti-MM response or do we need 
to deliver the Ag(s) via professional APC generated ex-vivo? 
At present, immunotherapy of MM is developing along two main themes, the more 
traditional vaccination based approach, and ex-vivo generated cellular therapies. 
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In the future it may be possible to combine these two approaches by pre- 
conditioning the site of vaccination with growth factors and chemokines in order to 
recruit APC. Efficient trafficking of these Ag loaded APC to LN could then be 
induced by vaccines containing adjuvants designed to promote maturation and 
migration of APC. This type of approach would avoid all the inherent costs and 
risks of having to collect cells and then ex-vivo generate Ag loaded, mature APC, 
for each individual patient. In addition, humoral as well as cellular immune 
responses may be induced. 
How does the MM tumour cell evade immune surveillance? 
The evidence to date indicates that the MM tumour cell is able to disable the 
immune system at multiple crucial points (Figure 1-5) We are beginning to 
understand this interplay between the malignant cell and the immune system of 
the tumour-bearing host. This is prompting researchers to devise strategies that 
overcome the immunosuppressive effects of the MM tumour cell, such as T cell 
pre-activation, in order to increase the effectiveness of immune therapy against 
the malignant clone. 
Can immunotherapies be effective when used alone, or are they best used in 
combination in the treatment of MM? 
In view of the hostile in-vivo environment induced by the MM tumour cell, and the 
disappointing clinical response seen thus far in immunotherapy trials in MM, it is 
our view that immune therapies may be more effective if used in combination. A 
number of groups are examining the effectiveness of combinations of 
immunotherapy, such as Id pulsed DC and IL-2, CTL and IL-2, and antibody 
therapy with 11-2. Another approach would be to combine a DC based vaccine to 
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prime the immune system, pre-stimulation of T cells to correct tumour induced 
anergy, followed up with low dose subcutaneous IL-2 to maintain the activation of 
the immune system. As previously discussed a number of groups are examining 
the use of combinations such as the adoptive transfer of Ag specific T cells and IL- 
2, and Ag-loaded DC and IL-2. 
Until we can answer these questions, effective immunotherapy in myeloma will 
remain a possibility not a probability. The on-going basic and translational 
research is encouraging, but the proof of principal in the clinical arena remains to 
be demonstrated. The design of good clinical trials will be crucial, as is optimal 
immunological monitoring to measure what, if any, effect such strategies will have 
on the host's immune system. As with other biological therapies in haemato- 
oncology, it is likely that these immune-based therapies will achieve their 
maximum effect when the tumour burden is reduced to a minimum. Thus, immune 
strategies against MM are likely to be useful adjuncts to conventional chemo- 
radiotherapy and auto HSCT. 
1.12 Aims 
The following aims will be dealt with in turn, within the relevant Results Chapter. 
1. To establish and validate that the BDCA assay can be used to measure 
mDC1, pDC, mDC2 and B lymphocytes in ND and MM patients. 
2. To determine whether the number of circulating DC subsets are abnormal 
in MM patients, and whether they change during the course of the disease 
and therapy. 
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3. To establish the method DC production using mobilised monocytes from 
ND and MM patients. 
4. To determine whether the cytokine combinations used during DC 
production influence the quality of the DC produced from ND ant MM 
patients. 
5. To determine whether pre-stimulation of T cells from MM patients alters 
their interaction with matDC, resulting in improved T cell proliferation and 
cytolytic activity. 
6. To determine whether the Luminex system can detected differences in the 
level of cytokines produced during the DC/T cell interaction, in cells derived 
from ND and MM patients using different cytokine combinations. 
7. To establish and validate the fluorescent chemokine uptake assay. 
B. To determine the chemokine receptor activity on cells from ND and MM 
patients during MoDC development and maturation. 
Each chapter begins with a short, focused introduction to the data and culminates 
in a brief discussion of the findings. 
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2. Materials and Methods 
2.1 Ethical approval and informed consent 
All primary human material was collected with the approval of the Local Research 
and Ethics Committee, North Glasgow University Hospitals Division. Written 
informed consent was obtained from each patient and donor prior to obtaining 
samples. 
2.2 Cell handling and culture 
2.2.1 Media 
PBS/Alba; Phosphate buffered saline (PBS) (Sigma, Poole, Dorset UK) and 0.5% 
Alba (4.5% human albumin solution, SNBTS, Edinburgh, UK). 
PBS/Alba/EDTA; PBS (Sigma) and 0.5% Alba and 2mM EDTA (Sigma). 
TC medium; RPMI 1640 media (Sigma) supplemented with 5% human AB serum 
(SNBTS), 2% L-glutamine (Sigma) and 2% penicillin-streptomycin (Sigma). 
DC medium; RPMI 1640 media (Sigma) supplemented with 2% human AB serum, 
2% L-glutamine (Sigma) and 2% penicillin-streptomycin (Sigma). 
Serum free (SF) medium: RPMI 1640 media (Sigma) supplemented with, 2% L- 
glutamine (Sigma) and 2% penicillin-streptomycin (Sigma). 
Cryopreservation medium; 10% DMSO (Quest Biomedical, Solihull, UK)/Alba 
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DAMP thawing solution; calcium and magnesium free D-PBS (Sigma), 0.5% Alba, 
2.5mM MgCI2 (Sigma), 1OU/ml pulmozyme (Roche Products Ltd, Welwyn Gardgn 
City, UK) 
FAGS-Fix solution; PBS, 1% paraformaldehyde (Sigma) and 0.5% Alba. 
2.2.2 Cytokines and chemokines 
All cytokines were purchased from PeproTec EC (London, UK), with the exception 
of IL-6 and GM-CSF (Stem Cell Technologies, Vancouver, Canada). All cytokines 
were re-constituted as per the manufacturers instructions, and stored at -80°C ýt a 
concentration of 1-10mg/m! 
All chemokines used in these experiments were kind gifts from Dr R. J. B. Nibbs, 
Glasgow University. 
2.2.3 Cell-lines 
All cell culture work was performed in a laminar flow cabinet using aseptic 
technique. All tissue culture flasks and plates were purchased from Corning life 
Sciences (Koolhovenlaan, Netherlands). 
MM cell lines were obtained from previously cryopreserved stocks at our institution 
or purchased from The European Collection of Cell Cultures (ECACC, Porton 
Down, Salisbury, Wiltshire, UK). All MM cell lines were maintained in suspension 
culture in 15mis of TC medium, in 75cm2 tissue culture flasks Cultures were 
maintained at 37°C in a 5% CO2 atmosphere. On reaching an approximate cell 
density of 1x106/ml, they were passaged and re-cultured at 3x105/ml. 
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The HEK293 cell line, wild type or stably transfected to express either D6 or CCR7 
(kind gifts from R. J. B. Nibbs, Glasgow University) were cultured at 37°C, 5% CO21 
in 75cm2 tissue culture flasks, and DMEM (Sigma) supplemented with 10% FCS 
(Sigma), plus 1% streptomycin and penicillin (Sigma), and 4mM glutamine 
(Sigma). The cells were adherent and had a doubling time of 24-36 hours. Cells 
were passaged when they became confluent on the bottom of the flask. The 
supernatant was removed by gentle pipetting and the cells were washed twice with 
PBS. Five mis of 0.25% trypsin was added to each flask, which was gently 
agitated until the cells lifted off the bottom of the flask. Twenty mis of DMEM, 10% 
FCS was added and the cells recovered by centrifugation at 1200 rpm, washed 
twice and plated out at a 1: 10 dilution. The transfected cells were normally 
maintained in selection culture, but this was not necessary for short-term culture, 
i. e. less than 7 days. 
2.2.4 Harvesting cells collected by apheresis 
Normal donors and MM patients had stem cells mobilised for therapeutic use as 
per the normal referring unit policy. Usually, ND received G-CSF 1 Opg/kg by 
subcutaneous injection (SCI) for 5 days, and MM patients were conditioned with 
cyclophosphamide 1-6gm/m2 on day 0, commenced G-CSF 5-1Opg/kg SCI on day 
4, and collected around day +10, when the peripheral blood CD34+ cell count was 
greater than 20 cells/pl. All subjects had cells collected using COBE® Spectral"' 
continuous flow Apheresis System (Gambro BCT, Lakewood, Co, USA) and the 
standard stem cell collection program by staff of the Apheresis Unit, Glasgow 
Royal Infirmary. The cells for therapeutic use were collected into a bag, which was 
then heat sealed and removed for processing. The tubing on the collection side of 
the collection side of the closed circuit was heat sealed and removed from the 
machine and processed within 4 hours of collection. 
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All cell manipulations were performed in a laminar flow cabinet using aseptic 
technique. The collection tubing was flushed with 20mis of TC medium pnd the 
cells were collected into a 50ml sterile conical tube (Greiner Bio-One, Longwood, 
Florida, USA). After gentle mixing by inversion, the cell suspension was carefully 
layered on top of 3mls of Histopaque®-1077 (Sigma) in 15ml test tubes (Greiner), 
and spun at 1700rpm for 20mins (density gradient separation). The serum was the 
pipetted off mononuclear cell layer leaving 0.5cm above the interface, which wad 
then carefully removed and placed in a fresh 15ml tube. The cells were washed 
three times in fresh TC medium, the first spin was at 1000rpm for 1 Omins to alsq 
remove any excess Histopaque and the next two spins were at 800 rpm for 
10mins to leave platelets suspended in the supernatant. The supernatant was 
removed by careful pipetting and the cells were resuspended by gentle flicking of 
the tube at 5x106ml TC medium and cultured overnight to rest, at 37°C, in 75cm2 
tissue culture flasks, in preparation for cell sorting. 
2.2.5 Red cell Lysis 
Red blood cells in peripheral blood mononuclear cell (PBMC) preparations were 
lysed with ammonium chloride solution (0.083%, Sigma) at 37°C for ten minutes 
and repeated if required. Cells were washed in PBS and recovered by 
centrifugation at 1000rpm for 10mins and resuspended in medium or PBS as 
required. 
Red blood cells in whole blood (WB) preparations were lysed with sterile, 
deionised water for 15secs (at a ratio of 1: 10 WB to H20), the cells were 
immediately washed in PBS/Alba (1: 4, water to PBS) and the whole procedure 
repeated once. Cells were then suspended in PBS/Alba or appropriate tissue 
culture medium as required. 
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2.2.6 Cell counting and assessment of viability 
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Clinical full blood counts were performed on a Coulter Gen-S analyser (Beckmann 
Coulter, Fullerton, CA, USA) in Glasgow Royal Infirmary and Sysmex SF9500 
analyser (Sysmex, Kobe, Japan) at the Western Infirmary, Glasgow. Both 
analysers use a sample size between 200 and 250pl to produce a full blood court 
and 5 part differential. Both laboratories participate in the United Kingdom National 
External Quality Assessment Service (NEQUAS) surveillance scheme fpr quality 
assurance. 
All other cell counts were performed manually with a haemocytometer and viability 
was assessed by Trypan Blue (Sigma) exclusion. Briefly, 90pl of 1: 10 Trypan Blie 
was added to 10pl of cell suspension and 10pl was then transferred to a 
haemocytometer (i. e. cells were diluted 1: 10) Blue stained cells were counted as 
non-viable, and the mean number of unstained cells counted in 5 large squares, 
multiplied by 10 (the dilution factor), was taken as the viable cell count X104/ml. 
2.2.7 Cryopreservation of cells 
All cells that required cryopreservation were washed once in cold Alba and 
resuspended at a concentration of not more than 2x107/ml in DMSO/Alba on ice. A 
1 ml aliquot of cell suspension was then transferred into 1.5ml Nunc Cryotubes 
(Nunc A/S, Roskilde, Denmark) and the cells were placed in a polystyrene box 
surrounded by polystyrene packing beads. The box was then cooled at -20°C for 1 
hour and -80°C overnight before the cryotubes were transferred to liquid nitrogen 
(LN) for storage. 
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2.2.8 Recovering cells from LN2 cryopreservation 
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Extreme care was taken to ensure good cell recovery, especially when thawing 
un-sorted PBMC from apheresis collections, which contain high numbers of 
granulocytes. On removal from LN, cryotubes were immediately placed in a 37°Q 
water bath until all ice crystals had melted. The cell suspension was the gently 
transferred into a 15ml test tube and DMP thawing solution was added slowly, 
drop by drop initially, with constant gentle agitation on ice until 14mis of DMP had 
been added. The tube was then placed in a 37°C water bath for 10mins to facilitpte 
the action of the enzyme. Cells were then spun at 1000rpm for 10mins, the 
supernatant removed by pipetting, resuspended in DMP and incubated at 37°C for 
a further 5mins. Cells were then washed twice in TC medium, counted and 
checked for viability. 
2.2.9 Preparation of Ag 
2.2.9. lTumour Lysate 
Tumour cell lysates were prepared by harvesting cells from culture, and placing 
them in 15m1 test tubes. The cells were recovered by centrifugation at 1200rpm for 
10mins, the supernatant discarded and the cells resuspended in 1ml of TC 
medium. The cells were then counted, and the cell suspension snap frozen at - 
80°C for 15mins. The cell preparation was rapidly thawed in a 37°C water bath, 
vigorously vortexed for 2mins, and the process of freezing, thawing and vortexing 
was repeated 3 times to ensure all cell were disrupted. TC medium was added to 
adjust the final cell concentration to 1x107/ml and the freeze/ thaw preparation was 
then stored at -80°C for future use. 
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2.2.9.2lnduction of tumour cell apoptosis 
Tumour cell lines were suspended at 1 x105/ml in SFM, and placed in a 75cm2 
culture flask in 15ml aliquots. The cells were exposed to a Philips SLPF15E ultra 
violet light source for 30mins and cultured overnight at 37°C to allow them to enter 
cell cycle and undergo apoptosis. Apoptosis was confirmed using Annexin-V and 
7AAD (Viaprobe) staining, and analysed by flow cytometry (as described in 2.3.7). 
The rates of apoptosis were compared in cells that had been irradiated and 
cultured overnight in SF medium and TC medium, with un-irradiated cells cultured 
under the same conditions, Figure 2-1. This confirmed that UV irradiation and 
overnight culture in SF medium (mean 40.5 ± 3.7, p<0.01) were the optimum 
conditions to induce apoptosis in U266 cells, as compared to serum free culture 
(mean 23.7 ± 2.5). UV irradiation alone (mean 12.8 ± 1.8, was not significantly 
different from the untreated control (mean 13.5 ± 1.6). 
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Figure 2-1 Apoptosis in irradiated and un-irradiated cells cultured overnight 
in SF medium and TC medium 
The proportion of U266 cells undergoing apoptosis was compared in cells that had 
been irradiated and cultured overnight in SF medium or TC medium, with un- 
irradiated cells cultured under the same conditions. Apoptosis was measured 
using Annexin-V and 7RAD (Viaprobe) staining, and analysed by flow cytometry. 
Assays were performed in triplicate. 
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2.2.10 Selection of CD14+ monocytes and CD3+ T cells 
To obtain monocytes and T cells with a purity of >90%, cells collected by 
apheresis were sorted using the MACS system (Miltenyi Biotec, Bergisch 
Gladbach, Germany). All sorts were performed as per the manufacturers 
instructions using the LS size column, allowing the selection of up to 1x108 
positively labelled cells from up to a total of 1x109 cells. Cells were placed into 2 
15ml test tubes, washed once in cold PBS/EDTA/Alba and resuspended in 7Opl of 
cold PBS/EDTA/Alba per 107 cells. We labelled one tube with CD14 microbeads to 
isolate monocytes, and the other with CD3 microbeads for T cells, both at 20pl/107 
cells and incubated at 4°C for 15mins under slow continuous mixing. Cells were 
washed in cold PBS/EDTA/Alba, passed through a pre-wetted 30pm filter and LS 
column in a midi-MACS magnet (all Miltenyi Biotec). The column was washed 
through with 3x3ml of PBS/EDTA/Alba and removed from the magnet. The 
positively selected cells were then eluted off the column in 5ml of PBS/EDTA/Alba 
with the supplied plunger. The cells were then counted and checked for viability 
and an aliquot of 5x105 was retained for flow cytometry. 
2.2.11 MoDC production 
Monocytes, purified from PBMC by CD14 magnetic bead separation, were 
suspended in DC medium at a density of 5x106/ml and placed in 75cm2 tissue 
culture flasks. The DC medium was then supplemented with GM-CSF 50ng/ml 
(Stem Cell Technologies) and either IL-4 30ng/mI (Peprotech) or IL-13 50ng/ml 
(Peprotech). Cells were cultured for 4 days at 37°C and 5% C02, counted, checked 
for viability, and the concentration of cells was adjusted to 1x106/ml by the addition 
of DC medium supplemented with the appropriate cytokines. The Ag preparation, 
either apoptotic or freeze-thawed U266 cells suspended at 1x107/ml, was added to 
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a final ratio of 1 iDC to 1 tumour cell (equivalent to an approximate protein 
concentration of 1 mg/ml) (Thumann, et a/ 2003). To induce iDC Ag IoaOing and 
maturation, either the monocyte conditioned medium mimic (MIMIC) combination 
of TNF-a (10ng/ml) (Peprotech), IL-1p (10ng/ml) (Peprotech), IL-6 (10np/ml) (Stem 
Cell Technologies) and PGE2 (10-7M) (Sigma) (Feuerstein, et al 2000), pr the 
novel in-house combination X4, TNF-a (10ng/ml), PGE2 (10"7M), Poly (l; C) 
(1 Ong/ml) (Sigma) and CD40L (250ng/ml) (Peprotech), and the Ag preparation 
were added at the same time (Thumann, et al 2003), The cells were cultured 
overnight at 37°C with tissue culture flasks standing up-right to facilitate cell 
contact and Ag phagocytosis. The antigen-loaded matDC were harvested the 
following morning, washed in warm TC medium and resuspended in 1 ml of TC 
medium. The mat DC were counted, assessed for viability, and resuspended at p 
concentration of 1x106/ml. An aliquot of 1x106 matDC was cryopreserved for use 
in the second DC stimulation step of cytotoxic T cell production. 
2.2.12 T cell pre-stimulation with T cell activation beads 
T cell activation beads (a kind gift, Dr John Campbell, Miltenyi Biotec), are 3.5pm 
inert, magnetic beads (2x10$/ml) conjugated to anti-biotin monoclonal antibody. 
This facilitates the beads being loaded with biotinylated molecules, in our case 
anti-CD2 (1 OOpg/mI), anti-CD3 (1 OOpg/mI) and anti-CD28 (100pg/mI). This was 
done in accordance with the manufacturer's protocol. Briefly, 500pl of beads, 
100NI of biotin-anti-CD2,100NI of biotin-anti-CD3,100NI of biotin-anti-CD28, and 
200pl PBS/EDTA/Alba were placed in a 1.5ml Eppendorf tube. This mixture was 
then mixed thoroughly by vortexing and incubated for 2hrs, at 4°C, under constant 
slow rotation (50-100rpm). This mixture is stable for 4wks at 4°C. Prior to use, the 
required number of beads was removed, placed in x10 volume of T cell culture 
medium in an Eppendorf tube, vortex and spun at 1200rpm for 5mins to remove 
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the excess antibody. The beads were recovered by pipetting off the supernatant 
and resuspended in 200p1 of TC media ready for use. 
The manufacturer suggests that when using beads alone to activate T cells, they 
should be used in the range of 1: 1 to 1: 2, beads to T cells, in order to avoid 
activation induce cell death. As the beads were used in conjunction with cytokine, 
they were added to the T cells (1-5x106/ml) at a ratio of 1: 4, in 6 well tissue culture 
plates. The T cell/bead mixture was supplemented with IL-2 (201U/ml) (MM and 
ND cells) or IL-15 (15ng/ml) (MM cells only) and incubated at 37°C for 3days. 
T cell activation beads were removed from the T cells as per the manufacturers 
instructions. Briefly, the T cell/bead culture mix was placed in a 15ml tube and 
washed in 15mis of cold PBS/EDTA/Alba, recovering the cells by centrifugation at 
1200rpm for 5 mins. The supernatant was then completely removed, the cells 
suspended at a maximum concentration of 2x107/ml and placed in the field of a 
Dynal magnet (Dynal AS, Oslo, Norway) for 2mins. The supernatant, which 
contains the cells, was then removed and placed in a fresh tube with the original 
tube still in the magnetic field to retain the beads against the sidewall of the tube. 
The original tube was then removed from the magnet, the 2ml of buffer was added 
to it, vortexed and the bead removal procedure was repeated to optimise cell 
recovery. The cells were then washed in TC medium, counted, checked for 
viability, and resuspended at 1x106/ml in TC medium ready for use in cytotoxicT 
cell generation experiments. Cell for use in T cell proliferation assays were 
cultured overnight in 6 well tissue culture plates to rest. 
2.2.13-Cytotoxic T cell generation 
Dendritic cells and either un-stimulated or pre-stimulated T cells were co-cultured 
for 3 days in TC medium at a ratio of 1 DC (1x105/mI) to 10 TC (1x106/mi) in 24 
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in 24 well tissue culture plates, with an aliquot of DC cryopreserved for use later in 
the experiment. After 3 days 50% of the media was removed and replaced with an 
equal volume of TC media supplemented with IL-2 (401U/ml). After 7 days, the 
cells were transferred into 12 or 6 well plates, the aliquot of cryopreserved Ag 
loaded matDC was thawed, washed, and added to the T cell/DC co-cultures in an 
equal volume of TC medium. The cultures were fed IL-2 supplemented TC 
medium, final concentration of 201U/ml, every 3-4 days until sufficient numbers of 
T cells were present to perform a cytotoxicity assay, between 3 and 6 weeks. 
2.3 Flow cytometry techniques 
2.3.1 Antibody labelling 
All fluorescently labelled antibodies were purchased from BD/Pharmingen (BD 
Biosciences, San Jose, CA, USA), with the exception of CD11 C-FITC 
(DakoCytomation Norden A/S, Glostrup, Denmark). All antibodies were titrated to 
determine the optimal concentration for staining, and pre-loaded in to the 75mm 
Falcon tubes (BD Biosciences). Cells were suspended in PBS/EDTA/Alba at a 
concentration of 5x105 -1x106/ml and 1 00NI was added to each tube. T cells were 
incubated at 4°C for 30mins in the dark. DC and monocytes were incubated in the 
dark at room temperature (RD for 15mins to avoid temperature related down 
regulation of chemokine receptors. Cells were then washed twice in 
PBS/EDTA/Alba, the cells recovered by spinning at 1000rpm for 1Omins and 
resuspended in 200pl of PBS/EDTA/Alba for analysis. All samples were analysed 
within an hour of antibody staining or fixed with 500pl of FACS-Fix solution, stored 
in the dark at 4°C, and analysed within 3days. 
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2.3.2 Cell staining 
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Tumour cells to be used as targets for phagocytosis and cytotoxicity assays were 
labelled with the PKH26 (red) and PKH67 (green) fluorescent membrane dyes 
(Sigma) as per the manufacturers instructions. Cells were washed twice in un- 
supplemented RPMI 1640 to remove any serum, 1x107 cells were suspended in 
Iml of diluent C and 2pls of dye was diluted in 1ml of diluent C in a 15ml test tube. 
The cell suspension was added to the dye and incubated at RT for 5mins. Excess 
dye was bound by adding 2mis of neat AB serum, incubating for 2mins at room 
temp and then adding 11 mIs TC medium. Cells were then washed twice in TC 
medium and resuspended in TC medium at the concentration required for the 
assay. 
2.3.3 Flow cytometric analysis 
All flow cytometric analysis was performed on a FACScaliber analyser using Cell 
Quest Pro software (both Becton Dickinson). The cell populations to be analysed 
were initially gated on using their forward scatter (size) and side scatter 
(granularity) characteristics with the detectors set on a linear scale. The 
fluorescence detectors (FLI-4) were set with a Log scale. To ensure the accuracy 
and reproducibility of the flow data, great care was taken to optimise the cytometer 
for each experiment. The level of background auto-fluorescence, non-specific 
staining and day-to-day drift in laser intensity and alignment was compensated for 
on each experiment. An aliquot of cells was stained with an isotype control 
antibody for each of the fluorochrome colours to be used and the detector 
sensitivity was adjusted so that the level of fluorescence fell within the first decade. 
Cells were deemed positive if their fluorescence level was greater than 101. The 
spectral overlap of fluorochromes was compensated for by staining an aliquot of 
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cells with a single positive antibody for the fluorochrome to be measured in FLI, 
FL2, FL3 or FL4 and with the isotype control antibodies for the other colours to be 
used in the experiment. The level of the compensation control was set to ensure 
that cells stained with an antibody measured in each channel, e. g. FL1, only 
appeared in the positive region of the analysis for that channel, FL1, and no othopr. 
This procedure was repeated for each colour of fluorochrome used in the 
experiment. 
Data was analysed using Cell Quest Pro or FlowJo (Tree Star Inc, Ashland, 
Oregon, USA) software. 
2.3.4- Mean fluoresence intensity (MFI) 
The MFI of a population of cells was calculated by subtracting the mean fluoresce 
of the negative control from the mean fluoresce of the target population. 
When a blocking was added to an assay, as in 6.1.3, the effect of this was 
quantified using the equation below. 
(Positive control MFI - Blocked MFI) X 100= % MFI Blocking 
Positive control MFI 
Equation 2-1 Percentage blocking of MFI 
2.3.5 Chemokine uptake assays 
This methodology is based on that previously optimised by collaborators I. 
Comerford and Dr R. J. B. Nibbs (Glasgow University). Biotinylated chemokines 
were synthesised by Albachem (Gladsmuir, East Lothian), with each molecule 
carrying an N-terminal biotinylated lysine residue. Other than this residue, Bio- 
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CCL19 was identical to human CCL19 provided by other commercial suppliers. 
The Bio-CCL3 was based on a mutated version of mouse CCL3 that does not 
aggregate beyond a dimer, and is described elsewhere (Weber, et a! 2004). Cells 
were harvested, resuspended at 5x1051ml and allowed to warm to 37°C. For eich 
sample to be tested, 10pl of the following mix was prepared in Falcon tubes and 
incubated in the dark at RT for 30-45 minutes: For CCL3 receptors, 2.5pl of 
0.05mg/ml Biotin CCL3,3u1 streptavidin PE (strep-PE) (Invitrogen, Paisley, UK) 
and 4.5pl PBS. For CCL19 receptors, 5pl of 0.05mg/ml Biotin CCL19,3u1 strep-FE 
and 2p1 PBS. Control mix, 3u1 strep-PE and 7u1 PBS. Aliquots of cells (2-500p1) 
were added to the biotinylated chemokine/Streptavidin-PE mix or strep-PE only 
control, and incubated at 37°C for 2 hrs with regular gentle agitation. Cells were 
then washed with ice-cold flow cytometry buffer, to stop the reaction. The cells 
were retrieved by centrifugation (1200 rpm, 5 min, 4°C), resuspended in 400 pi 
PBS/EDTA/Alba, and analysed immediately by flow cytometry. 
2.3.6 CCL1 surface staining 
The CCL1 (1-309) Fluorokine kit, (R and D systems, Minneapolis, MN, USA. ) was 
used to examine the expression of CCR8 on monocytes and DC. Cells were 
suspended in cold PBS at 1x106/ml. An aliquot of cells (100pl) was added to 2 
Falcon tubes and 20pl of biotinylated CCL1 (2.5ug/ml) or negative control was 
added. The samples were incubated for 1 hour at 4°C and then 20NI of avidin- 
FITC was added and incubated for a further 30mins in the dark at 4°C. Samples 
were then washed twice in 1x RDF1 buffer and analysed by flow cytometry. 
To test the specificity of the staining, 20p1 of Bio-CCL1 was incubated with 40p1 of 
anti-human CCL1 blocking antibody, prior to the addition of the cells. The assay 
was then completed as normal. A competitive binding assay was also performed 
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by pre-blocking I00pl of test cells with 20pl of 25ug/ml non-biotinylated CCL1 
(Peprotech) for 1 hour. The assay was then completed as normal. 
2.3.7 Cytotoxicity assays 
Target cells, U266 MM cell line, were prepared the day before setting up the 
assay. Debris and dead cells were removed by density gradient centrifugation. 
The cells were then stained with PKH 26 and cultured overnight in fresh TC 
medium. The target cells were then washed in fresh warm medium and suspended 
at 1x106/ml. The T cells were washed in warm TC medium, counted and set up at 
8x106/ml and 10 doubling dilutions were set up in Falcon tubes, final volume 
200pl. An equal volume of target cells was then added to produce the 
effector: target cell ratios 8: 1,4: 1,2: 1,1: 1 etc. Assays were performed in duplicate. 
Target cells alone and TC alone were set up to act as negative and gating 
controls. The tubes were then capped and cultured over night at 37°C. Culturing 
PKH-26 stained target cells in serum free media after exposure to UV light for 
30mins provided positive controls for Annexin-V and 7RAD staining. 
The following morning, the tubes were centrifuged at I000rpm for 10 minutes, the 
supernatants were removed, and cells resuspended by gentle agitation. We then 
added 5pI of Annexin-V-FITC (Pharmingen), 10pl of 7RAD (Pharmingen), and 
100pl of Annexin-V binding buffer to each tube and incubated for 15mins at RT. 
The reaction was stopped by adding 400p1 of Annexin-V binding buffer to each 
tube and the assays were read by flow cytometry within I hour. A total of 20,000 
target cell events were collected per tube and the results for each dilution were 
expressed as the mean number of dead test cells minus the number of dead cells 
in the Target alone control. 
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2.4 T cell proliferation assays 
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All proliferation assays were set up in 96 well tissue culture plates, with 100pi of T 
cells (1x106/ml) added to quadruplicate (quad) sets of wells. 100pl of TC medium 
supplemented with IL-2 (401U/ml) was then added to each test well. Negative 
controls were set up by adding I00pl of TC medium to a quad set of T cells. The 
plates were incubated at 37°C for 3 days, 10 pL of TC media containing a dose of 
0.25 NCi 3H-thymidine (Amersham Biosciences, Chalfont St. Giles, UK) was added 
per well for the final 18 hours. The plates were harvested using a 96 well cell 
harvester (Micromate 196, Packard, Pangboume, UK) onto a fittermat, which was 
dried and read on a beta counter (Matrix 96 Direct Beta Counter, Packard) for 5 
minutes. The results were expressed as the mean number of counts of each test 
quad minus the mean of the control quad. 
T celVmatDC proliferation assays were performed by setting up two test quads 
containing 1 00NI of T cells (1x106/ml) and 1 00NI of matDC (1x105/ml). One test set 
was supplemented with IL-2, final concentration 201U/ml. Negative controls of 
matDC and T cells were performed along with a positive control of T cells plus 
201U/ml IL-2 on each occasion. All reactions were performed in 200p1. The assays 
were then completed as above, and the results were expressed as the mean of 
each test quad minus the mean of T cell only and DC only quads. 
2.5 Luminex assays 
A multiplex kit was used to measure GM-CSF, IFN-a, IL-2, IL-4, IL-6, IL-7, IL-10, 
IL-12p70, IL-15, TNF- a, and VGEF (Biosource International Inc, Camarillo CA, 
USA. ). The assay was performed as per the manufacturers instructions and read 
on a Luminex I OOTIA instrument. The working concentrations of all reagents were 
prepared as follows; a working wash solution (WWS) was prepared by diluting 
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15mis of x20 wash solution concentrate in 285ml of deionised water. The assay 
diluent was diluted in an equal volume of TC medium (AD). The 11 detgctor 
antibody x10 concentrates were combined and diluted in the biotin diluent, final 
volume 2.5ml. The Strep-PE x10 concentrate was diluted in 9 parts of Strep-PE 
diluent, total volume 1Oml, for use within 15mins of reconstitution. The capture 
bead x10 concentrates were combined and diluted in the volume workirpg wash 
solution, total volume 10mis. 
A 96 well filter plate (Millipore, Billerica, MA, USA. ) was pre-wet with 200pl of 
WWS for 30secs and then aspirated with the vacuum manifold (VM) (Millipore) at 
5psi. All work was then performed with the plate on the VM, having first released 
the pressure. The bead solution was vortexed and 25pl was added to each well. 
The plate was shaded from light from this point onward to prevent bleaching of the 
fluorochromes. The beads were washed twice with 200pl of WWS (the residual 
liquid on the underside of the plate was removed after every wash step by blotting 
with clean paper towels) and 50pl of incubation buffer was added to each well. The 
standard curve was set up by reconstituting the standard in 150p of AD, serially 
diluting this in 300pi of AD (1: 3), and adding 100pl of each standard dilution in 
duplicate to the appropriate wells. Sample (50pl) and AD (50pl) were then added 
to each sample well in duplicate. The plate was then incubated for 2hours at RT 
on an orbital shaker (500-600 rpm). The assay liquid was aspirated with the VM, 
the plate was washed twice with WWS. Biotinylated detector antibody (100pl) was 
added to each well and incubated for 1 hr at RT on an orbital shaker. The assay 
liquid was aspirated with the VM, the plate was washed twice with WWS. 
Streptavidin-PE (100pl) was added to each well and incubated for Ihr at RT on an 
orbital shaker. The assay liquid was aspirated and the plate was washed three 
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times with WWS. Working wash solution (100pl) was added to each well, placed 
on the orbital shaker for 2mins and read on a Luminex I OO instrument. The 
concentrations of the standard curve samples were determined using the curve 
fitting software, with a four-parameter algorithm and multiplied by 2 to correct for 
the 1: 2 dilutions. The software then calculated the concentrations of each analyte 
in each well 
2.6 Molecular techniques 
2.6.1 RT-PCR 
Cells stored at -80°C as a concentrated cell pellet (5x105) were thawed, and 1 ml 
of TRIzol® added. Following incubation at RT for 5mins, 200pl of chloroform 
(Sigma) was added, shaken vigorously for 15secs and incubated at RT for 3mins. 
The samples were microfuged at 12000g and 4°C for 5mins and the supernatant 
transferred carefully into a fresh Eppendorf tube. The RNA was precipitated by 
adding 0.5ml of isopropyl alcohol per Iml original volume of TRlzol®, mixing and 
incubating at RT for 10mins, and centrifuging at 12,000g for 10mins at 4°C. The 
supernatant was discarded and the RNA pelleted, washed in 70% alcohol (to an 
equal volume to the original volume of TRlzol®, and dried. The dried RNA was re- 
dissolved in 100pl of RNAse free water (Sigma). The samples were then treated 
with DNAsel (DNA free, Ambion, Huntington, UK) according to the manufacturers 
instructions. The quantity of nucleic acids was analysed spectrophotometrically 
using an Eppendorf Biophotometer according to the manufacturer's instructions 
and the sample was diluted in RNAse free water to a final concentration of 
0.15ug/mI. 
Dr Simon J Harrison, 2005 Chapter 2-81 
The Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen) was 
used to synthesise cDNA according to the manufacturer's instructions, using 1 NI of 
RNA template in a 20pl reaction. 
Aliquots of cDNA (2pl) were subjected to PCR using Reddy Mix PCR tubes 
(Abgene, Epsom, UK), which contain all PCR components, except primers and 
Template. The following primer pairs were added to a final concentration of 1Ong/ 
pl. Forward and reverse primers for CCR5 (AGATATTTCCTGCTCCCCAGT and 
TGGCCTGAATAATTGCAGTA, ) CCR7 (AACTTGACGCCGATGAAG and 
TACCTTGTCATCATCCGCA) and D6 (CTGGAGTGCGTAGTCTAGATCC and 
CTCTCATGCTCAGCCCTAC, all MWG Biotec, Ebersberg, Germany) were added 
to each reaction for each sample. Samples were incubated at 92°C for 2mins to 
denature template, then a repeating cycle for 40 cycles of 92°C for 30 secs, 54°c 
for 30secs, and 70°C for 3mins. The final cycle was 70°C for 10 mins, after which 
reactions were chilled at 4°C. 
The products of the PCR reaction were analysed by conventional gel 
electrophoresis, using a1% agarose, 1x TAE (40mMol Tris-acetate, 1 mMol 
EDTA), 1 pg/ml Ethidium Bromide gel, to allow UV visualisation of DNA. The gel 
was placed in 1x TAE buffer, and the samples were electropharesed at 1 00mA for 
2 hours. 
2.7 Statistical analysis 
All statistical tests were two sided. Comparisons between paired groups of 
normally distributed continuous variables were performed using the paired student 
T-test. Unpaired groups of normally distributed continuous variables were 
compared using the student T-test. The Mann-Whitney rank sum test was used to 
compare groups of non-parametric continuous variables. Comparisons of two 
Dr Simon J Harrison, 2005 Chapter 2-82 
groups of repeated measure data (i. e. cytotoxicity experiments) were performed 
using a two way repeated measures analysis of variance (2 way ANOVA). 
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3. Results 1 
3.1 Enumeration of blood dendritic cells in multiple 
myeloma patients at presentation and through 
therapy 
3.1.1 Introduction 
Although DC play a central role in the adaptive and, as is becoming clear, the 
innate immune system, they are difficult to quantify in-vivo. This is because iDC 
reside in the peripheral tissues where they constantly sample the environment. 
When iDC encounter antigen and a second maturation signal, they then traffic to 
the secondary lymphoid tissues under the influence of chemokines such as ELC 
and SLC in order to present antigen to other immune cells such as T lymphocytes. 
It has been known for some time that there is a small number of DC present in the 
peripheral blood and they represent a precursor population of conventional 
myeloid and plasmacytoid DC (Reid, et al 1990). Precursors of the two main DC 
populations that have been identified in the peripheral blood are becoming known 
as the pre-myeloid blood DC (blood mDC) and pre-plasmacytoid blood DC (blood 
pDC), although an increasing amount of plasticity in the DC system has been 
described recently (Zuniga, et a/ 2004). Blood DC are classically identified in the 
peripheral blood by a complex flow cytometry analysis that involve the lineage 
exclusion of the common blood cell types (myeloid, lymphoid, stem cells and NK 
cells) and the positive identification of blood mDC using CD11c, with blood pDC 
expressing CD123 in the absence of CD11c. These experiments are complex and 
time consuming to optimise because they involve analysis of forward scatter/side 
scatter characteristics combined with a large number of antibodies (CD3,19,20, 
33,34,14,16 and 56), as well as being relatively expensive. A number of new 
antibody staining strategies have been proposed to simplify the identification of 
blood DC. The CMRF-44 antibody was derived by Hart's group (Hock, et a! 1994), 
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but DC require overnight incubation before they express the relevant antigen. This 
strategy may be flawed for a number of reasons; firstly it does not directly identify 
blood mDC, rather an intermediate stage between blood mDC and iDC that is 
dependant upon maturation in culture. Secondly, in diseases such as MM, DC 
have problems developing in the normal fashion, thus they may fail to up-regulate 
surface markers that are dependant upon DC maturation for their expression. 
Finally, the CMRF-44 antigen is not expressed by blood pDC. More recently, 
Dzionek described novel antigens that are present on blood DC subsets (Dzionek, 
eta12000). BDCA-2 and BDCA-4 are expressed only on CD11c%CD123+ blood 
pDC. BDCA-3 is expressed at high levels on a small population of CD11c+ICD123" 
blood mDC (Blood MDC2), but at low levels on blood pDC, blood mDC, 
monocytes and granulocytes. CD1c (BDCA-1) is expressed on blood mDC as well 
as on CD19+ B lymphocytes. This degree of co-expression requires the 
granulocytes, monocytes and B lymphocytes to be gated out of the analysis. 
As mentioned earlier, the MM clone is known to affect blood mDC was discussed 
earlier. There is still some debate as to whether blood mDC in MM patients are 
present in normal numbers (Brown, et a12001) or are reduced in number (Ratta, et 
a/ 2002). Some of these discrepancies may be explained by the fact that these 
studies have used different antibodies to identify the blood mDC populations. The 
study by Brown et al used the CMRF-44 antibody to identify blood mDC, while 
Ratta employed the more traditional lineage exclusion method. However, there is 
agreement that blood mDC in MM patients do not function normally. In contrast, 
little has been published on what happens to circulating blood pDC in MM. 
Plasmacytoid DC are the main natural IFN-a producing cells and they are involved 
in regulating both the adaptive and innate immune responses (McKenna, et al 
2005), with both immunogenic and tolerogenic effects. Mature pDC seem to 
amplify mDC responses by initiating DC differentiation from monocytes, promoting 
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DC maturation and polarising the T cell response to a Th1 phenotype through the 
secretion of IFN-a and OX40L expression. Plasmacytoid DC also interact with the 
innate immune system by recruiting and activating NK cells, thus playing a vital 
role in anti-viral immunity. There has been increasing interest in the part these 
cells play in the immune response to malignancies (Mohty, et al 2005, Salio, et al 
2003). The only study which has reported blood pDC numbers in MM, suggested 
that they were reduced (Ratta, et a! 2002). It is known that in diseases such as 
HIV/AIDS, the number of both blood blood mDC and blood pDC are reduced 
(Pacanowski, eta! 2001), whilst in infections such as Dengue, a rise in blood pDC 
seems to modify the severity of the disease (Pichyangkul, et a/ 2003). The 
mechanisms by which pDC induce tolerance are poorly understood, and they are 
not just dependant upon the state of pDC maturation. Thus by preventing pDC 
development and maturation, tumours such as MM could have a negative impact 
on both the adaptive and innate immune systems. 
The initial aim of our study was to examine the numbers of circulating blood 
myeloid and plasmacytoid DC subsets in patients with MM as compared to normal 
individuals. In addition, we wanted to look at how the DC numbers and proportions 
may change in response to conventional anti-MM chemotherapy, following 
autologous and allogeneic HSCT, and whether the immunomodulatory drug, 
thalidomide induced any significant changes in the blood DC compartment. Our 
secondary aims were to determine whether we could reliably measure a third, 
recently identified and poorly studied blood DC subset, blood mDC2, in both 
normal subjects and MM patients, and if we could use this assay to simultaneously 
measure the CD19 positive B lymphocytes. 
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3.1.2 Measurement of circulating blood DC by flow-cytometry 
using the BDCA 1,2 and 3 antibodies in normal individuals 
The normal control population was selected from normal individuals to reflect thT 
mean age of patients with MM in trials (controls 50.2yrs, MM 55-65yrs) and M=F 
(controls 10: 11). The BDCA antibody kit (Miltenyi Biotec) allows the rapid 
identification of circulating blood DC directly from fresh whole blood collected into 
a standard EDTA tube, as used for full blood counts in routine clinical practice. 
The assays were performed on WB, anti-coagulated with EDTA, within 24hrs of 
sampling and stored at 4°C if required. The antibody staining was performed on 
two 150ul aliquots of WB in 12x75 mm Falcon tubes. The test sample was stained 
with 10ul of BDCA antibody cocktail and the control sample with 1 Oul of control 
cocktail. Each sample had 5ul of dead cell discriminator added. Both samples 
were mixed gently but thoroughly and then incubated for 10 minutes, in a 
horizontal position on ice, under a 60w white light bulb in order to activate the 
dead cell discriminator staining. Red cells were lysed twice with sterile water, the 
sample was resuspended in 300ul of buffer and then analysed by flow cytometry, 
after having run the appropriate negative and positive compensation controls for 
channels FL1-4. If the samples could not be analysed immediately, 2.5ul of 
discriminator stop solution (Deoxyribonucleic acid in 10 mM NaCI, 1 mM EDTA, 
pH 8) and 150 ul of FACSfix solution was added and the samples analysed within 
12 hours. 
The control antibody cocktail contains mouse IgGl-FITC, IgG2a-PE and IgGI- 
APC monoclonal antibodies and CD14-PE-CY5 (mouse IgG2a) CD-19-PE-CY5 
(mouse IgG1). This allows the neutrophils, B-lymphocytes and monocytes to be 
gated out of the target population on an FL3 vs. side scatter plot (Figure 3-1). The 
control cocktail is also used to set the background level of non-specific staining in 
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the channels used for measurement of blood pDC (FL1), blood mDC1 (FL2) and 
blood mDC2 (FL4). The test antibody cocktail contains the same CD14 and CD19 
exclusion antibodies, along with the antibodies to identify blood mDC1, blood pDC 
and blood mDC2, CD1c-PE (BDCA-1)(mouse IgG2a), BDCA-2-FITC (mouse 
IgGI) and BDCA-3-APC (mouse IgGI) respectively. Dead cells are excluded from 
the analysis by the addition of a fluorescent photolytic dye to both the control and 
test samples. 
Gate Region(s) Cell Type 
G1 R1 All live Cells 
G2 R2 Non B cell, Non monocyte, Non neutrophils 
G3 R1+R2 All Cells, not B cell, monocyte, neutrophil 
G4 R1+R2+R3 blood mDC1 
G5 R1+R2+R4 blood pDC 
G6 R1+R2+R5 blood mDC2 
G7 R1+R6 B lymphocytes 
Table 3-1 Logic gates for Blood DC analysis 
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Figure 3-1 Flow-cytometry plots required for the measurement of circulating 
blood DC subsets in a normal individual. 
In plot A, all cellular events are gated (R1) in a forward side (linear) versus scatter 
(linear) plot composed of all acquired events. Plot B shows CD19 positive B 
lymphocytes, CD14 positive monocytes dead cells and neutrophils being excluded 
on an FL3 (log) vs. side scatter plot of all events. Plots C-F show only events in R1 
and R2. Plot C shows the isotype controls for FL2 (log) (blood mDC1) and FL1 
(log) (blood pDC). Plot D shows CD1c PE positive blood mDC1 in R3 and BDCA2 
FITC positive blood pDC in R4. Plot E shows the negative control for blood mDC2 
on an FL4 (log) versus FL2. Plot F shows blood mDC2 (R5), which are high 
expressers of BDCA3 (FL4) versus blood pDC (FL1, BDCA2) which are 
intermediate expressers of BDCA. 
Absolute number of 
DC's of each DC = 
(% Gated sample -% Gated control) x WCC 
subset per ml of blood 100 
Equation 3-1 Determination of the number of monocytes and blood DC 
subsets per ml of peripheral blood. 
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Figure 3-2 Total WCC and circulating B lymphocyte numbers in normal 
subjects n=21. 
The white blood cell count for normal subjects was measured using a Coulter Gen- 
S or Sysmex SE9500 haematology laboratory analyser, on the same sample on 
the same day as the blood DC assay was performed. The B cell population was 
estimated using the BDCA kit, gating on the CD19 positive cells (G7 = R1 + R2 
+R6) and then the absolute number was calculated using Equation 3-1. 
Figure 3-2 shows the results of the white blood cell counts (WBCC) and B cell 
numbers for normal subjects (n=21). The WBCC were performed on the same 
sample, on the same day as the blood DC assay was performed. The mean value 
was 6.75 ± 1.67 x106/mI, well within the reference range for both laboratories (4-11 
x106/ml). The B cell population was estimated using the BDCA kit, gating on the 
CD19 positive cells (G7 = R1 + R2 +R6) and then the absolute number was 
calculated using Equation 3-1, mean 3.35 ± 1.32 x105/ml, again, well within 
quoted normal ranges (0.6-6.6 x105/mI, HMDS, Leeds. 2.0-6.0 x105/mI, GRI, 
Glasgow. ), validating the use of this method to accurately reflect the number of ß 
cells in the peripheral blood. 
The number of each blood DC subset detected in normal individuals is shown in 
Figure 3-3. The proportion of each blood DC subset out of the total cell population 
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was measured using the BDCA antibody kit and the gating strategy outlined in 
Table 3-1. The absolute number of each blood DC subset was calculated using 
Equation 3-1. The mean number of blood mDC1 was 2.35 ± 1.37 x104/ml, blood 
pDC 1.65 ± 0.74 x104/ml and blood mDC2 1.21 x103/ml +0.86 x103/ml. These 
results are comparable with the manufacturers reference range (blood mDC1 
1.56-3.28 x104/ml, blood pDCO. 45-2.04 x104/mI and blood mDC2 0-2.16 x103/mI). 
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Figure 3-3 Number of DC per ml in the blood of normal subjects n=21 
Each blood DC subset was analysed by flow cytometry using the BDCA antibody 
kit. Blood mDC1 were measured in G4 (R1+R2+R3), blood pDC in G5 
(R1+R2+R4) and blood mDC2 in G6 (R1+R2+R4), estimating each population as 
a percentage of the total cells present. The absolute number of each blood DC 
subset was calculated using Equation 3-1. 
3.1.3 Measurement of circulating blood DC by flow-cytometry 
using the BDCA 1,2 and 3 antibodies in patients with 
multiple myeloma 
Ethical approval for this study was obtained from the North Glasgow University 
Trust Hospital (East) ethics committee and all samples were taken with the 
patients having given prior written informed consent. Samples were obtained from 
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patients with MM attending the MM clinics at the Western Infirmary, Glasgow and 
Glasgow Royal Infirmary. Samples were stored and analysed as previously 
described. Samples were obtained at the time of diagnosis prior to the start of 
chemotherapy (n=7). As a second control group, samples were also obtained from 
patients with a plasmacytoma and a detectable paraprotein following radiotherapy 
or patients with monoclonal gammopathy of uncertain significance (MGUS) (n=12). 
These diseases are also characterised by the presence of a paraprotein in the 
peripheral blood, and MGUS is regarded as pre-maligant condition which occurs in 
1% of the over 50s and 3% of the over 70's (Kyle and Rajkumar 2003). In contrast 
to MM, there is much less immunosuppression associated with these disorders 
such as an increase incidence of infection, reduction in the normal levels of 
immunoglobulins (immune paresis) or cellular immune defects, but around 1% of 
patients with MGUS progress to MM each year. Representative flow cytometry 
plots are shown in Figure 3-4. The number of circulating B lymphocytes in normal 
subjects vs MM patients at diagnosis and MGUS/Plasmacytoma patients was 
quantified using the BDCA antibody kit, Figure 3-5. 
B lymphocytes were measured in G7, and the number of cells per ml of blood was 
calculated using Equation 3-1. The number of circulating B lymphocytes in MM 
patients at diagnosis (mean 0.9 ± 0.3 x105 /ml, n=7) was significantly lower 
(p<0.001) than in the blood of normal subjects (mean 5.2 ± 0.4 x105 /ml, n=21). 
The number of circulating B lymphocytes in MGUS and plasmacytoma patients 
was also significantly lower (p<O. 005) than normal subjects. The clone used for 
marking B cells is the LT1 9 (Mason, et al 2002) which is a commonly used for 
phenotyping normal and malignant B lymphocytes and is not positive on normal or 
MM plasma cells. 
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Figure 3-4 Flow cytometry plots from a patient with MM at diagnosis 
Blood DC subsets can be readily identified in MM patient samples using BDCA 
antibodies. Plot D shows blood mDC in R3, blood pDC in R4. In plot F, blood 
mDC2 present in R5 are identified by their high expression of BDCA 2. Of 
particular note is the marked reduction in circulating CD19 +ve B lymphocytes 
seen in plot B. 
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Figure 3-5 Circulating B cell numbers in normal subjects vs MM patients at 
diagnosis and MGUS/Plasmacytoma patients 
Circulating B lymphocytes were quantified using flow cytometry and the BDCA 
antibody kit. B lymphocytes were measured in G7, and the absolute number of 
cells per ml of blood was calculated using Equation 3-1. 
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Blood DC subsets were quantified in samples from normal subjects, MM patients 
at diagnosis and patients with MGUS or plasmacytomas using flow cytometry and 
the BDCA antibody kit, Figure 3-6. The number of blood mDC1 (mean 1.065 ± 
0.35 x104/ml) and blood pDC (mean 0.454 ± 0.10 x104/ml) detected in the blood of 
MM patients at diagnosis was significantly lower than that seen in normal subjects 
(p<0.03 and p<0.001 respectively). The number of blood mDC2 in MM patients 
(mean 0.5 ± 0.016 x103/mI) and the number of all DC subsets observed in the 
blood of patients with MGUS/plasmacytoma, blood mDC1 (mean 1.9650 ± 0.74 
x104/ml), blood pDC (mean 1.1533± 0.32 x104/ml) and blood mDC2 (mean 1.04 ± 
0.3 x103/mI), was not significantly different from normal subjects. 
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Figure 3-6 Circulating DC subsets in MM patients at diagnosis and 
MGUS/plasmacytoma vs. normal subjects 
The numbers of blood mDC1, blood pDC and mDC2 were quantified in samples 
from normal subjects, MM patients at diagnosis and patients with MGUS or 
plasmacytomas using flow cytometry and the BDCA antibody kit. Blood mDC1 
were measured in G4 (R1+R2+R3), blood pDC in G5 (R1+R2+R4) and blood 
mDC2 in G6 (R1+R2+R4). The absolute number of each blood DC subset was 
calculated using Equation 3-1. 
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3.1.4 Analysis of blood DC subsets in MM patients throughout the 
course of the disease. 
We have shown above that at diagnosis the number of blood DC in MM patients is 
reduced. During the treatment of their disease, MM patients receive 
chemotherapy, usually on a monthly basis, until their paraprotein levels stabilise, 
i. e. plateau phase. Further conventional therapy at this stage has no additional 
benefit to the patient in terms of length of plateau phase or survival. In qrder to 
ascertain whether there was any recovery in the numbers of blood DC during 
plateau phase, samples were obtained from patients who were in stable plateau 
phase following induction chemotherapy (n=21). These results were compared 
with those results obtained at the time of diagnosis (n=7). Samples were also 
analysed from patients who had relapsed (n=12), prior to commencing rescue 
therapy. When malignant diseases such as MM relapse, the malignant clone will 
often gain further mutated genes, which provide it with a further survival 
advantage. These additional genetic abnormalities may render the clone more 
resistant to chemotherapeutic agents by a number of mechanisms. These 
protective mutations include the up regulation of genes that protect the cell from 
apoptosis, i. e. BCL-2, or proteins that actively pump drugs out of cells, such as 
MDR1. The tumour burden at the time of relapse is also rapidly increasing. This 
may suppress normal cell production by simple marrow infiltration, or, as may be 
more important in MM, by increased production of suppressive cytokines such as 
IL-6, IL-10, TGF-ß and VEGF. These analyses were performed to determine 
whether any additional suppression of the blood DC system was associated with 
the relapse phase of the disease and the results are shown in Figure 3-7. No 
statistically significant increase in the number of B cells or any DC subset was 
noted between the time of diagnosis (n=7) and the attainment of plateau phase 
following chemotherapy (n=21). At the time of relapse there was a further 
significant fall in the number of blood mDCI compared with diagnosis (p< 0.05) 
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and plateau phase (p< 0.005). There was an even more striking decrease in the 
number of blood pDC at the time of relapse compared with diagnosis (p< 0.05) 
and plateau phase (p< 0.001). The number of B cells did not fall further at relapse. 
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Figure 3-7 Circulating DC subsets in MM patients at strategic points in the 
disease course 
The number of B cells, blood mDC1, blood pDC and mDC2 were quantified in 
samples from MM patients at diagnosis (n=7), in plateau phase following 
chemotherapy (n=21) and at the time of relapse, using flow cytometry and the 
BDCA antibody kit. The results were compared with those obtained from ND. 
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3.1.5 Blood DC subsets in MM patients following aptologpus and 
allogeneic HSCT. 
Stem cell mobilisation and autologous HSCT as consolidation therapy fpr MM 
patients who are in plateau following chemotherapy has become the st9ndard of 
care for patients below the age of 70 years who are otherwise fit enough to 
tolerate the therapy. This therapy is associated with an over all improvement in 
response rate, EFS and OS as compared to conventional therapy alone. Patients 
who have a further significant reduction in their disease burden, i. e. reduction in 
the level of the paraprotein, have significant improvements in time to progression, 
EFS and OS (Child, et al 2003, Harousseau and Attal 2002, Harousseau, et al 
1995). 
These studies were designed to assess two important aspects of the immune 
response to this therapy. Firstly, is this treatment associated with an improvement 
in the number of circulating DC subsets as compared with diagnosis or following 
conventional chemotherapy? Secondly, how rapidly do the DC subsets recover 
following autologous HSCT? 
A small number of patients are suitable to undergo alto HSCT, because of their 
age (i. e. <55years) and the availability of a suitable donor (HLA matched sibling or 
volunteer unrelated donor). This treatment represents the only chance of cure in 
patients with MM via the GVM effect, but it is associated with significant risks, as 
discussed in chapter 1. By examining blood DC subsets in individuals who have 
undergone alto HSCT, we hoped to see whether this therapy was associated with 
any significant differences in blood DC levels as compared with auto HSCT, which 
could be attributed to the immune nature of the therapy. This picture may be 
complicated by the fact that the treatment protocols for alto HSCT may contain 
antibodies such as Campathl-H as part of the conditioning regimen for non- 
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myeloablative (NM) and VUD alto HSCT, and immunosuppressive drugs, such as 
cyclosporin as prophylaxis or treatment for GVHD after myeloablative a`lo HSCT. 
Samples were obtained pre and post auto and alto HSCT from in-patients in the 
bone marrow transplant unit in Glasgow Royal Infirmary and the haematology 
ward in Gartnavel General Hospital, Glasgow. Samples were analysed from 
patients undergoing auto HSCT (n=11) pre-transplant, at the time of engraftment, 
D100 and 1year post transplant. Samples from MM patients undergoing alto HSQT 
(n=3 NM) were analysed at D100. This time point was chosen because by this 
time, the majority of DC will be of donor origin. There is some evidence that 
autologous DC are present for some time following alto HSCT, and may contribute 
to the development of GVHD (Cowing and Gilmore 1992, Duffner, eta! 2004). 
There is no data as to whether blood DC are of donor or host origin at the time of 
engraftment, but there is one report that blood DC are >99% donor at day 60 
(Mohty, et al 2002a). This report also observed that the blood DC subsets in 
patients undergoing NM HSCT peaked at day 60 with a significant decline noted at 
day 90 post HSCT in seven patients. 
The data illustrated in Figure 3-8 shows that following autologous HSCT, blood 
mDC1 show a rise back into the normal range (mean 1.52 ± 0.28 x104 /ml) 
(p>0.05), which is maintained at D100 (mean 1.55 ± 0.24 x104 /ml), but by one 
year the numbers (mean 0.98 ± 0.36 x104 /ml) are back to levels seen at diagnosis 
(mean 1.07 ± 0.35 x104 /ml). The numbers of blood pDC show a rise at the time of 
engraftment, although not back into the normal range, but then decline at D100 
and one year. The numbers of blood mDC2 show a similar trend to blood mDC1. 
At D100 following NM alto HSCT, the numbers of blood mDC1 (0.4600 ± 0.04 XI 04 
/ml), blood pDC (0.31 ± 0.11 x104 /ml) and blood mDC2 (0.350 ± 0.07 x103 /ml) 
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were reduced as compared to normal, MM at diagnosis and post treatment, but 
due to the small sample size these data are difficult to interpret. 
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Figure 3-8 Circulating blood DC subsets in MM patients following auto and 
NM alto HSCT 
Using flow cytometry and the BDCA antibody kit, we quantified the number of 
blood mDC1, blood pDC and mDC2 were in samples from MM patients 
undergoing autologous HSCT (n=1 1) and NM alto HSCT (n=3). The auto group 
were analysed pre-conditioning, at the time of engraftment and at D100 following 
stem cell re-infusion. Samples from the NM alto HSCT group were analysed at 
D100 to ensure that DC were of donor origin. The results were compared with 
those obtained from at MM patients at diagnosis (n=7), following chemotherapy 
(n=21), at the time of relapse (n=12), and ND (n=21). 
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3.1.6 Blood DC subsets in MM patients following therapy for 
relapse with thalidomide and bortezomib. 
At the time of relapse, a number of treatment options are available. Thalidomide is 
increasingly one the first line drugs to be used to treat relapsed MM patients, 
either alone or in combination with steroids and conventional chemotherapeutic 
agents such as cyclophosphamide. The mode of action of thalidomide is complgx 
and is not fully understood. It's anti-MM properties include inhibition of 
angiogenesis, induction of MM plasma cell apoptosis in combination with steroids, 
prevention of adhesion and cytokine signaling and enhancement of the TH1 
immune response. By measuring blood DC subsets in patients taking this drug we 
hoped to gain a further insight into the immunostimulatory properties of 
thalidomide, and whether they may be mediated in some way by the DC system. 
Samples were obtained from patients at the time of relapse (n=12) and when they 
were taking more than 100 mg of thalidomide for 1-3 months (n=12), the normal 
starting dose being 50mg, which is then usually increased to 100mg after 2-4 
weeks if the patient is able to tolerate the therapy. 
A small number of samples were obtained from patients with refractory MM who 
were entered into the bortezomib (Velcade®) phase 11113 clinical study (n=5). 
Velcade is a proteosome inhibitor that has been shown to be active against MM in 
earlier studies (Richardson, et a/ 2003) and has recently been granted a licence 
for use in MM patients at the time of relapse. There is currently no data that 
bortezomib has any direct effects on the DC system, although there is a report that 
bortezomib mediated cancer cell apoptosis preferentially induces DC maturation 
(Demaria, et a! 2005). 
There was a significant increase in the number of blood mDC1 (meant . 1247 ± 
0.2122 x104/ml) in patients who were taking more than 100mg of thalidomide for 1- 
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3 months (n=12) as compared to patients at the time of relapse (n=12) (p<0.005), 
Figure 3-9. There was no significant change in the number of blood pDG 
(meanO. 3271± 0.0808 x104/mI) and blood mDC2 (0.78 ± 0.16 x103/ml) in patients 
taking thalidomide. The patients in the bortezomib study (n-5) showed no change 
in the number of blood mDC1 (mean 0.5856 ± 0.3490 x104/ml) and blood pDC 
(mean 0.8274 ± 0.7142 x104/ml). There was a statistical significant fall in the 
number of blood mDC2 (0.129 ± 0.048 x103/ml) in the bortezomib group as 
compared to the relapse and thalidomide patients (p<0.05). 
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Figure 3-9 Blood DC subsets at the time of relapse and following therapy 
with thalidomide and bortezomib 
Using flow cytometry and the BDCA antibody kit, we quantified the number of 
blood mDC1, blood pDC and mDC2 in samples obtained from MM patients when 
they had been taking more than 100 mg of thalidomide for 1-3 months (n=12), and 
1 month after receiving bortezomib (n=5). These results were compared to those 
obtained in patients who had relapsed disease (n=12). 
0.1 
0.01 
P<0.005 
" 
" 
" 
P<0.05 
P<0.05 
Dr Simon J Harrison, 2005 Chapter 3-101 
3.1.7 Maturation of blood DC subsets from normal subjects and 
MM patients 
The DC system in MM patients is functionally abnormal. They fail to up-regulate 
costimulatory molecules such as CD80 and CD40, and they are inefficient at 
priming naive T cells against tumour antigen. However, in the study by Brown et 
al, blood mDC from MM patients were identified using the CMRF-44 antibody 
following overnight culture and 30% of these cells were already expressing CD80 
on their surface, prior to maturation. In the Ratta study all blood DC were 
examined for their expression of maturation markers after 72 hours of culture in 
medium without any specific maturation stimulus and then enrichment by 
sequential density gradient centrifugation. They showed a significant reduction in 
the expression of CD40 CD80 and CD86 in MM blood DC compared to time 0, Lut 
no data was collected on the state of maturation of each DC subset and the data 
represents three repeat experiments on cells from the same patient. 
These types of experiments are difficult to perform. They require a large number of 
very rare cell populations, which do not express exclusive surface markers, thus 
they are obtained by a number of negative and positive selection steps. In order to 
simplify this process, we examined whether we could combine blood DC subset 
identification using the BDCA antibodies with an assay which would show the DC's 
ability to up-regulate the surface expression of co-stimulatory molecules such as 
CD40, CD80, CD86 along with expression of phenotypic markers CD1a and 
CD123. Mononuclear cells were isolated by density gradient centrifugation and 
placed in DC culture medium. A sample of cells was analysed for co-expression of 
BDCA, co-stimulatory and phenotypic markers at time zero. The remainder of the 
cells were divided into two aliquots. One was cultured in medium alone, while the 
other had a maturation stimulus added in the form of TNF-a (20ng/ml) and PgE2 
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(10-7M). Cells from each culture condition were analysed after 4 hours and 
overnight culture. 
Cells were analysed by flow cytometry using the BDCA kit having run the 
appropriate negative and compensation controls. As well as analysing the contr9l 
and test samples, 5 additional tubes were stained with the BDCA test antibody 
cocktail, with the addition of an extra FL4 antibody to measure the surface 
expression of CD1a, CD40, CD83, CD86 and CD123. These experiments were 
repeated on three occasions on samples from normal subjects. 
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Figure 3-10 BDCA2 and CD123 double staining of blood pDC control and 
after 4 hours culture 
At time zero, blood pDC were positive for the additional FL4 CD123, as expected, 
and this antibody was included in the panel to act as a positive control. None of 
the other additional antibody stains were positive prior to culture. After 4 hours of 
culture in medium the level of CD123 staining is reduced on the blood pDC (100% 
vs 14%) 
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Figure 3-11 Blood DC expression of CD83 and CD86 after 4 hours culture in 
medium supplemented with TNF-a and PgE2. 
After 4 hours culture in DC medium alone and DC medium supplemented with 
TNF-a and PgE2, the control (plot A) and Test (plot B) are still able to identify the 
blood mDC and blood pDC populations. Plot C and D shows blood pDC 
expression of CD 83 and 86 respectively. Plots E and F show blood mDC 
expression of CD 83 and 86. At 4 hours the number of cells expressing these 
markers of DC maturity has increased from 0% pre-culture, to between 3% and 
7% of each of the DC subset population. 
At 4hrs we were able to show that there is a small but detectable increase in the 
levels of CD83 and CD86 surface staining on both blood mDC and blood pDC9, 
Figure 3-11 and Table 3-2. There was no increase in the level of CD1 a or CD40 
at 4 hours. The surface expression of CD123 on blood pDC was almost 
completely down regulated (-84.64 ± 5.2) after 4 hours of culture in both 
supplemented and plain DC medium. However, following overnight culture in 
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medium alone or supplemented with TNF-a and PgE2, the numbers of cells that 
remained in the blood mDC and blood pDC gates were so low that no meaningful 
estimate of surface expression of other markers could be made. 
CD83 CD 86 CD123 
blood 7.34+0.8 10.03+0.7 
mDC1 
blood 5.52+0.6 8.52+0.5 -84.64+5.2 
pDC 
Table 3-2 Change in the mean fluorescence intensity of maturation markers 
in blood mDC and blood pDC following 4 hours culture in TNF-a 
and PgE2 supplemented DC medium 
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Figure 3-12 BDCA 1 and 2 surface expression after overnight incubation in 
medium supplemented TNF-a and PgE2 
Plot A and B show BDCA 1 and 2 surface expression following overnight culture in 
DC medium (A) or DC medium supplemented with TNF-a (20ng/ml) and PgE2 
(10-7M) (B). 
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3.1.8 Discussion 
Chapter 3-105 
The presence of DC subsets in the blood gives a unique window into the DC 
system in both normal subjects and those patients with malignant disease, such as 
MM. Using the BDCA kit we were able to reliably measure the number 9f blood 
mDC, blood pDC and blood mDC2 in the peripheral blood of normal subjects, with 
our results being comparable with the manufacturers reference range. We also 
validated the use of the kit to reliably measure the number of B lymphocytes in tie 
blood of normal subjects and our results are within a number of published 
reference values (HMDS, Leeds) (Glassman and Bennett 1977, Reichert, et al 
1991). Having validated its use, we went on to use the BDCA antibody kit to 
analyse samples from patients with MM at a number of time points during the 
disease course. 
Using this assay, we found that the number of B lymphocytes in the blood of MM 
patients (mean 0.9386 ± 0.2750 x105 /ml) was significantly lower than in normal 
subjects (p<0.001). There is some debate in the published literature as to whether 
B lymphocyte numbers are suppressed in MM, with various groups reporting 
normal, low and heterogeneous numbers of B lymphocyte in the blood of MM 
patients (Kay, et a11997, Pilarski, et a11984, Rasmussen, et a/2000, Schutt, et al 
2005). Why should B lymphocyte numbers be reduced in MM? MM is a clonal 
disorder of the B cell compartment, and as with other clonal disorders, this may 
represent a simple replacement of the normal cells by the malignant clone. 
Another possibility is that the immunosuppressive cytokines, such as IL-6, IL-10, 
TGF-ß and VEGF secreted by the (pre-) malignant MM plasma cell are actively 
suppressing the development of normal B lymphocytes. A third possibility is that 
epitopes expressed in the CD19 molecule are altered in MM and MGUS patients 
by the cytokines secreted by the malignant clone, preventing some antibodies 
such as Leu-12, FMC-63 and B4 from detecting CD19 molecules. This may go 
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some way to explain the differences in B cell numbers reported in MM patients in 
the literature. The antibody used in our analysis is produced by the LT19 clone, 
which is commonly used for phenotyping CD19+ cells and there are no reported 
discrepancies between normal and MM B cell staining. We also found that the 
number of B cells in the blood of patients with MGUS and plasmacytoma (1.5883 ± 
0.3405 x105 /ml) was also lower than in normal subjects (p<O. 005). This last 
finding was unexpected, as there are no previous reports of cellular immune 
defects in MGUS. However, there are a number of reports of clonal B cell 
populations in the blood of MGUS patients (Pilarski, et al 1996). There is 
speculation as to whether this represents a pre-malignant clone that is awaiting p 
further genetic mutation (2"d hit) to become truly malignant, or a malignant clone, 
that is being held in check by the immune system which is allowed to progress 
when the immune system is down regulated by mechanisms we have discussed 
previously. We feel that these observations warrant further investigation, as they 
may reveal further mechanisms by which the MM clone evolves and induces an 
immunosuppressive state in its host. 
The number of blood mDC1 and blood pDC detected in the blood of MM patients 
with the BDCA antibodies was significantly lower than in the control group. This 
effect was even more pronounced at the time of relapse. The number of blood 
pDC seemed to be particularly affected, especially at the time of relapse. Standard 
induction chemotherapy made no significant improvement in the number of blood 
mDC1 or blood pDC seen in the blood of MM patients. The number of blood 
mDC2 seen throughout the course of the disease was not significantly different 
from the normal population. The number of DC improve in the short term after auto 
HSCT, with the numbers of blood mDC1 returning to within the normal range at 
the time of engraftment (mean 1.52 ± 0.28 x104 /ml) (p>0.05) and subsequently 
maintained up to D100, but then fall back again at one year post auto HSCT. The 
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improvement in blood pDC and blood mDC2 after HSCT is less impressive and 
again the levels were low at one year post auto HSCT. These findings qre 
encouraging, as they reflect the improved survival data that suggest auto HSCT 
has an important role in further reducing the tumour burden in MM patients as 
compared to conventional therapy alone. In the future, these kinds of data may be 
important in deciding upon the timing of immune based therapies, which should 
have the best chance of inducing significant benefits when the disease burden, 
and hence it's immunosuppressive potential, is at it's lowest. Our data on the 
recovery of blood DC following NM alto HSCT was limited due to the very small 
numbers of patients that are eligible for this treatment option. We found that the 
level of all blood DC subsets were low at D100, which appears to be at odds with 
data generated within our group from patients undergoing NM alto HSCT for the 
treatment of CML, which showed that at D100 blood mDC1 numbers were 27-fold 
higher than ND, and the other blood DC subsets were relatively normal (Harrison, 
et a/ 2003). Both of these findings offer only snap shots of complex, dynamic and 
rapidly evolving interactions between the prolonged effects of conditioning therapy 
(i. e. Campath 1 H), the process of immune reconstitution, response to infections 
and the underlying malignant disease. The true picture seems to be one where the 
numbers of blood DC subsets vary dramatically throughout the first year following 
alto HSCT in a series of peaks and troughs (Hart, personal communication). The 
process of blood DC recovery following HSCT will only become better understood 
by studying these aspects of immune reconstitution in a formal, longitudinal study. 
Thalidomide is playing an increasingly important role in the management of 
patients with MM. In the MRC UK myeloma IX study, it is being used in both the 
induction regime for new patients and as single agent maintenance therapy 
following autologous HSCT. Of the many putative modes of action of thalidomide, 
its immuno-stimulatory properties are some of the most interesting. Our finding 
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that the number of blood mDC1 in patients taking thalidomide was significantly 
higher than patients at relapse suggests that thalidomide is able to either stimulate 
the DC system or allow it to recover somewhat from the added insult of disease 
relapse. There are no published data on the clinical effect of thalidomide on bloqd 
DC, but our data are in keeping with the in vitro data which suggests that 
thalidomide is able to improve the ability of MoDC to induce TH1 type responses 
(Mohty, et a! 2002b). The number patients in the bortezomib study were small and 
they had been heavily pre-treated, making the data difficult to interpret. Even so, it 
was interesting to note that the blood mDC1 and pDC numbers were similar to the 
relapse group, while the blood mDC2 numbers were significantly lower that at 
relapse and following thalidomide treatment. As this drug becomes more widely 
used it will be important to assess the impact that it has on the immune system in 
MM and other malignant diseases. 
In the final set of experiments we attempted to use the BDCA antibodies to 
monitor the blood DC response to a maturation signal in a mononuclear cell 
population. We were able to show early up regulation of surface expression of the 
costimulatory molecules CD83 and CD86 on blood mDC and blood pDC and down 
regulation of CD123 on blood pDC at 4 hours. Following overnight culture we were 
not able to reliably identify the blood DC subsets due to down regulation of CD1 c 
and BDCA2. These experiments were able to give some insight into the timing of 
changes in the surface phenotype of blood DC. In order to take these experiments 
further, formal isolation of the DC subsets by either FAGS or magnetic bead 
sorting would need to be performed prior to culture. These experiments require a 
large number of starting cells because of the small target populations and the 
magnitude of cell loss encountered at each step. 
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In summary, The BDCA antibodies allowed us to reliably measure the DC subsets 
and B cell in the blood of normal subjects and patients with MM throughout the 
disease course. The numbers of blood mDC and blood pDC are low thrpughout 
the course of the disease, and only improve for a short period of time following 
autologous HSCT. Thalidomide is able to increase blood mDC1 and blood pDC 
numbers in patients with relapsed disease. 
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4. Results 2 
4.1 MoDC Generation in NDs and MM-patients 
4.1.1 Introduction 
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Multiple myeloma is not curable in the majority of patients, however the immune 
system is able to affect the cure of a small number of young patients via the GVM 
effect seen in alto BMT, but at the cost of increased toxicity. The introduction of 
non-myeloablative alto BMT has attempted to reduce the toxicity of alto BMT and 
thus make it a more viable treatment option in older patients (Shaw, et a! 2003). 
However, this may also reduce the effectiveness of the immune component of the 
therapy against the disease, especially in groups with advanced and heavily pre- 
treated disease (Crawley, et a! 2005a). Many groups around the world are 
therefore attempting to use the autologous immune system to eradicate residual 
MM following standard and high dose conventional chemotherapy. Dendritic cells 
are seen as one of the most promising tools that we can manipulate in order to 
increase a patient's immunity against their residual tumour cells. In the previous 
chapter it was shown that circulating BDC in MM patients are quantitatively 
abnormal. As previously discussed, these cells are also qualitatively abnormal in 
MM patients, thus it is difficult to justify using BDC from MM patients in the 
treatment of their disease. It is possible to produce iDC from steady state or 
mobilised monocytes from ND and patients with malignant disease (Morse, et al 
1999b, Syme, et a! 2001). Alternatively, monocytes can be separated by plastic 
adherence or CD14 selection (Motta, et al 2003, Suen, et a! 2001) and they are 
then cultured in medium supplemented with cytokines such as GM-CSF, IL-4, IL- 
13 and lFN-a (Della Bella, et a/ 2004, Gabriele, et a! 2004, Motta, et a! 2003). To 
date, there are few comparative studies to show if these methods are equally 
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effective and there are almost none to show whether they are equivalent when 
using monocytes from patients with diseases such as MM (Syme, et a/ 2001, 
Tarte, et al 1998). In addition, we are only just beginning to explore how 
therapeutic interventions and the level of residual disease may influence our ability 
to produce immune therapies in the context of malignant disease states. For 
example, Schutt has shown that if MM patients are taking thalidomide, dendritic 
cells produced by in vitro culture from monocytes have a reduced expression of 
DC surface markers such as CD1 a, CD40, CD83, and HLA-DR (Schutt, et al 
2005). The question on how to mature OC is also confused. There are many 
published cytokine combinations containing TNFa, PGE2, IL-1 P, IL-6, CD40L, 
Poly(I; C), IFNs (Luft, et al 2002b) etc. in numerous combinations and doses that 
can be used to produce matDC from Ag-loaded iDC, but there are few 
comparative studies in MM (Curti, et al 2004). 
lt is therefore conceivable that in view of the hostile environment induced by the 
MM tumour cell, with high levels of TGFß etc, monocytes from MM patients may 
produce overall less efficient MoDC. Thus, culture conditions may be even more 
critical for the production of DC for clinical use, which may eventually translate into 
more effective immunotherapy for use in clinical trials, when these cells are 
injected back into the patient and a hostile cytokine environment. 
The aim of the experiments described in this chapter was to examine whether the 
method of iDC production from monocytes influenced the quality and function of 
immature MoDC produced from MM patients vs. ND. We also examined whether 
different maturation cytokine combinations were able to overcome any blockade of 
maturation in MM patient derived DC as compared to cells from ND. 
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4.1.2 A comparison of iDC generation using GM-CSF and IL-4 or 
IL-13 from mobilised monocytes collected from ND$ and h IM 
patients 
In order to examine whether monocytes from NDs and MM patients could equally 
be used to produce iDC using the cytokine combinations GM-CSF and IL-4 or GM- 
CSF and IL-13, monocytes were obtained from subjects who gave informed 
consent and were undergoing stem cell collection at the Apheresis Unit, GRI. NQs 
were conditioned with growth factor (G-CSF) alone, while most MM patients were 
mobilised with growth factor (G-CSF) following myelosuppressive chemotherapy. 
Excess cells that remained in the apheresis harness were harvested immediately 
following the procedure. The PBMC were obtained by density gradient 
centrifugation and then cultured overnight in DC medium to allow the cells to rest 
following the mobilisation and apheresis procedures. The following morning, 
monocytes were purified from PBMC by CD14 magnetic bead separation (Miltenyi 
Biotech). An aliquot of monocytes (2x106) was retained for flow cytometric analysis 
of surface phenotype (Figure 4-1), while the remainder were suspended in DC 
medium at a density of 5x106/ml and placed into 75cm2 tissue culture flasks 
(Coming Life Sciences). The DC medium was then supplemented with GM-CSF 
50ng/ml (Stem Cell Technologies, Vancouver, Canada) and either IL-4 30ng/ml 
(Peprotech) or IL-13 50ng/ml (Peprotech). Cells were cultured for 4 days at 37°C 
and 5% C02, and then assessed by flow cytometry for surface expression of 
markers of DC phenotype (Figure 4-2). 
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Figure 4-1 ND and MM monocyte surface phenotype prior to DC induction 
Monocytes from NDs (n=10) and MM patients (n=10) were collected during stem 
cell mobilisation and purified by density gradient centrifugation and CD14 
magnetic bead separation. Cells were cultured overnight in DC medium and the 
surface phenotype was analysed by flow cytometry prior to culture in DC medium 
supplemented with GM-CSF and IL-4 or IL-13. The results are expressed as the 
percentage of total cells that were positive for the marker. 
The purity achieved by CD14 magnetic bead separation was similar in both the ND 
and MM patient samples (mean 93.8 ± 1.8% vs. 89.9 ± 3.2%). The proportion of 
cells that expressed CD86 (mean 74.4 ± 6.2% vs. 44.7 ± 10.2%, p<0.03), HLA-DR 
(mean 83.6 ± 5.2% vs. 55.8 ± 8.8%, p<0.05) and CCR5 (mean 45.1 ± 6.5% vs. 
21.6 + 10.0%, p<0.05) on their surface was significantly higher in the ND 
monocytes as compared to MM cells. There was also a small, but significant 
increase in the surface expression of CD40 on MM monocytes compared to ND 
cells (mean 7.0 ± 1.9% vs. 3.1 ± 0.7%, p<0.05). 
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Figure 4-2 ND and MM iDC surface phenotype on D+4 DC induction 
An aliquot of ND (n=20) or MM (n=17) iDC (1-2xl 06) was removed after 4 days in 
culture with GM-CSF (50ng/ml) and either IL-4 (30ng/mi) or IL-13 (50ng/mI). The 
number of cells expressing DC markers were analysed by flow cytometry. 
Following 4 days culture in DC medium supplemented with GM/IL-4 or GM/IL-13, 
all iDC down regulated CD14, with no significant difference between ND and MM 
0 
cells. There was an up regulation of the surface expression of CD86, HLA-DR, 
CCR5, CD1 a, and CD1 c on both ND and MM iDC as compared to monocytes. The 
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proportion of ND iDC that expressed CDIc (mean 63.4 ± 4.6% vs. 36.0 ± 6.5%, 
p<O. 003), CD86 (mean 87.2 ± 3.0% vs. 70.9 ± 3.4%, p<O. 001), and CCý5 (mean 
49.1 ± 5.6% vs. 34.2 ± 6.3%, p<0.05) was significantly higher as compared to MM 
iDC. The MFI of HLA-DR (mean 223.0 ± 40.7 vs. 126.3 ± 20.2, p<0.05)'and CD1a 
(mean 34.3 ± 7.2 vs. 11.3 ± 2.0, p<O. 001) surface expression was also 
significantly higher on ND iDC as compared to MM iDC (Figure 4-2). 
There were no significant differences in the surface expression of CDla, CD40, 
CD86, HLA-DR and HLA-class I between iDC from ND and MM patients 
generated with GM-CSF and IL-4, as compared with cells generated with GM-CPF 
and IL-13. These findings are summarised in Table 4-1. 
ND IL-4 ND IL-13 MM IL-4 MM 1113 
CDIa 
CDIc 
42.8+7.0% 
37.2+10.6 
68.6+5.6% 
20.1+3.4 
37.6+8.5% 
30.8+9.9 
29.9+7.5% 
10.7+3.2 
35.6+9.0% 
37.2+10.63 
CD40 
CD86 
CCR5 
HLA-DR 
HLA-class I 
57.2+7.5% 
12.9+2.8 
34.0+8.1% 
6.2+1.7 
51.0+9.0% 40.5+ 10.4% 44.6+8.5% 
19.1+7.3 15.9+8.3 10.5+2.9 
85.7+4.8% 
64.0+16.0 
89.1+3.4% 
51.4+12.8 
72.1+4.0% 
48.4+23.0 
46.9+8.2% 
9.6+3.8 
94.7+2.1% 
197+47.2 
89.4+2.7% 
73.4+18.3 
58.6+9.0% 
12.9+4.3 
94.8+2.7% 
255+71.5 
90.3+3.2% 
93.4+31.9 
27.0+7.8% 
4.8+2.1 
88.8+4.8% 
124+24.8 
81.5+4.0% 
42.2+6.7 
38.4+11.1% 
12.8+7.2 
49.7+10.4% 
11.7+3.6 
69.5+6.0% 
70.4+44.9 
43.9+9.61% 
6.3+2.2 
91.8+3.2% 
129+35.0 
83.7+6.0% 
60.0+13.3 
Table 4-1 Surface phenotype of iDC from ND and MM patients generated with 
GMIIL-4 or GMIIL-13 
The surface phenotype of OC from ND and MM patients generated with GMIIL-4 
(n=1 1 and 9) or GM/IL-13 (n=9 and 8) was expressed as the mean percentage of 
positive cells + SEM (top line) and mean MFI + SEM (bottom line). 
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ND iDC generated with GM-CSF and IL-4 expressed significantly higher levels of 
CD1c (68.6+5.6%, MFI 20.1+3.4) as compared with iDC generated with GM-CSF 
and IL-13 (57.2±7.5%, MFI 12.9±2.8) (p<O. 03 and p<O. 005). Immature QC 
i 
generated from MM patients had significantly higher expression of CD4p when 
generated with GM-CSF and IL-4 (MFI 10.5±2.9) compared with those generated 
with GM-CSF and IL-13 (MFI 11.7±3.6, p<O. 01). In contrast, MM iDC cultured with 
GM-CSF and IL-13 had a higher proportion of CCR5 positive cells (43.9±9.61 %) 
compared with those produce with GM-CSF and IL-4 (27.0+7.8%, p<0.03). Thus 
DC from patients with MM were consistently of poorer quality than cells from NQ 
irrespective of the cytokines used to generate them. 
4.1.3 Phagocytosis of Ag by ND and MM patient iDC generated 
using GM-CSF and IL-4 or IL-13 
One of the main functions of DC is to continuously monitor the in-vivo 
environment for Ag. Immature DC encounter Ag in the peripheral tissues in many 
forms, such as apoptotic bodies, cell debris following necrosis, bacteria, food and 
purified proteins following vaccination. The main way in which iDC take up Ag is by 
simple phagocytosis. Immature DC may also employ a number of more specific 
mechanisms that enhance the efficiency of Ag loading such as CD68 mediated 
uptake of antibody coated particles, HSP uptake via CD91 and the uptake of 
apoptotic bodies via various receptors, including the phosphotidylserine receptor, 
vitronectin receptor and CD36. In order to assess whether iDC from ND and MM 
patients generated with GM/IL-4 and GM/IL-13 were equally efficient at 
phagocytosing particulate Ag, we performed phagocytosis assays using 1 or 2pm 
latex beads that were coated with PE (Sigma). 
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Dendritic cells were suspended in DC medium at a concentration of 1x106/mI, and 
100pl was added to a Falcon tube. Latex-PE beads (1 mg/ml) were diluted 1: 100, 
and 1 Opi was added to each sample. The assay was then incubated at 37°C for 1 
hour. The cells were counter stained with CD11c-FITC, which was added to the 
assays for the final 10mins of the incubation. Excess antibody and non 
phagocytosed beads were removed by washing the cells in 5mls of cold PBS. Toe 
cells were recovered by centrifugation at 800 rpm for 10 minutes, before 
completely removing the supernatant. This was repeated and the cells were 
suspended in 300pl of PBS prior to analysis by flow cytometry, having first run the 
appropriate compensation controls (i. e. unstained cells, Isotype control PE and 
FITC cells, CD11c-FITC positive cells, PE bead positive cells) (Figure 4-3). 
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Figure 4-3 iDC bead phagocytosis assays 
ND OC generated with GM-CSF and either IL-4 or IL-13, were incubated with PE 
labelled 1 or 2 um latex beads and incubated for one hour. Immature DC were 
counter stained with CD1 1cFITC, washed twice in PBS and analysed by flow 
cytometry. Cells may phagocytose more than one bead, and this produces an 
incremental increase in the fluorescence of the cell per bead, as illustrated by the 
arrows and the characteristic 'stripes' within the plots. 
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immature DC generated from ND (mean 59.4 + 3.9%) were significantly better at 
phagocytosing fluorescent latex beads compared to those generated from MM 
patients (mean 20.1 + 2.1 %, p<0.001). The cytokines used to generate the iDC 
made no significant difference to the ability of ND (IL-4 mean 57.2 + 6.6%, IL-13 
mean 61.6 + 4.6%) or MM iDC (IL-4 mean 19.5 + 0.6%, IL-1 3 mean 20.8+ 2.3%) 
to phagocytose fluorescent beads. 
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Figure 4-4 ND and MM iDC latex bead phagocytosis assays 
ND (n=7) and MM OC (n=4) were generated with GMAL-4 and GMAL-13. 
Fluorescent latex bead phagocytosis assays were performed on D4 of culture. 
Live DC were gated on by forward and side scatter and CD1 1c expression, and 
the percentage of cells that have phagocytosed at least one bead are expressed 
as the mean + SEM. 
In order to assess the ability of DC to phagocytose tumour Ag we modified the 
phagocytosis assay by using MM turnour cells, labelled with fluorescent dye, in 
place of PE labelled latex beads. The U266 myeloma tumour cells (HLA-A2) were 
labelled with the PKH-67 green fluorescent dye, which is detected in FL1 and 
washed three times in DC medium. Labelled tumour cells were added to the DC 
at a ratio of 5: 1 to ensure that the number of available tumour cells did not limit the 
rate of DC phagocytosis, and the cells were incubated for 1 hour at 370C. 
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Dendritic cells were counter stained with CD1 1c-PE. The cells were washed in 
PBS and the results were analysed immediately by flow cytometry (Figure 4-5). 
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Figure 4-5 Fluorescent tumour cell phagocytosis assay 
ND DC generated with GM-CSF and either IL-4 or IL-13, were incubated with 
PKH-67 labelled U266 tumour cells and incubated for one hour. Immature DC 
were counter stained with CID1 1c-PE, washed twice in PBS and analysed by flow 
cytometry. 
The results from the fluorescent tumour cell assay were in keeping with the bead 
phagocytosis assay, although iDC were better able to take up turnour-derived 
material as compared to the latex beads. ND derived DC were more efficient at 
phagocytosing tumour cell Ag (mean 70.2 + 3.9%) as compared to OC generated 
from MM patients (mean 34.2 + 6.9%, p<0.001). Once again, the cytokine 
combination that was used to generate the iDC had no significant impact on the 
ability of ND (IL-4 mean 69.8 + 4.2%, IL-13 mean 70.7 + 5.3%) or MM DC (IL-4 
mean 32.5 + 10.3%, 1 L-1 3 mean 36.0 + 10.7%) to phagocytose turnour cell 
derived Ag (Figure 4-6). 
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Figure 4-6 ND and MM patient iDC fluorescent tumour cell phagocytosis 
assay 
ND (n=7) and MM DC (n=4) were generated with GM/IL-4 and GM/IL-13. 
Fluorescent tumour cell phagocytosis assays were performed on D4 of culture. 
Live DC were gated on by forward and side scatter and CID 11 c expression, and 
the percentage of cells that have phagocytosed tumour derived Ag are expressqd 
and the mean + SEM. 
4.1.4 Maturing iDC from ND and MM patient iDC using thq MIMIp 
and X4 cytokine combinations 
It has been known for some time that iDC do not induce potent anti-tumour 
responses, and may even induce tolerance when administered to patients as 
immune therapy. Thus it is crucial to any immunotherapeutic strategy that DC 
achieve a state of full maturity, i. e. up regulate co-stimulatory molecules such as 
CD40, CD80, CD83, CD86 and HLA class I and 11 prior to being given to patien% 
(Nieda, et al 2003). The process of maturation also alters the chemokine receptor 
profile, i. e. down regulation of CCR5 and up regulation of CCR7, which facilitates 
the migration of matDC from peripheral tissues to lymph nodes where they are 
brought into close proximity to na"fve T cells for Ag presentation to occur. As 
previously discussed BDC from MM patients do not up regulate co-stimulatory 
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molecules in response to maturation signals such as TNF-a and PGE2as 
compared to cells from normal subjects. There is some debate as to whether 
MoDC from MM patients mature normally in response to standard matufation 
stimuli (Ratta, et al 2000). A number of strategies have been shown to ipduce DC 
maturation. One of the first methods that was shown to induce effective DC 
maturation was the use of monocyte conditioned medium (Bender, et al 1996), 
however these media are time consuming to produce and are subject to marked 
inter batch variation in responses. Cytokines such as TNF-a can be used alone to 
induce DC maturation, but may be used more effectively in combination with 
PGE2, which seems particularly important in the up regulation of CCR7 (Scandeýla, 
et al 2002). The interaction between CD40 and CD40L is particularly important ip 
the induction of DC maturity in-vivo, and it has been shown that it can be used 
alone or in combination with other cytokines such as ILAP and IFN-a to induce a 
potent maturation of iDC in-vivo (Caux, et al 1994, Luft, et al 2002a, Luft, et al 
2002b). 
The aim of the next set of experiments was to compare the ability of two cytokine 
combinations to induce the maturation of iDC from ND and MM patients generated 
with GM/IL-4 and GM/IL-13. We compared the monocyte conditioned medium 
mimic (MIMIC) combination of TNF-a (10ng/mI) (Peprotech), ILAP (10ng/ml) 
(Peprotech), IL-6 (10ng/ml) (Stem Cell Technologies) and PGE2 00-7M) (Sigma) 
(Feuerstein, et al 2000) with the novel in-house combination X4, TN F-a (1 Ong/ml), 
PGE2 00-7M), Poly (I; C) (10ng/mI) (Sigma) and CD40L (250ng/ml) (Peprotech). 
The X4 combination was rationally designed to maximise the stimulus to the MM 
iDC. In particular, by incorporating the signalling of CD40L via CD40 with the more 
traditional TNF-a signalling via CD120, PGE2 via the eicosanoid receptors 2 and 4 
(EP2 and 4), and finally polyriboinosinic polyribocytidylic acid (poly I: C), which is a 
member of the path ogen-associated molecular patterns (PAMP) group of 
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molecules and signals through Toll-like receptor 3, X4 may overcome the relatively 
poor expression of co-stimulatory molecules on MM DC and the impairment of i 
their up regulation seen in MM BDC, as discussed in the previous chapjer. 
Immature DC were prepared from CD14 selected monocytes from MM patients 
and ND cultured for 4 days in DC medium supplemented with GM/lL-4 or GM/IL, 
13. The DC were then counted and fresh DC media, supplemented with the 
appropriate cytokines, was added so that DC were at a final concentration of 
1 x1 06/ml and placed in two 25CM2 tissue culture flasks. The Ag preparations, 
either apoptotic or freeze-thawed U266 cells suspended at 1 x1 07/ml, were addeo 
to a final ratio of 1 iDC to 1 tumour cell (equivalent to an approximate protein 
concentration of 1 mg/ml) (Thumann, et al 2003). The X4 or MIMIC maturation 
cytokine combinations were added immediately and the cells were cultured 
overnight at 37"C (Thumann, et a/ 2003), with tissue culture flasks standing up- 
right to improve cell contact and phagocytosis. The following morning 2A 06 
matDC generated with the X4 and MIMIC cytokine combinations were removed for 
flow cytometric analysis of their surface phenotype (Figure 4-7a and b). 
The results of the phenotypic analyses of matDC from ND and MM patients are 
surnmarised in Table 4-2. In ND, both X4 (n=15) and MIMIC (n=14) induced up 
regulation of the costimulatory molecules CD40, CD80, CD83, CD86, HLA-DR and 
HLA-Class 1, with X4 producing significantly higher expression of CD80 (mean 
17.1 + 1.8) compared to MIMIC (mean 9.7 + 1.5, pýý0.02). The expression of 
CCR7 in both groups was disappointing, but the proportion of positive cells and 
the level of expression were higher in the X4 treated matDC (mean 12.1 + 2.3%. 
mean 3.3 + 0.9) as compared to the MIMIC treated group mean (mean 9.4 + 1.8% 
p<O. 05, mean 1.8 ± 0.6 p<O. 05). 
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Figure 4-7 Surface phenotype of ND matDC matured overnight with the X4 
(A) and MIMIC (B) cytokine combinations 
DC were gated on using forward and side scatter, and expression of CD1 1c. 
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proportion of CD83 positive cells than the MIMIC treated matDC (mean 65.5 
5.6% vs. 46.3 + 8.3%, p: SO. 05). The level of CD83 expression was also hg er in 
the X4 matDC, but this failed to reach statistical significance. 
All 
Normal Donor 
X4 mimic All 
MM Patient 
X4 mimic 
76 6+3 9% 79.7 + 4.6% 73.3 +6.4% 65.6+5.2% 70.8 + 5.3% 56.0 + 11.0% CD40 . . 43.0±6.1 42.7 ± 6.7 43.3 ±10.8 24.8+3.3 27.8+3.8 19.1+6.7 
6+4.6% 59 67.2+6.4% 51.4+6.2% 64.3+5.4% 70.0+6.0% 53.4+10.6% CDBO . 13.6 ±1.3 17.1 ±1.8 9.7 ±1.5 11 15.9+1.8 17.6+2.0 12.8+3.7 
4% 72 1+4 77.1+5.5% 66.8 + 6.7% 58.9 + 4.9% 65.5+5.6% 46.3+8.3% CD83 . . 30.7 ±4.0 36.4 ±6.6 24.6 ±3.7 15.8+2.3 17.5+6.7 12.5+2.7 
9+3 1% 91 94.1+3.3% 89.6+5.6% 87.7+1.9% +2.3% 88.8 85.7+3.5% CD86 . . 366 ± 57.0 332 ± 77.4 403 ± 85.6 157+32.1 - 158+41.9 143+50.9 
8+1 4% 10 12 1+2.3% 9.4+1.8% 6.5+1.7% 8.3+2.5% 3.1+0.6% CCR7 . . 2.6 ±0.6 . 3.3 ±0.9 1.870.6 4.573.3 1.4+0.4 1.4+0.9 
HLA- 95.6+1.5% 95.1+1.8% 96.1+2.5% 
- 
97.7+4.1% 95.2+1.0% 95.2+12.1% 
DR 394 48.9 371765.1 419 75.5 213731.4 262+41.4 121+30.2 
HLA- 96.4+1.0% 96.3+1.7% 96.5+1.2% 87.2+2.6% 89.3+2.9% 83.2+5.0% 
Class 1 169+18.4 181+24.3 155+28.3 123+22.5 145+30.0 83.5+30.5 
Table 4-2 Phenotype of ND and MM matDC generated with X4 and MIMIC 
cytokine combinations 
Immature DC from ND (n=1 1) and MM (n=9) patients were loaded with Ag and 
simultaneously matured by overnight culture with the X4 (ND s=1 5, MM s=1 9) or 
MIMIC cytokine combination (ND s=14, MM s=7). The results are shown as the 
mean percentage expression + SEM (top line) and the mean MFI + SEM (bottom 
line). 
The results of the surface phenotype of MM matDC were compared to those from 
ND. It was found that the levels of CD40 (mean 24.8 + 3.3 vs. 43.3 + 6.1, 
p: SO. 002), CD83 (mean 58.9 + 4.9% vs. 72.1 + 4.4%, p:! jO. 05 and 15.8 + 2.3 vs. 
30.7 + 4.0, p: SO. 002), CD86 (mean 156.9 + 32.1 vs. 366.3 + 57.0, p: SO. 002), HLA- 
DR (mean 213.0 + 31.4 vs. mean 394.0 + 48.9, p:! iO. 005) and HLA-Class I (mean 
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87.2 + 2.6% vs. 96.4 + 1.0%, p<0.002) expression were significantly reduced 
(Figure 4-8). The level of CD80 and CCR7 expression was similar in the both 
groups. 
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Figure 4-8 Co-stimulatory markers on ND and MM matDC 
Mature DC were generated from ND and MM patient DC by loading with Ag and 
overnight incubation with the X4 or MIMIC combination of cytokines. Samples 
were analysed for surface expression of co-stimulatory molecules by flow 
cytometry. 
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Although the expression of the co-stimulatory molecules on both ND and matDC 
following either the X4 or MIMIC cytokine combination was satisfactory, the level 
of CCR7 up regulation was poor. Therefore, the expression of CCR7 on ND 
matDC was examined after an additional 24hrs incubation in X4 maturation 
medium (n=4) or after 24 hours interacting with autologous T cells (n=6) isolated 
from the apheresis sample by anti-CD3 magnetic bead isolation and cryo- 
preserved in LN2 until the day of the assay. The cells were placed in 24 well plates 
(Corning) at a ratio of 1 DC (JX105/ml) to 10 T cells (1 X1 06/M 1) in TC medium. The 
surface expression of CCR5 and 7 was analysed by flow cytometry (Figure 4-9) 
with live matDC gated by forward and side scatter in both analyses, as there was a 
clear separation between matDC and T cells in the co-culture experiments. 
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Figure 4-9 CCR5 and 7 expression on ND matDC after an extra 24 hrs culture 
in X4 supplemented media or co-culture with autologous T cells 
Immature DC were cultured in X4 supplemented DC medium for overnight. Cells 
were divided into two aliquots. The first was cultured in X4 supplemented medium 
for a further 24 hrs (left), while the second aliquot was cultured with autologous T 
cells at a ratio of 1 DC to 10 T cells for 24hrs (right). The surface phenotype of the 
cells was then analysed by flow cytometry. 
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There was a highly statistically significant up regulation of CCR7 expreýsion in ND 
mat DC culture for 42 hours in X4 (32.4 + 15.7% and 13.4 + 6.3) as compared with 
overnight culture (10.8 + 1.4% and 2.6 + 0.6, p<0.001). Extended culture in 
maturation media, or 24hrs co-culture with autologous T cells produced no 
significant differences in the level of CCR7 expression (13.4 + 6.3 vs. 1 ?. 7 + 2.4) 
or the proportion of positive cells (32.4 + 15.7% vs. 28.69 + 7.6%), as shown in 
Figure 4-10. There was no significant increase in the level of expression of the 
other co-stimulatory molecules in either the extended X4 or T cell matDC. Thesq 
findings indicate that DC rapidly up regulate surface expression of co-stimulatory 
markers during maturation. However, the level of CCR7 expression continues to 
increase with prolonged exposure to a maturation stimulus, such as cytokine or T 
cells. 
0 
CL 
r- 
so 
B Extra 24hrs maturation or co-cutture with autologous TC A 24hrs maturabon 
35 
30 
25 
20 
15 
10 
so 
40 
30 LL 
2 
10 
(D 40 
0 
CL 
30 
020 
P<0.001 % D2 cytokine 
MFI D2 cytokine 
% post TC 
% ND matDC P<0.001 MFI post TC 
MFI ND matDC 
Figure 4-10 CCR7 expression on ND mat DC after overnight maturation 
compared with an additional 24hrs maturation or 24 hrs co-culture with 
autologous T cells 
ND DC were incubated with X4 overnight to induce maturation. The surface 
expression of CCR7 was measure by surface antibody staining and flow cytometry 
(A). Two aliquots of cells were culture for a further 24hrs in either X4 or in co- 
culture with auto T cells, isolated by CD3 magnetic bead isolation, at a ratio of 10 
T cell to 1 DC and the CCR7 expression measured by flow cytometry (B). 
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Dendritic cell based immune therapy of MM has thus far failed to produce 
significant benefits to patients in terms of time to progression and OS. If we are to 
generate meaningful clinical responses, we must learn how to induce autologous 
matDC from MM patients that are able to migrate efficiently to lymph nodes using 
chemokine receptors. Once there, anti-MM matDC should prime an immunogenic 
response to the turnour Ags by the interaction of matDC and T cell via the HLA-Ag 
complex and T cell receptor, and driven by the matDC co-stimulatory molecule 
expression profile. During this process, the therapeutic DC should be resistant to 
the hostile in-vivo cytokine environment generated by the MM tumour plasma cell. 
These experiments shown that, as with the circulating BDC, monocytes from MM 
patients are already different from ND monocytes. They have reduced expression 
of CD86, HLA-DR and CCR5, thus the building blocks of the cellular therapy would 
seem to be abnormal. These changes are almost certainly induced by cytokines, 
such as IL-6 and TGF-P, produced by the MM plasma cells. The reduction of 
CCR5 is interesting in that it's ligand, MIP-l a, is present in increased amounts in 
MM patients and it correlates with the extent of MM bone disease and survival 
(Terpos, eta/ 2003). The increased MIP-1 a levels may directly lead to a 
homeostatic down regulation of CCR5 expression on MM monocytes, interfering 
with their ability to respond to pro-inflammatory chemokines. 
Using CD14 positively selected monocytes collected during stem cell mobilisation, 
iDC were produced using either GM-CSF/IL-4 or GM-CSF/IL-13 from both ND and 
MM patients. Within the two subject groups, the cytokines used to generate the 
DC made little impact on the quality of the cells that were produced in terms of 
their phenotype and phagocytic function. However, when MM iDC were compared 
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with ND iDC they were found to be of infefior quality. The surface expression of 
CD1 a, CD1c, CD86, HLA-DR and CCR5 was significantly reduced on MM iDC, 
and their ability to phagocytose Ag was also significantly impaired, as measured 
by the fluorescent latex bead and tumour cell assays. It was not possible to 
overcome these deficiencies in the MM iDC using either of the cytokine 
combinations chosen to generate iDC. The question that was addressed next wps 
whether the X4 or MIMIC maturation cytokine combinations were able to produce 
improved maturation of the MM iDC. 
The maturity of the DC used in immunotherapy is crucial. Immature DC will tend to 
induce a toleragenic rather than immunogenic T cell response. It was hoped that 
by maximising the maturation stimulus it might be possible to overcome the 
inhibition of MM DC maturation previously reported. The X4 and MIMIC cytokine 
combinations were given to the iDC from ND and MM patients in overnight culture 
at the same time as the Ag preparations for two reasons; firstly to speed up the 
process of DC production, and secondly to give the Ag in the context of a pro- 
inflammatory environment, in a bid to increase the chances of generating an 
immunogenic rather than a toleragenic response to the chosen Ag. ND matDC 
generated with X4 had an increase in the expression of CD80 and CCR7 
compared to MIMIC matured matDC, while the MM X4 matDC had an increase in 
CD83 expression. Unfortunately, MM matDC had significantly reduced CD40, 
CD83, CD86, HLA-DR and Class I expression compared to ND matDC 
irrespective of the maturation cytokine combination used. The level of CCR7 
expression was disappointing in both ND and MM patient cells. We went on to 
show that this continues to up regulate for 24hrs when ND DC are cultured with 
cytokines or autologous T cells, thus increasing the time in the cytokine 
combination media seems to have no benefit over placing the mat DC in culture 
with T cells in-vitro. However in-vivo, DC need to migrate to lymph nodes in order 
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to encounter naive T cells to interact with. Thus when producing matDC for use in 
patients, extending the time spent in maturation media is likely to be of benefit, as 
the DC need to be administered in a state that enables them to migrate 
immediately to lymph nodes. 
Overall these results show that MoDC from MM patients are phenotypically and 
functionally abnormal at all stages of the production process, including the freshly 
isolated monocytes. It was not possible to completely overcome these defects 
using the various combinations of cytokines, however, cells generated with IL-4 or 
11-13, and matured with X4, produced the best quality matDC. In order to further 
improve the quality of DC obtained from MM patients a number of strategies could 
be investigated. Monocytes were obtained from MM patients that had been 
harvested following chemotherapy and G-CSF, rather than G-CSF alone, as in the 
ND group. In order to examine the impact of the mobilisation regimen on DC 
production on cells from MM patients' further, chemo-mobilised cells from could be 
compared with monocytes obtained with G-CSF alone or collected in a steady 
state. It is not ethical to mobilise cells from ND using chemotherapy. To examine 
the impact of MM on the quality of DC produced using chemo-mobilised cells, it 
may be better to compare MM cells to those collected from patients with malignant 
diseases such as Non-Hodgkin's Lymphoma (NHL), as these conditions are not 
thought to have a significant negative impact on the host immune system. 
The experiments described in this chapter, cells were collected at an unspecified 
level of residual disease. Therefore it is not possible to say whether cells collected 
from patients with a higher level of residual disease produced DC that were of 
poorer quality than those from patients with undetectable disease. This is an 
obvious comparison to perform in future studies. Finally, there are other 
compounds such, as IFN-a, that have been used for MoDC production, and the 
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use of more novel cytokine combinations for DC production could be examined in 
mm. 
In conclusion, matDC were produced from MM patients and ND using monocytes 
mobilised at the time of stem cell collection. The matDC produced from MM 
patients were of poorer quality as compared to those from ND, despite using 
combinations of GM/IL-4, GM/IL-13, X4 and MIMIC in the production prpcess. Te 
combinations that contained the X4 maturation cocktail produced the best quali 
matDC. In the next chapter the functional interaction of MM matDC with 
autologous MM T cells will be discussed. 
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5. Results 3 
5.1 Optimisation of autologous anti-MM cytotoxic T cell 
production using matDC and T cell pre-stimulation 
5.1.1 Introduction 
Dendritic cells are crucial to the initiation and co-ordination of the immune 
response. However, one of the most important, complex, and perhaps least 
understood parts of this process, is the interaction of DC with immune effector 
cells such as T, NK and NKT cells. These interactions require close cell-to-cell 
contact and the interface between DC and T cells via receptors and cytokines has 
become known as the immunological synapse (Creusot, et al 2002). In this 
chapter we will concentrate on the interaction between DC and T cells, one of the 
main effector cells of the adaptive immune system. Na*fve T cells can be primed by 
DC to differentiate into antigen specific cytotoxic T cells, and this is the main goal 
when using DC as an anti-tumour immune therapy, where the antigen is an tumour 
specific one. Unfortunately, this is not the only possible outcome of this interaction. 
Depending on the state of DC maturation (Benvenuti, et al 2004), the affinity of the 
T cell receptor for the antigen being presented, the availability of T cell 
help/regulation and the cytokine environment, DC may induce abortive T cell 
proliferation, T regs (Fiore, et a/ 2005) or even clonal deletion. T cells are also 
susceptible to the immunosuppressive effects of the MM turnour cells induced by 
cytokines such as IL-6, IL-10, TGF-P and VEGF. 
Previously, our group has described a defect in MM T cells, induced by TGF-P, 
which prevented normal T cell proliferation in response to IL-2 (Cook, et a/ 1999). 
It was also reported that pre-stimulation with anti-CD3 antibody and IL-1 5 
reinstates the MM T cell proliferative response to IL-2. It is not known whether this 
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method of reinstating the T cell response to IL-2 can be transferred to the DC: T 
cell interaction, thus improving the proliferative capacity of T cells in response to 
DC stimulation alone, or combined with IL-2. It is also not known whether this can, 
in turn, increase the ability of antigen primed MM T cells to kill MM turnour cells. 
The aims of the expedments described in this chapter are to answer the following 
questions. 
1. Can MM T cell pre-stimulation improve the proliferative response to DC 
alone and in combination with IL-2? 
2. Do MM matDC produced with the MIMIC or X4 cytokine combinations 
have the same ability to induce MM T cell proliferation? 
3. Does the cytokine profile produced during the DC: T cell interaction vary 
with T cell pre-stimulation? 
4. Are pre-stimulated, DC primed MM T cells better able to kill MM tumour 
cells compared to un-stimulated and ND T cells? 
5.1.2 AID and MM T cell proliferation in response to IL-2 with and 
without T cell pre-stimulation. 
In the published experiments that showed pre-stimulation of MM T cells with anti- 
CD3 antibody and IL-15 improved the proliferative response of MM T cells to IL-2, 
we used tissue culture plates pre-coated with anti-CD3 antibody. This is a 
relatively inefficient method to stimulate T cells, as the antibody is only available in 
one plane of the T cell at a time. Physiologically, T cells are stimulated in 3- 
dimensions, and grow best when allowed to form cell balls or clusters. To improve 
the efficiency of our pre-stimulation system we substituted the pre-coated plates 
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with T cell activation beads (a kind gift, Dr John Campbell, Miltenyi Biotec), which 
are inert, magnetic particles conjugated to anti-biotin monoclonal antibody. This 
facilitates the beads being loaded with biotinylated molecules, in our carpe anti- 
CD2, anti-CD3 and anti-CD28. 
T cells were collected from ND and MM patients at the time of stem cell harvest 
and prepared by density gradient separation and anti-CD3 magnetic bead 
isolation. Sixty percent of the T cells were cryo-preserved, while 40% were pre- 
stimulated With beads and either IL-2 or IL-15 (MM cells only). Prior to re- 
stimulation with IL-2, the beads were removed from the T cells, resuspended at 
5x1 06/ml in T cell medium and cultured overnight in 6 well tissue culture plates tp 
rest. The cryo-preserved T cells were recovered, washed and cultured overnight in 
T cell medium, in a6 well plate at a density of 5x1 06/ml. Both cryopreserved and 
Pre-stimulated T cells were then used in T cell proliferation and DC co-culture 
expe(iments. 
The following morning, the rested T cells were harvested into 15ml tubes, 
centrifuged at 1200rpm for 5mins and resuspended in fresh warm T cell medium at 
5A 05/ml. The proliferation assays were then set up with 2 quad sets of 200pl 
samples for each test condition. Interleukin-2 was added to one set of samples, 
final concentration 20p/ml, while the other set of samples acted as an un- 
stimulated control. The results were analysed using the mean values of the total 
counts for each sample quad minus the mean of the background rate of 
proliferation in the un-stimulated control quad (Figure 5-1). 
There was no statistical difference between the un-stimulated ND (mean 
13329+2569) and MM (mean 10573+2228) T cell proliferative response to 11-2. 
The IL-2 proliferative response of either ND (mean 22643+3403) or MM (mean 
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24772+ 5250) T cells pre-stimulated with beads and IL-2 was significantly 
enhanced as compared to un-stimulated cells (p<0.05 and p<0.01 respectively). 
The response of the IL-15 and bead pre-stimulated MM T cells (mean 
12525+3130) was not improved. 
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Figure 5-1 ND and MM T cell proliferation in response to IL-2 with and 
without pre-stimulation 
T cells from ND and MM patients were isolated using anti-CD3 magnetic beads at 
the time of stem cell harvest. An aliquot of cells was pre-stimulated with T cell 
activation beads and either IL-2 or IL-15 (MM patients only) for 3 days. The 
remaining cells were cryopreserved and recovered on day 3. Both the activated 
and cryopreserved cells were rested over night and then set up at 1 X1 06/M I in aT 
cell proliferation assay with and without IL-2 (201U/ml) and read on day 3 having 
been exposed to 3H-thymidine for the final 18hrs. 
These findings would appear to be at odds with our previously published results. 
However, our previous results were obtained using cells from MM patients at the 
time of diagnosis. The cells used in these experiments were obtained at a time 
when the patients have had a significant amount of therapy, and the disease 
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burden is likely to be at a much lower level. Consequently, any suppressive effects 
of tumour cell defived TGFP may be less pronounced or absent. 
5.1.3 The proliferative response of ND and'MM cryopreserved and 
pre-stimulated T cells to autologous matDC in the presence 
and absence of IL-2 
In our next set of experiments we examined the T cell proliferative response, with 
and without pre-stimulation, to autologous matDC from ND and MM patients in the 
presence and absence of exogenous IL-2. T cells and monocytes were obtained at 
the time of stem cell harvest, and purified by density gradient centrifugation and 
magnetic bead isolation. Mature dendritic cells were generated with GM/lL-4 or 
GM/IL-13 and simultaneously loaded with antigen (U266 apoptotic cells or lysate 
preparation) and matured with the X4 or MIMIC cytokine combination. T cells were 
pre-stimulated with T cell activation beads, and either I L-2 or I L-1 5 for 4days, then 
rested overnight. An aliquot of T cells was cryopreserved to act as an un- 
stimulated control. 
A proliferation assay was set up With a DC: TC ratio of 1: 10 in the presence and 
absence of IL-2 (201U/ml), with matDC alone and T cells + IL-2 as controls. The 
cultures were analysed after 3 days incubation at 370C and the results are 
expressed as the mean number for DC: TC or DC: TC: IL-2 quads minus the means 
of the DC and T cell quads alone, as shown in Figure 5-2. 
The most striking observation was that pre-stimulation of T cells blocks the ability 
of ND (mean 3815 + 1632) and MM (mean 2492 + 874) T cells to proliferate in 
response to matDC as compared to un-stimulated T cells (ND mean 12794 + 1455 
and MM 10890 + 2542). The proliferative response of un-stimulated ND and MM T 
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cells to matDC alone was similar (mean 12794 + 1455 vs. mean 10890 + 2542) as 
was the result obtained using pre-stimulated T cells and matDC in the presence of 
IL-2 (ND mean 31501 + 3362 vs. MM 30583 + 2397). 
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Figure 5-2 ND (A) and MM (B) patient un/pre-stimulated T cell proliferative 
response to autologous matDC in the presence and absence of 
IL-2 
ND and MM T cells and monocytes were isolated at the time of stem cell harvest. 
An aliquot of T cells was cryopreserved to act as controls; the remainder were 
stimulated for 4 days with T cell activation beads and either IL-2 or 11-15 and the 
rested overnight. Monocytes were cultured with GM/IL-4 or GM/IL-1 3 for 4 days, 
and then simultaneously loaded with antigen and matured with the X4 or MIMIC 
cytokine combinations. The Proliferation assays were set up in quadruplicate at a 
DC: TC ratio of 1: 10 + IL-2 (201U/ml) with stimulated and un-stimulated T cells. T 
cells + IL-2 and DC alone were used as positive and negative controls. The results 
represent the mean of each test quad minus the means of the T cells and DC 
alone quads. 
There was a trend for the ND T cell +DC + IL-2 proliferation (mean 31259 + 3838) 
to be higher than that seen in the MM patients (mean 24246 + 4381), but this did 
not achieve statistical significance. The pre-stimulated MM T cells proliferated 
better in response to matDC and IL-2 (mean 30583 + 2397), as compared to the 
un-stimulated MM T cells (mean 24246 + 4381), but this again failed to achieve 
statistical significance. 
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We went on to examine whether the DC maturation cytokine combination or the 
cytokine used for the T cell stimulation had an impact on the proliferative response 
of the T cells to DC in the presence and absence of IL-2 (Figure 5-3). 
A NU unstimulaiea 
40000 
8 
2 
0 
c cc 
0 
40000 
20M 
0 
ND x4 DCTC n=10 
ND X4 DCTC IL-2 
ND MIMIC DCTC 
ND MIMIC DCTC IL-2 
It, 
,, ) 40OW 
m 20000 
0 
.4 
40000 
20000 
(5 
B ND pre-stimulated TC 
0123 
I= ND prestim x4 DCTC n=9 
ND prestim X4 DCTC IL-2 
ND prestim MIMIC DCTC 
ND Prestim MIMIC DCTC IL-2 
D MM pre-stimulated TC 
012345012345 
= MM X4 OCTC KM MM p(OSUM X4 DCTC n=8 M UM X4 DCTC IL-2 ý MM pmstim X4 DCTC IL-2 
= MM MIMIC DCTC ü= MM prffln DCTC 
= MM MIM#C DCTC IL-2 M MM prestim DCTC IL-2 
Figure 5-3 ND and MM patient un-stimulated and pre-stimulated T cell 
proliferative response to autologous X4 and MIMIC matDC 
ND and MM T cells and monocytes were isolated at the time of stem cell harvest. 
An aliquot of T cells was cryopreserved to act as controls; the remainder were 
stimulated for 4 days with T cell activation beads and IL-2 or 11-15 and the rested 
overnight. Monocytes were cultured with GM/IL-4 or GM/IL-1 3 for 4 days, and then 
simultaneously loaded with antigen and matured with the X4 or MIMIC cytokine 
combinations. The Proliferation assays were set up in quadruplicate at a DC: TC 
ratio of 1: 10 + IL-2 (201U/ml) with stimulated and un-stimulated T cells. T cells + IL- 
2 and DC alone were used as positive and negative controls. The results 
represent the mean of each quad, minus the means of the T cells and DC alone 
quads. 
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Although the proliferation of un-stimulated T cells was greater with MIMIC than X4 
matDC in both the ND and MM patients, there were no significant differences in 
the ability of ND or MM patient matDC generated with X4 or MIMIC to induce 
control or pre-stimulated T cell proliferation and the results are summarised in 
Table 5-1. 
DC TC DC TC IL-2 Pre Stim Pre Stim DC TC DC TC IL-2 
ND X4 10108 27150 2245 30365 
+1755 +5279 +1363 +4865 
ND MIMIC 14344 33640 5032 31595 
+2258 +4325 +2780 +4484 
10468 22378 2502 30582 MM X4 +3326 +5045 +1115 +3046 
mm mimic 11624 27107 2476 30585 +2972 +5981 +1462 +4104 
Table 5-1 ND and MM patient mean and SEM of control and pre-stimulated T 
cell proliferation in response to X4 and MIMIC matDC 
We found that there was a trend for the proliferation of MM T cells pre-stimulated 
with beads and IL-2 in response to matDC, in the presence of IL-2 (mean 33626 
2936) to be greater than MM T cells stimulated with beads and IL-1 5 (mean 23737 
7458), but this just failed to achieve statistical significance (p=0.055), Figure 
5-4. 
In summary, we found that T cells collected at the time of stem cell harvest are 
able to proliferate relatively normally in response to IL-2. Pre-stimulation of ND and 
MM patient T cells with anti-CD2, anti-CD3 and anti-CD28 coated beads, and IL-2, 
significantly increases their proliferative response to IL-2, but pre-stimulation of 
MM T cells with beads and IL-1 5 had no significant effect. 
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Figure 5-4 The proliferative response of ND and MM patient T cells pre- 
stimulated with beads and IL-2 or IL-15 to matDC in the presence 
of IL-2 
ND and MM T cells and monocytes were isolated at the time of stem cell harvest. 
An aliquot of T cells was cryopreserved to act as controls; the remainder were 
stimulated for 4 days with T cell activation beads and IL-2 or IL15 and the rested 
overnight. Monocytes were cultured with GM/IL-4 or GM/IL-1 3 for 4 days, and then 
simultaneously loaded with antigen and matured with the X4 or MIMIC cytokine 
combinations. The Proliferation assays were set up in quadruplicate at a DC: TC 
ratio of 1: 10 + IL-2 (201U/ml) with stimulated and un-stimulated T cells. T cells + IL- 
2 and DC alone were used as positive and negative controls. The results 
represent the mean of each quad minus the means of the T cells and DC alone 
quads. 
Pre-stimulation blocks the proliferative response of ND and MM patient T cells to 
autologous matDC alone. Although the proliferation of pre-stimulated T cells in the 
presence of IL-2 and mat DC was higher than the un-stimulated T cells, it did not 
achieve statistical significance. The proliferation of MM T cells pre-stimulated with 
beads and IL-2 induced by autologous mat DC in the presence of IL-2 was 
significantly better than that achieved by those pre-stimulated with beads and U 
15 
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5.1.4 The measurement of cytokines secreted during the T cell 
matDC interaction by Luminex technology from MM patients 
and ND 
The interaction between T cells and DC is complex, and involves both contact and 
cytokine dependant processes. Cytokines, such as IL-2, may be secreted within 
the immunological synapse, while others may be secreted in a more generalised 
manner. Traditionally these cytokines have been detected using a solid phase (96 
well plate) ELISA for each analyte to be measured, making it difficult to measure a 
number of cytokines because of cost, the size of the sample required and the time 
taken for each ELISA. Luminex technology allows multiple different ELISAs to be 
performed concurrently on the same sample in the same well (Carson and Vignali 
1999). 
This has been achieved by linking the capture antibody for each analyte to a 
polystyrene bead that has a unique and fixed fluorescence signature (Vignali 
2000). This signature is achieved by mixing two fluorescent dyes in up to 100 
different ratios to allow labelling of 100 different analytes simultaneously. The 
detection antibody is biotinylated, and the binding of a streptavidin-PE conjugate 
to the detection antibody allows the system to identify beads that have bound to 
their specific analyte. The detection system is based around two lasers and a flow 
cell similar to that of a flow cytometer. The sample is passed through the beams of 
each laser sequentially in a stream that allows one bead to be interrogated by the 
laser at a time. The first laser determines the identity of the bead (i. e. which 
analyte is being detected), and the second laser determines whether there is 
analyte bound to the bead, i. e. is there Strep-PE bound to the bead? The machipe 
aspirates a fixed volume of sample and the concentration of beads is fixed, 
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allowing the analysis software to calculate the concentration of each analyte to be 
measured. 
The DC and T cells used in these experiments were prepared as described above 
in 5.1.3, washed once in fresh T cell medium and co-cultured at a ratio of 1 DC 
(1 x1 06/ml) to 10 T cells (1 x1 06/ml) in 24 well tissue culture plates. The 
supernatants were collected after 3 days, snap frozen in 1.5ml Eppendorf tubes 
and stored at minus 800C. A multiplex kit was used to measure GM-CSF, IFN-a, 
IL-2, IL-4, IL-6, IL-7, IL-10, IL-12p7O, IL-15, TNF- a, and VEGF. The assay was 
performed as per the manufacturers instructions and read on a Luminex 1 OOTm 
instrument. Each sample was analysed in duplicate and the results were 
expressed as the mean of the two observations. Data was obtained from 38 DC T 
cell supernatants, from 6 ND and 4 MM patients and is shown in Figure 5-5. The T 
cells from 2 ND and MM patients had been pre-stimulated with beads and IL-2, 
and un-stimulated T cells were used from all 10 subjects. 
The most striking observation was that there was almost no IL-2 detected in the 
supernatant from the reactions in which T cells that had been pre-stimulated With T 
cell stimulation beads (mean 0.3pg/ml + 0.1), as compared to un-stimulated cells 
(mean 98.2pg/ml + 33.42), and this was highly statistically significant (p: s 0.001). 
The level of I L-1 0 detected in the un-stimulated T cell group (mean 62pg/ml + 32) 
was significantly higher than the bead-stimulated cells (mean 2pg/ml + 2, p: SO. 01). 
The amount of GM-CSF (mean 348pg/ml + 168, p: SO. 05) and TNF-a (mean 
991pg/ml + 470, p: ý0.01) was also significantly higher in the un-stimulated T cell 
reaction (mean 24.8pg/ml + 14.6, mean 18.6pg/ml + 9.4 respectively) as 
compared to the bead-stimulated cells. 
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Figure 5-5 IL-2, IL-10, GM-CSF and TNF-cx levels detected in the supernatants 
of ND and MM DC and T cell co-cultures by LurninexTm 
technology 
To facilitate antigen presentation, DC from ND (n=6) and MM patients(n=4) 
produced from monocytes collected at the time of stem cell harvest, cultured with 
GM/IL-4 or GM/IL-1 3, Ag primed with U266 cell lysate and matured with X4 or 
MIMIC cytokine combination were co-cultured with T cells pre-stimulated with 
beads and IL-2 (n=4, MM=2, ND=2) or cryopreserved un-stimulated cells (n=10, 
MM=4, ND=6). The supernatants were harvested after 3 days and the levels of IL- 
2, IL-10, GM-CSF and TNF-cx were measured using the Luminex system. 
There was some concern that these levels could, at least in part, have been due to 
the cytokines added to the DC cultures during the generation of maturation phase. 
However, all cells were washed prior to the co-culture experiments, and the DC 
used in each arm of the experiments had had identical treatment and cytokine 
exposure. 
The level of IL-6 detected in the un-stimulated T cell group (mean 48.8pg/ml 
22.5) was similar to the bead stimulated T cell group (mean 31.0pg/ml ± 4.8) 
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Figure 5-6. However, a statistically higher amount of IL-6 was detected in the 
supernatants from DC matured with X4 cocktail (mean 57.05pg/ml + 9), which 
contained no IL-6, as compared with MIMIC matured cells (mean 31.8pg/ml + 6, 
p<0.005), which were exposed to lOng/ml IL-6. 
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Figure 5-6 IL-6 levels detected in the supernatants of ND and MM DC and T 
cell co-cultures by LumineXTM technology 
To facilitate antigen presentation, DC from ND and MM patients produced from 
monocytes collected at the time of stem cell harvest, cultured with GM/IL-4 or 
GMAL-13, Ag primed with U266 cell lysate and matured with X4 or MIMIC cytokine 
combination were co-cultured with T cells pre-stimulated with beads and IL-2 or 
cryopreserved un-stimulated cells. The supernatants were harvested after 3 days 
and the levels of IL-6 were measured using the Luminex system. 
We did not detect any significant levels of IL-4, IL-7, IL-12p7O, IL-15, IFN-a or 
VEGF. Interestingly, no differences in cytokine levels were detected between ND 
and MM cells, or between the cytokines used to generate the DC. 
In summary the LuminexTm system is a reliable, straightforward method to detect 
multiple cytokines simultaneously in small volume samples. Pre-stimulation of T 
cells with T cell activating beads and IL-2 significantly reduces the amount of GM- 
CSF, IL-2, IL-10 and TNF-a detected in the supernatants of T cell, DC co-cultures, 
as compared to those using un-stimulated cells. The IL-6 detected was higher in 
the X4 matured DC cells. No significant amounts of IL-4, IL-7, IL-12p7O, IL-15, 
IFN-a or VEGF were found. 
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5.1.5 In-vitro cytotoxicity of AID and MM T cells following co- 
culture with autologous matDC and the effect of T cell pre7 
stimulation with T cell activation beads and IL-2 
The anti-tumour effects of DC based immune therapies are mainly mediated via 
cytotoxic T cells, although a number of groups are investigating effects that may 
be induced by the interaction of DC with NK and NKT cells. In order to quantify the 
potency of the cytotoxic T cells generateed from ND and MM patients, it was 
decided to use a modification of the flow cytometry based assay in which 
fluorescently stained target tumour cells are co-incubated with un-labelled effector 
cells. This allows the target cells to be easily gated and then the number of dead 
target cells can be quantified by annexin-V (a marker of early apoptosis) and either 
I 
PI or MAD (necrotic) staining (Derby, et al 2001, Fischer, et al 2002). In these 
analyses 7AAD was used rather than propidium iodide because it has much less 
spectral overlap and is therefore much easier to compensate. 
The first set of experiments investigated whether the pre-stimulation of ND and 
MM patient T cells with T cell activation beads and IL-2, and then further 
expansion with IL-2 alone, was sufficient to induce significant cytotoxicity using the 
annexin-V/ MAD assay. T cells were stimulated for 3 or 4 days with T cell 
activating beads and IL-2. The beads were then removed and the T cells were 
expanded in IL-2 supplemented TC medium for 2-4 weeks. Prior to use in the 
cytotoxicity assay dead cells were removed by density gradient centrifugation 
Cytotoxicity assays were set up in duplicate with effector: target cell ratios ranging 
from 16: 1 to 1: 16, cultured for 18hrs and the assays were read by flow cytometry 
within 1 hour of annexin-V and MAD staining. A total of 20,000 target cell events 
were collected per tube and representative plots are shown in Figure 5-7. 
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Figure 5-7 Cytotoxicity assay gating for controls and 2 dilutions 
The left-hand plot shows that only cellular events are gated in R1. The middle plot 
shows that T cells are excluded from the analysis using R2. The right-hand plot 
shows that >95% are alive control target cells in the logic gate G3 (R1 and R2), 
less than 1% of T cells appear in the analysis, and that the cytotoxic effects of the 
T cells are dose dependant. 
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The results for each dilution were expressed as the mean number of dead test 
cells minus the number of dead cells in the Target alone control and the results 
are shown in Figure 5-8. 
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Figure 5-8 ND and MM bead pre-stimulated T cell cytotoxicity assay 
T cells from ND(n=4) and MM (n=5) patients were collected at the time of stem cell 
harvest, pre-stimulated with T cell activating beads and IL-2 and expanded with U 
2 for 2-4 weeks. They were placed in culture with PKH-26 labelled U266 MM cell 
targets at effector target ratios between 16: 1 and 1: 16, incubated overnight, and 
the degree of target cell kill was assessed using Annexin-V and 7AAD staining by 
flow cytometry. 
There was a small cytotoxic effect detected at the highest effector target ratio 8: 1 
using MM bead T cells, with a mean of 29.5% + 8.3 of targets killed, and at 16: 1 
with ND bead T cells, 18.4% + 7.4. At the effector target ratio of 8: 1, MM pre- 
stimulated T cells produced statistically more tumour cell kill than ND pre- 
stimulated T cells (p< 0.005). There was no difference in the cytotoxic activity of 
pre-stimulated T cells from ND or MM patients at any other dilution. 
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We next compared the cytotoxic activity of MM pre-stimulated T cells with T cells 
that had also had been primed with antigen loaded autologous DC, and un- 
stimulated T cells that had been primed with antigen loaded autologous DC, 
Figure 5-9. 
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Figure 5-9 Cytotoxicity of pre-stimulated MM T cells, DC primed pre- 
stimulated MM T cells and DC primed un-stimulated MM T cells 
T cells from MM patients (n=5) were collected at the time of stem cell harvest. An 
aliquot of cells was cryopreserved and the remainder were pre-stimulated with T 
cell activating beads and IL-2 for 3-4 days. An aliquot of pre-stimulated T cells was 
expanded with IL-2 for 2-4 weeks as an antigen negative control. The remainder of 
the pre-stimulated cells, and the cryo-preserved un-stimulated T cells, were 
primed with autologous antigen loaded DC, expanded in IL-2, re-stimulated with 
DC after 7days and expanded in IL-2 for 3-6 weeks. T cells were placed in culture 
with PKH-26 labelled U266 MM cell targets at effector target ratios between 8: 1 
and 1: 8, incubated overnight, and the degree of target cell kill was assessed using 
Annexin-V and 7AAD staining by flow cytometry. 
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Pre-stimulated MM T cells primed with autologous DC were significantly more 
effective at killing target cells, compared to un-stimulated, DC primed, MM T cells 
with (p< 0.05). Pre-stimulated T cells that had been primed with autolo 9 ous DC 
were significantly more effective at killing target cells at all ET ratios compared to T 
cells that had only been pre-stimulated with beads and IL-2 (p< 0.05). Although 
un-stimulated DC primed T cells were more effective at killing targets compared to 
pre-stimulated only T cells, this did not reach statistical significance at Iny effector 
target ratio. 
The results obtained using ND pre-stimulated T cells were then compared with 
those generated using ND un-stimulated T cells, primed with autologous antigen 
loaded DC, Figure 5-10. Again no difference was observed between the two 
groups at any effector target ratio. 
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Figure 5-10 Cytotoxicity of pre-stimulated ND T cells and DC primed un- 
stimulated ND T cells 
T cells from ND (n=5) were collected at the time of stem cell harvest. An aliquot of 
cells was cryopreserved and the remainder were pre-stimulated with T cell 
activating beads and IL-2 for 3-4 days and expanded with IL-2 for 2-4 weeks as an 
antigen negative control. The cryo-preserved un-stimulated T cells were primed 
with autologous antigen loaded DC, expanded in IL-2, re-stimulated with DC after 
7days and expanded in IL-2 for 3-6 weeks. T cells were placed in culture with 
PKH-26 labelled U266 MM cell targets at effector target ratios between 8: 1 and 
1: 8, incubated overnight, and the degree of target cell kill was assessed using 
Annexin-V and MAD staining by flow cytometry. 
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In the final analysis the effectiveness of MM pre-stimulated and un-stimulated T 
cells were compared with un-stimulated ND T cells, which had all been primed 
with autologous antigen loaded DC, Figure 5-11. 
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Figure 5-11 Comparing the cytotoxicity of DC primed pre-stimulated MM T 
cells (n=19) with DC primed un-stimulated MM (n=14) and ND T 
cells (n=20) 
T cells from ND (n=5) and MM patients (n=5) were collected at the time of stem 
cell harvest. T cells were cryopreserved. An aliquot of MM T cells were pre- 
stimulated with T cell activating beads and IL-2 for 3-4 days and then rested 
overnight. All T cells were primed with autologous antigen loaded DC, expanded in 
IL-2, re-stimulated with DC after 7days and expanded in IL-2 for 3-6 weeks. T cells 
were placed in culture with PKH-26 labelled U266 MM cell targets at effector target 
ratios between 8: 1 and 1: 8, incubated overnight, and the degree of target cell kill 
was assessed using Annexin-V and 7AAD staining by flow cytometry. 
Multiple myeloma DC primed, pre-stimulated T cells were significantly better at 
killing target tumour cells compared to ND un-stimulated DC primed T cells 
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(p: S 0.001). T cells from MM patients that had only been primed with DC were 
significantly better at killing targets at the highest two effector target ratios 
(P: s 
In summary, it was found that the flow cytometry based cytotoxicity assay was an 
effective way of determining the killing ability of T cell line generated by pre- 
stimulation with T cell activating beads and/or antigen loaded autologous DC. The 
most effective cytotoxic cells were MM patient T cells that had been pre-stimulated 
and primed with DC, followed by MM patient T cells that had only been primed 
with DC. T cells from ND primed with DC, MM patient and ND T cells pre- 
stimulated with T cells activating beads and IL-2 were relatively ineffective at killing 
target cells in this assay. This observation may be linked to the conditions under 
which the cells were originally collected. 
5.1.6 Discussion 
Immune based therapies are normally considered for use in patients who have 
malignant disease, such as MM. When designing the methods for the production 
of these therapies we must take into account that the immune systems in these 
patients will almost certainly not be normal. This may be due to a number of 
factors, such as immune suppression by the malignant clone, the effects of 
previous therapy and more general issues such as nutrition and co-morbidities. 
The cells used in these experiments were collected at a time when the MM 
patients had received at least 6 courses of MM induction therapy and a course of 
intravenous cyclophosphamide prior to the start of G-CSF for the mobilisation of 
stem cells. In contrast, the previously published experiments (Campbell, et al 
2001) used cells from MM patients who were at diagnosis and so the immune 
systems were likely to have been subject to a greater disease burden at that time. 
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This is likely to be at least part of the explanation for the current finding that there 
was no difference between the abilities of ND and MM patient T cells to proliferate 
in response to IL-2. Thus we should aim to collect immune effector cells at a time 
when the disease is either in remission, or is at its lowest level during the disea§e 
course. This observation may be crucial in determining the success of immune 
therapies for MM patients, but also for patients with other malignant diseases that 
induce immune suppression by secreting cytokines such as TGF-P, IL-10 and 1ý-6. 
Pre-stimulation of MM T cells with T cell activation beads and IL-2 significantly qp- 
regulated the T cell proliferative response to IL-2, in a similar manner to that seen 
in ND cells. In contrast to the previous experiments, we did not see an improved 
response when MM T cells were pre-stimulated with beads and I L-1 5. This is 
again likely to be due to the more normal baseline responses of the MM T cells 
that we used in these experiments. How ever, the activation beads deliver a co- 
stimulatory signal via CD28 as well as cross-linking T cell CD3 in three 
dimensions. This is a more physiological stimulus compared to plate bound anti- 
CD3 alone, and this may contribute to the improved level of proliferation of MM T 
cells that were pre-stimulated with beads and IL-2, compared to beads and ILA 5. 
It was hoped that this would translate into a better response to autologous antigen 
loaded DC. 
There was a normal proliferative response by MM un-stimulated T cells to 
autologous antigen loaded DC in the presence and absence of IL-2. However, the 
pre-stimulated T cells completely failed to proliferate in response to autologous DC 
alone. The same cells proliferated normally in response to autologous DC in the 
presence of IL-2, suggesting that these cells had been rendered IL-2 dependant. 
This is of some concern if these cells were to be used as part of an immune based 
therapy in MM patients as IL-2 would be need to be given in conjunction to ensure 
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an adequate initial proliferative response to antigen presenting cells. It is likely that 
this would have to be continued for a time afterward to ensure the survival of any T 
cell clones that were produced by this interaction. We do not currently know what 
the minimum concentration of IL-2 is which ensures this response, or whether this 
is safely achievable in patients. IL-2 has been given to patients by both IV infusipn 
and SC injection, however the IV route is associated with a number of potentially 
fatal side-effects, making the SC route the only feasible option. These 
observations were important when interpreting the data obtained by the LumineýTm 
analysis of the cytokine levels in the supernatants from the DC T cell interactions. 
The LuminexTIA system is a convenient way to examine the levels of multiple 
cytokines in small volume samples. This method provided another way in which 
the DC T cell interactions could be investigated to see how the pre-stimulation of T 
cells modifies the process. This system was able to measure levels of IL-2, IL-6, 
IL-10, GM-CSF and TNF-a in the supernatants obtained from DC: TC co-cultures. 
With the exception of IL-6, the level of these cytokines in the supernatants 
collected from the interactions between DC and pre-stimulated T cells were 
significantly lower than that seen with DC and un-stimulated T cells. This suggests 
that the pre-stimulation process is interfering with the DC T cell interaction. It is 
most likely that both pre-stimulated CD4+ and CD8+ cells are unable to secrete 
these cytokines in the absence of IL-2. 
The level of IL-6 detected did not vary in respect to the T cell pre-stimulation; 
rather it varied in respect to the maturation stimulus received by the DC. DC 
matured by X4 produced significantly more IL-6 as compared to MIMIC mature 
DC. This is in keeping with data from Fillatreau's group in Berlin, who have shown 
that DC actively secrete IL-6 in response to microbial products or CD40L, and was 
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highest in cells that had received both (www. drfz. de/i)df/arO4/aq fillatreauO4. pdf and 
personal communicabon). 
At first glance this combination of cytokines may seem a little confusing, being a 
combination of TH1 and TH2 type responses. When the pattern is examined as a 
whole it becomes clear that the cells are attempting to induce a pro-inflammatory 
environment favouring the development of a CD8 cytotoxic T cell respopse, 
Figure 5-12. Pre-stimulation of the T cell blocked the secretion of all T cell derived 
cytokines, but had no effect on matDC production of IL-6. Currently, there is no 
data to determine whether supplementation of the matDC: pre-stimulated T cell 
co-cultures is able to reinstate the cytokine response of the T cells, or whether 
201U/ml of IL-2 simply over-rides these mechanisms and directly induces T cell 
proliferation, enhanced by the DC antigen and co-stimulatory signals. However, in 
view of the fact that matDC primed, pre-stimulated T cells produce the best target 
cell kill in the cytotoxicity assay, it can be speculated that when IL-2 was added to 
the matDC: T cell co-cultures, at least some of these mechanisms were re- 
instated. 
The flow cytometry based cytotoxicity assay was easy to handle, as compared to 
the more traditional radioactive chromium release assay, although great care is 
needed when setting up the initial compensations. Both ND and MM patient pre- 
stimulated T cells produced some target cell killing at the highest effector target 
cell ratios. This is most likely due to effects mediated by minor histocompatibility 
antigen mismatch, as all effector cells were HLA-class I (HLA-A2) matched with 
the U266 cell line (Kloosterboer, et al 2005). Interestingly, pre-stimulated MM T 
cells produced statistically better killing than ND pre-stimulated T cells at the 
highest Eff ratio. There are a number of likely explanations for this observation. 
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Figure 5-12 Cytokine interactions during co-culture of matDC and un- 
stimulated T cells to facilitate antigen presentation 
Mature DC present antigen to T cells in the context of co-stimulatory markers. This 
activates both CD4 and CD8 T cells in an antigen dependant manner. The CID4 
cells produce iL-2, IL-10 and TNIF-a, which along with IL-6 from the matDC, 
preferentially induce the CID8 T cells to proliferate and differentiate into cytotoxic T 
cells. The CID8 cells also secrete IL-10, which recruits other CID8 cells by 
chemotaxis. In-vivo, the GM-CSF produced by activated CID8 T cells and other 
cells, such as fibroblasts and endothelial cells, under the influence of TNF-a, 
induce monocytes to differentiate into DC, completing the loop. 
It is known that MM patients have circulating T cells that have anti-MM activity 
(Beckhove, et al 2003, Yi, et al 1995). Thus the pre-stimulation process may 
simply be un-masking this activity. However, the MM cells were collected after a 
number of courses of chemotherapy and immediately after a course of IV 
cyclophosphamide, a very powerful T cell immunosuppressive agent (Winkelstein 
1973). It is possible that these pre-treatments are depleting the MM patients of 
regulatory cells, thus allowing greater anti-MM cytotoxic activity. It may be possible 
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to differentiate between these two possibilities by repeating these experiments 
using cells mobilised with a similar regime in non-MM patients, such as those with 
follicular lymphoma, who should not be able to mount an anti-MM mempry T cell 
response. These two explanations may also help us understand the re§ults 
obtained using ND and MM patient matDC primed T cells. 
The cytotoxic activity of ND matDC primed un-stimulated T cells was significantly 
less than that seen in cells from MM patients. The ND T cells and monocytes were 
I 
collected after G-CSF alone. This is known to induce T cell hypo-responsiveness 
(Jun, et al 2004) and increase the number of toleragenic DC present in the graft 
(Lonial, et al 2004), which may go some way to explain the reduced incidence of 
acute GVHD following the use of mobilised stem cells. The cytotoxicity of the MM 
cells was further enhanced by the pre-stimulation step. Again this could be 
because we are simply un-masking and enhancing the inherent anti-MM potentiRl 
of the MM patient T cells, but there was a substantial DC dependant increase in 
the target cell killing ability of the MM patient T cells. This would favour the 
hypothesis that collecting the T cells following immunosuppressive chemotherapy 
has down regulated any suppressive effects induced by the G-CSF and the 
disease. 
In summary, pre-stimulation of MM T cells with beads and IL-2 enhanced their 
proliferative response to IL-2 and matDC+IL-2, but blocked proliferation in 
response to matDC alone. Pre-stimulation also blocked T cell cytokine secretion in 
response to DC alone. Despite this, pre-stimulated matDC primed T cells 
produced the best killing of MM tumour cell targets, followed by un-stimulated 
matDC primed T cells, with ND un-stimulated matDC pdmed T cells producing 
poor cytotoxic effects. These results suggest that a combined immunotherapy 
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approach using pre-stimulated T cells, MM Ag primed DC and IL-2 may produce 
better clinical responses in patients. 
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6. Results 4 
6.1 Chemokine receptor expression/activity on 
monocytes and monocyte derived dendritic cells 
assessed by fluorescent labelled chemokine up takq 
6.1.1 Introduction 
The interaction between chemokines and their receptors is vital to the function of 
the immune system. The homeostatic migration of cells such, as DC and T cells, 
from the bone marrow to peripheral tissues and then lymph nodes, is governed by 
changes in of chemokine receptor gene expression during differentiation and 
maturation, and their interaction with ligands that are constitutively expressed by 
tissues. Inflammatory processes up-regulate inducible CCL, inducing leukocyte 
chernotaxis towards pro-inflammatory CCLs, such as CCL3 (Figure 1-3). 
Professional antigen presenting cells, such as DC, mature during these 
interactions. This induces down regulation pro-inflammatory CCRs, and up 
regulation of CCRs, such as CCR7, that promote APC migration to lymph nodes, 
facilitating Ag presentation by the co-localisation of naive T cells, which also 
express CCR7. 
The chemokine expression pattern of the tumour may also have a direct bearing 
on the host's ability to mobilise monocytes, DC, T cells and NK cells against the 
tumour. The chemokine balance within the patient and the tumour may be crucial 
in determining the type of immune response that is mounted, in that the tumour 
may shift the balance from an immunogenic response to a toleragenic response by 
the expression of a different chemokine 'signature'. 
The study of the chemokine system is made more difficult by the structural 
constraints imposed by the GPCR, which makes it difficult to produce good quality 
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antibodies for use in experimental work. In addition, antibody staining dpes not 
give any indication of functional receptor activity. During the experiments in the 
previous chapters, the level of CCR7 expression on matDC, as detecteý by 
surface antibody staining, was not as good as expected in view of the lqvel of 
expression of the other co-stimulatory markers such as CD40, CD80, CP83 and 
CD86. This led us to explore other ways in which we could examine chomokine 
receptor expression and function on normal and MM DC and monocyteý. 
Biotinylated chemokines (biokines), such as CCL3 (Bio-CCL3) and CCL1 9 (Bio- 
CCI-19), can be synthesized with an additional biotinylated lysine residue on the C 
terminus (Ravkov, et al 2003, Weber, et a/ 2004). These biokines retain the full 
functional activity of the wild type molecules, and they can be labelled with 
streptavidin-linked fluorochromes. The labelled biokine retains it's ability to bind to 
CCR on the surface of the target cell and, crucially, to be internalised. This leads 
to accumulation of fluorochrome within the cell, which can be detected by 
fluorescence microscopy or flow cytometry. The main advantage of these 
techniques is that they allow analysis to be performed on a cell-by-cell basis, 
rather than on the population as a whole, as is the case when using radio labelled 
CCL. These reagents have been used to great effect in the analysis of D6 and 
CXC-CKR by local collaborator Dr RAB. Nibbs (Weber, et al 2004) and others 
(Ravkov, et al 2003). This method can be combined with other fluorescent surface 
markers, allowing further characterisation of cells taking up the fluorescent ligand. 
In view of the recent evidence, the expression of CCR8 on MM monocytes and DC 
compared to cells from normal individuals was of considerable interest (Qu, et a/ 
2004, Sebastiani, et al 2002). There were no reliable anti-CCR8 antibodies 
available at the time these experiments were performed. Therefore alternative 
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methods to detect the level of CCR8 surface expression are required. To address 
these issues, the use of biotinylated chemokines was explored 
6.1.2 Optimisation of fluorescent chemokine uptake in CCR 
transfected cell lines and monocyte derived DC 
Firstly, to establish these approaches in the lab, HEK293 cells that had been 
stably transfected to express D6 or CCR7 were assessed for their ability to take up 
Bio-CCL3 or Bio-CCL19 respectively. These biolkines were mixed with PE-coupled 
streptavidin and these complexes or Strep-PE alone were fed to harvested cells. 
As can be seen in Figure 6-1, D6 or CCR7 expressing cells became strongly 
fluorecent after incubation with Bio-CCL3/PE or Bio-CCL1 9/Pecomplexes 
respectively. Parental untransfected HEK293 cells failed to internalise these 
tagged chemokines, (Data not shown). These assays act as positive controls for 
the subsequent experiments on primary human material. 
A Bio-CCL3 uptake via D6 B Bio-CCL19 uptake via CCR7 
6tmp rt 
Figure 6-1 Fluorescent chemokine uptake in HEK cells stably transfected 
with D6 and CCR7 
HEK 293 cells transfected with D6 (A) or CCR7 (B) were analysed for their ability 
to take up fluorescently labelled biokines, CCL3 (A) and CCL1 9 (B), as compared 
to control samples stained with strep-PE alone. 
stmp pe 
Strep-PE 
Biokine-PE 
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For the next experiment, iDC were generated from CD14 selected monocytes, by 
culture in GM-CSF and IL-4 for 4 days. On day 4 an aliquot was removed for 
analysis and the remaining cells were fed with GM-CSF and IL-4 supplemented 
media, pulsed with U266 lysate as a source of antigen and cultured over night. On 
day 5, an aliquot of antigen pulsed DC was removed for analysis and the 
remaining cells were then divided in half for maturation. The antigen-loaded DC 
were cultured with either the MIMIC or X4 maturation cocktail and incubated 
overnight prior to analysis. The biokine uptake assays were all performed in 500ul, 
on the same day as the aliquots were removed from the parent culture. The 
surface expression CD1a, 1c, 14,40,80,83,86, HLA class 1, HLA DR, CCR5 and 
CCR7 of each sample was determined by surface antibody staining and flow 
cytometry. The results of the surface phenotype and fluorescent chemokine 
uptake are shown in Figures 6-2a-d. 
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Figure 6-2a Fluorescent chemokine uptake and surface phenotype of iDC 
Immature DC, generated from CD14 positive monocytes were analysed after 4 
days of culture in GM-CSF and IL-4 supplemented DC medium. Live cells have 
been gated on forward and side scatter. The uptake of fluorescent Bio-CCL3 and 
Bio-CCI-19 is shown in the upper histogram plots and the surface antibody 
staining is shown in the lower dot plots. 
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Figure 6-2b Fluorescent chemokine uptake and surface phenotype of iDC 
post antigen loading with turnour lysate 
Immature DC were loaded with tumour antigen by adding U266 cell lysate to the 
culture medium, incubated overnight and analysed on D5 of culture. Live cells 
have been gated on forward and side scatter. The uptake of fluorescent Bio-CCL3 
and Bio-CCL1 9 is shown in the upper histogram plots and the surface antibody 
staining is shown in the lower dot plots. 
Neg control 
Bio CCL3 
101 162 i03 104 
CCL3 PE 
0 
0 
0 
C 
0 
CD83 FITC 
Chapter 6-162 
Neg control 
BioCCI-19 
C, 
.. PIP. I 012 63 4 1 
;o 
10 
joC IOI 102 
tbt 0(70 
jC 101 
-- 
10, 
-_ 
Figure 6-2c Fluorescent chemokine uptake and surface phenotype of MIMIC 
matured DC 
Antigen loaded DC were give the MIMIC cytokine cocktail as a maturation 
stimulus and analysed after overnight culture. Live cells have been gated on 
forward and side scatter. The uptake of fluorescent Bio-CCL3 and Bio-CCL1 9 is 
shown in the upper histogram plots and the surface antibody staining is shown in 
the lower dot plots. 
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Figure 6-2d Fluorescent chemokine uptake and surface phenotype of X4 
matured DC 
Antigen loaded DC were give the X4 cytokine cocktail as a maturation stimulus 
and analysed after overnight culture. Live cells have been gated on forward and 
side scatter. The uptake of fluorescent Bio-CCL3 and Bio-CCL19 is shown in the 
upper histogram plots and the surface antibody staining is shown in the lower dot 
plots. 
In chapter 4, DC and antigen-loaded DC were found to strongly express CCR5 (a 
CCL3 receptor) by surface antibody staining (Table 4-1). However, using the 
experimental conditions optimised for use with transfected cell lines, the uptake of 
Bio-CCL3 was poor (Figure 6-2a+b). In contrast, there was significant uptake of 
Bio-CCL1 9 by the matDC, with 61 % of the X4 (Figure 6-2d) and 37% of the 
MIMIC (Figure 6-2c) matured cells becoming positive indicating that these cells 
were expressing CCR7 or, less likely, CCR1 1, another receptor capable of binding 
CCL1 9. A small number (17%) of antigen-loaded DC were positive for Bio-CCL1 9 
uptake, whilst still being CCR5 positive by surface antibody staining (Figure 6-2b). 
This indicated that turnour lysate alone was sufficient to initiate the up regulation of 
CCR7 activity, but a stronger signal is required to complete the process of DC 
maturation, a matter discussed earlier. 
With regard to the suitability of biokine usage, it is first clear that the Bio-CCL1 9 
approach provides a sensitive method for detecting CCL1 9 receptors, which is 
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arguably better than CCR7 antibodies. CCL3 uptake was disappointing, as there 
was little BioCCL3 uptake despite the presence of surface CCR5, as indicated by 
anti-CCR5 antibody staining. 
The amount of fluorescence accumulated by a cell during the biokine uptake 
assay is dependant upon receptor activity during the assay, biokine concentratiQn 
and time. In order to optimise the Bio-CCL3 uptake in primary human material, I 
fluorescent Bio-CCL3 assay was performed with an increased incubation time of 
4hrs. A second assay was performed with an increased concentration of 
fluorescent Bio-CCL3, by reducing reaction volume of the assay from 500pl to 
200pl. 
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Figure 6-3 Reducing the reaction volume from 500pl to 200pi significantly 
improves Bio-CCL3 uptake by CD14 selected monocytes (n=3) 
Normal monocytes were obtained by CD14 selection and suspended in DC 
medium at 1X106/Ml . Fluorescent chemokine assays were performed on 200pl and 500pl aliquots of cells. The 500pl aliquot samples were incubated for 2 (plot shown 
in Figure 6-2a) or 4hrs (above), the 200pl samples were incubated for 2hrs. 
Controls (Strep-PE alone) were performed for each culture condition, and each 
condition was set up in triplicate. Samples were analysed by flow cytometry with a 
negative gate set on 99% of cells in each control sample. 
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Reducing the reaction volume to 200pl improved the fluorescent chemqkine 
uptake (Figure 6-3), to a level more in keeping with results from surfacT antibody 
staining. Increasing the incubation time from 2-4hrs for the 200pl assayp only 
served to increase the level of non-specific uptake of the control. It was decided at 
this point that all further assays would be performed in 200pl for both Bio-CCL3 
and Bio-CCL19 uptake assays, as there was no significant change in the Bio- 
CCL19 uptake using 200pl samples (data not shown). 
6.1.3 Specificity of fluorescent chemokine uptake by competitive 
blocking with non-biotinylated chemokines 
As previously discussed, chemokine receptor-ligand binding is uniquely 
promiscuous in the way ligands and receptors can bind in a number of 
combinations. In order to determine whether the uptake of Bio-CCI-19 was via 
CCR7 or CCR1 1, a blocking step was added to the assay. Aliquots of matDC were 
pre-stimulated with either non-biotinylated CCL1 9, to block uptake via CCR7 and 
CCR1 1, or CCI-25, which should specifically block uptake via CCRI 1. These 
unlabelled chemokines were added at a concentration A0 greater than the 
concentration of CCL1 9 used in the fluorescent biokine uptake assay. Cells were 
incubated at 370C for 1 hour, and then washed twice in warm DC medium. A 
fluorescent biokine uptake assay was then performed as previously described with 
a negative control and an untreated sample of matDC (Figure 6-4). 
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Figure 6-4 Pre-stimulation of matDC with CCL19 and CCL25 shows that Bio- 
CCL19 uptake is mediated by CCR7 
Mature DC, generated from CD14 selected monocytes, cultured in GM-CSF and 
IL-4 supplemented DC medium for 4 days. The DC were pulsed with U266 tumour 
cell lysate overnight and then matured overnight with the X4 cytokine cocktail. Two 
aliquots of matDC were pre-stimulated for 1 hour with non-biotinylated CCL1 9 to 
block uptake via CCR7 and CCR1 1, or CCL25 to block uptake via CCR1 1. 
Unblocked cells were incubated for 1 hour in medium alone. All cells were then 
washed in warm medium and the fluorescent chemokine assay was performed on 
blocked and unblocked matDC. Repeat experiments gave similar results. 
The CCL19 and CCL25 pre-blocking experiment confirmed that Bio-CCL19 uptake 
was mediated via CCR7. Pre-stimulation with CCL25 had no effect on Bio-CCL19 
uptake (79.22 + 1.0%, positive, MFI 54.55) as compared to the unblocked positive 
control (75 + 0.85%, MFI 47.66). Pre-stimulation with CCL19 significantly reduced 
Bio-CCL19 up-take (8.74 + 0.2% positive, MA 9.67) (p< 0.001). 
The task to determine receptor specificity for Bio-CCL3 uptake is a more complex 
one, as CCL3 can bind to CCR1, CCR3, CCR5 and the decoy receptor D6. To 
attempt to address this, fluorescent Bio-CCL3 uptake assays were set up as 
normal with the addition of a ten times excess of unlabelled human (h)CCL31-1, 
murine (m)CCL3, hCCL3L1 -2, hCCL3L1 -4 and hCCL4. There are two naturally 
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occurring isoforms of CCU in humans, called CCU and CCI-31-1. CCL3LI is 
viewed as the true human homologue, and binds CCRI, CCR3, CCR5 and D6 
(Nibbs, et al 1999). Confusingly, CCI-31-1 is also the true functional homologue of 
murine CCL3. The truncated form CCI-31-1 -2 is missing the final 2 amino acid 
residues from the N terminal, and has increased specificity for CCRI and CCR5, 
and no ability to bind CCR3 and D6. The CCI-31-1-4 protein is missing the N 
terminal 4 amino acid residues. It retains its ability to bind CCL1, has reduced 
specificity for CCR-5 and no ability to interact with CCR3 or D6. Finally, CCL4 was 
included because it binds to CCR5 and D6. The results are shown in Figure 6-5 
and it was hoped that the use of these chemokines would give an indication of the 
Bio-CCL3 receptors present on the cells. The amount of blocking of Bio-CCL3 
uptake in each assay was calculated using Equation 2-1. 
Significant inhibition was achieved with all CCL3 variants, mCCL3 (mean 57.05 + 
16.24), hCCL3L1 (mean 48.68 ± 13.53), hCCL3L1 -2 (mean 45.64 ± 15.64) or 
hCCI-31-1-4 (mean 36.86 + 12.54). Overall, these data suggest that Bio-CCL3 
uptake was mediated by either CCR5 or CCR1. To further elucidate which of these 
two receptors was responsible for Bio-CCL3 uptake, blocking would need to be 
performed using CCU, which has specificity for CCR1, and CCL8, which only 
binds CCR5. Another method would be to use cell that genetically lack one of the 
receptors, such as A32 homozytes who do not express CCR5. None of these 
reagents was available at the time these assays were performed. Interestingly, 
competition with CCI-4 did not block Bio-CCL3 uptake but rather induced a 
significant up regulation of Bio-CCL3 uptake (mean 116.78 + 17.57, p< 0.005) and 
the mechanisms that may induce this phenomenon will be discussed later. 
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Figure 6-5 Competitive blocking of Bio-CCL3 with non-biotinylated 
chemokines, which have varying CCR specificities, suggests 
uptake is mediated by CCR5 
Monocytes from normal individuals (n=4) were purified by density gradient 
centrifugation and CD14 magnetic bead selection. The fluorescent chemokine 
uptake assay was performed for Bio-CCL3 uptake with the addition of 12.5ul of 
0.1 ug/ml (x1 0 excess) of the non-biotinylated blocking chemokines hCCL3L1, 
mCCL3, hCCI-31-1-2, hCCL3L1-4 and hCCL4. Samples were incubated for 2 
hours and analysed by flow cytometry. Samples were set up in duplicate and the 
results represent 4 separate experiments. The data shown is the mean percentage 
blocking of the positive control MFI induced by each chemokine and was 
calculated as shown in Equation 6-1. 
The competitive blocking experiments for Bio-CCL3 uptake shown in Figure 6-5 
did not show complete inhibition, as seen when matDC were pre-stimulated with 
CCL1 9, prior to a Bio-CCL1 9 assay being performed (Figure 6-4). Thus, the 
impact of CCL3 pre-incubation prior to Bio-CCL3 uptake was assessed. Pre- 
stimulation induces receptor desensitisation, making the cells refractory to 
subsequent ligand interactions. A pre-stimulation blocking experiment of Bio-CCL3 
uptake was performed in triplicate using normal monocytes, cultured with a ten 
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times excess of hCCL3Ll, mCCL3, hCCL3Ll-2, hCCL3Ll-4 and hCCL4 for an 
hour at 370C. The fluorescent Bio-CCL3 uptake assays were performeq as 
previously described. The data in Figure 6-6 shows that pre-stimulation with 
CCL3Ll (mean 86.03 + 2.78%, p<0.03) and CCL3Ll-2 (mean 77.94 + 1.80%, p 
0.03) increased the degree of inhibition of Bio-CCL3 uptake compared to 
competitive co-blocking (Figure 6-5). There was also a higher level of blocking 
with mCCL3 (mean 88.0 + 1.15%) and CCL3Ll -2 (mean 81.62 + 1.01 %) pre- 
stimulation compared with the competitive blocking, but this failed to achieve 
statistical significance. Pre-stimulation with CCL4 again increased the Bio-CCL3 
uptake (mean 20.54 + 10.54%), but this was significantly less than that seen witý 
competitive blocking alone (p < 0.03). 
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Figure 6-6 Pre-stimulation of normal monocytes with non-biotinylated 
chemokines further reduces Bio-CCL3 uptake 
Aliquots of normal monocytes used in one of the experiments in Figure 6-8 and 6- 
9 were incubated with a X10 excess of non-biotinylated CCL31-1, mCCL3, 
CCI-31-1 -2, CCL3L1 -4 and CCL4. They were incubated for 1 hour and then a Bio- 
CCL3 uptake assay was performed in triplicate, in the presence of the non- 
biotinylated chemokines. The assays were then incubated at 37'C for 2 hours and 
analysed by flow cytometry. The assays were set up in triplicate and compared 
with the results of the assays incubated at 370C to calculate the inhibition of Bio- 
CCL3 uptake as shown in Equation 6-1. 
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In summary, biokines can be used to assess the capacity of primary hu1nan cells 
to take up chemokines such as CCL3 and 19, giving an indication of aclive, 
functional receptor expression on these cells. Pre-stimulation blocking Issays, 
using CCL1 9 and 25, showed that the uptake of Bio-CCL1 9 was mediaýed by 
CCR7. Of the possible receptors that could have mediated the uptake qf Bio- 
CCL3, CCR1 and 5 are the most likely candidates. However, the lack of receptor 
specificity in the Bio-CCL3 assay may have advantages. It may be useq to 
simultaneously probe for the presence of all pro-inflammatory CCL3 receptors 
(CCL1,3,5) on target cells, avoiding the use a number of reagents, as would bq 
the case when using antibodies. Indeed, in many cases, particularly in species 
other than humans, high quality antibodies are often unavailable for chemokine 
receptors. Biokines may represent a suitable alternative. More over, the biokine 
methodology is a useful approach when examining the shift from an iDC to a 
matDC phenotype, as it will give a better overall view of the changes in the cell's 
capacity to interact with CCL3. 
6.1.4 Tracking Chemokine Receptor activity in normal and MM 
MoDC production using the fluorescent chemokine uptake 
assay 
As discussed previously, DC migrate under the control of different 
chemokine/receptor interactions at various stages of development. These 
mechanisms are vital to the DCs ability to generate an immunogenic response. 
They encounter antigen at sites of inflammation, then mature and migrate to lymph 
nodes, where DC present these antigens to immune effector cells in the context of 
appropriate co-stimulation. The fluorescent chemokine uptake assay was used to 
track changes in CCR7 and CCL3 receptor activity during the different phases of 
MoDC production. Monocytes were collected from MM patients and ND 
undergoing stem cell mobilisation, and purified by density gradient centrifugation 
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and CD14 magnetic bead selection. Immature DC were produced from monocytes 
by 4-day cultures in DC medium supplemented with GMALA or GMAL-13. 
Immature DC were simultaneously matured and loaded with antigen by overnight 
culture in medium supplemented with either the X4 or MIMIC maturation cocktail, 
and U266 tumour cell lysate. This study has revealed a number of fundamental: 
changes in CCR7 and CCU receptor expression during MoDC development ano 
maturation that vary between ND and MM patients. 
A significant number of monocytes isolated from ND following stem cell 
mobilisation were found to have CCR7 activity using the chemokine uptake assay 
(mean 31.37 + 9.91%) (MFI 10.93 + 5.75), shown in Figure 6-7. This expression is 
maintained by iDC and up regulated following maturation (mean 49.35 + 6.12%) 
(p: ý 0.05). The MFI of CCR7 activity is markedly up regulated during maturation 
(mean 27.86 + 4.12%) (p: ý 0.001). The activity of CCL3 receptors progressively 
down regulates during MoDC production (monocytes 44.28 + 8.22%, iDC 19.41 + 
4.00% and mat DC 15.8 + 3.9%) (p< 0.01). 
Figure 6-8 shows the MFI and percentage positive cells for monocytes, iDC and 
mat DC produced from MM patients undergoing chemotherapy and G-CSF stem 
cell mobilisation. Monocytes from MM patients show a reduced level of CCL3 
receptor activity (mean 20.12 + 4.26%) as compared to monocytes from normal 
donors (*p: ý 0.01). The pattern of change seen in the OC and mat DC is similar in 
MM patients compared to normal donors. However, the level of expression of 
CCR7 in MM mat DC (30.33 + 6.81 %) is lower than that seen in matDC from 
normal donors (mean 49.35 + 6.12%), but this fails to achieve statistical 
significance (+ p=0.055). 
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Figure 6-7 CCL3 receptor and CCR7 activity during MoDC production from 
normal stem cell donors, measured using the fluorescent 
chemokine uptake assay 
The chemokine uptake assays were performed using monocytes (n=9), iDC 
(n= 12) and matDC (n= 18) isolated from normal donors (n=9) undergoing stem cell 
mobilisation with G-CSF 1 Opg/kg for 5 days. Plot A show the mean fluorescence 
intensity and plot B shows the percentage of positive cells. * Denotes significant 
difference from MM patients, + denotes a trend towards a difference. 
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Figure 6-8 CCL3 receptor and CCR7 activity during MoDC production from 
MM patients undergoing stem cell mobilisation, measured using 
the fluorescent chemokine uptake assay 
The chemokine uptake assays were performed on monocytes (n=9), iDC (n=12) 
and matDC (n= 18) isolated from MM patients (n=9) undergoing stem cell 
mobilisation with chemotherapy and G-CSF 5-1 Opg/kg for 5 days. Plot A shows 
the mean fluorescence intensity and plot B shows the percentage of positive cells. 
* Denotes significant difference from ND, + denotes a trend towards a difference. 
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Immature DC analysed in the above analyses had been produced using one of 
two cytokine cocktails, GM-CSF combined with either IL-4 or IL-13. Thus, they 
were examined separately. The OC produced from ND (n=9) showed no 
significant difference in chemokine receptor activity between the cells produced by 
GM/IL-4 (n=5) (mean 38.1 + 6.9%) (MFI 9.8 + 1.7) and GM/IL-13 (n=7) (mean 26.2 
1.6%) (MFI 8.0 + 0.8). However, the percentage of cells positive for Bio-ELC 
uptake and the level of activity, as indicated by the MR, were significantly lower in 
the MM patient (n=9) DC produced with GMAL-13 (n=5) (mean 7.56 + 2.67%) 
(MFI 5.05 + 1.33) as compared to those produced with GM/IL-4 (n=4) (mean 23.79 
5.29%, p<0.01) (MFI 10.95 + 1.16, p<0.05), (Figure 6-9). 
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Figure 6-9 CCR7 activity on iDC from MM patients 
Immature DC were produced from MM patient (n=9) monocytes collected following 
stem cell mobilisation. Samples were cultured for 4 days in DC medium 
supplemented with GM-CSF and either IL-4 (n=4) or IL-13 (n=5). CCR7 activity 
was analysed using Bio-CCL1 9 uptake as a marker of receptor activity. 
pý 0.01 
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In order to assess the quality of the rnatDC induced by the X4 and MIMIC 
maturation stimulus, we compared the results of Bio-CCI-19 uptake in cplls that 
had been matured with the two maturation cocktails. Samples from all nine ND 
were matured with both MIMIC and X4, and results are shown in Figure 6-10. A 
lower proportion of ND MIMIC matured matDC exhibited CCR7 activity (mean 
38.63 + 6.33%) compared to those matured with X4 (mean 58.86 + 9.3%, p<0.05). 
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Figure 6-10 CCR7 activity is lower in normal matDC matured with the MIMIC 
cytokine cocktail compared to those matured with X4 
Mature DC, produced from normal donors (n=9), were analysed to ascertain 
whether the maturation stimulus they received influenced the level of CCR7 
activity. Aliquots from all Nine ND were matured with MIMIC (n=9) and X4 (n=9). 
The majority of samples from MM patients were matured with X4 (8/9). Thus we 
compared the level of CCR7 activity in these cells with those from normal donors 
that had been matured with X4 (n=9) (Figure 6-11). This analysis showed the MM 
matDC matured with X4 had a significantly lower percentage of Bio-CCL1 9 
positive cells (mean 30.32 + 6.81) as compared to the normal donor controls 
(mean 58.86 + 9.3%, p<0.02). 
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Figure 6-11 CCR7 activity is higher in normal matDC matured with X4 
cytokine cocktail compared to MM matDC matured with X4 
The uptake of Bio-CCI-19 by normal donor matDC matured with X4 (n=9) was 
compared with MM matDC matured with X4 (n=8) in order to assess the quality of 
MM matDC. 
These experiments have shown that the biokine uptake assay can be used to 
monitor the level of CCR7 and CCL3 receptor activity during MoDC development. 
The level of receptor activity can vary depending upon the method of DC 
production, and between cells from ND and patients with malignant disease, such 
as MM. DC produced with GM/IL-4 and matured with X4 may be of better quality, 
with regards to CCR7 activity and homing to lymphoid tissue, than those produced 
with GM/11-1 3 or matured with MIMIC. However it will be important to correlate 
these findings with those from migration and chernotaxis assays before deciding 
whether this is the preferred method for DC production for patients with MM. 
Monocytes were found to express a significant level of CCR7 activity in these 
assays. The level of CCR7 activity on MM monocytes is much more variable than 
that seen on ND monocytes. This could be due to the different regimes used to 
mobilise cells, or to inherent differences in MM monocytes 
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6.1.5 Analysis of the expression of the chemokine receptors 
CCR5, CCR7 and D6 by reverse RT-PCR 
Intriguingly, the fluorescent chemokine uptake assay indicates that monocytes, 
collected during stem cell mobilisation, and OC have some detectable CCR7 
activity. This is at odds with the data in the published literature generated by 
surface antibody staining, which suggest that these cells do not express 
detectable CCR7. In order to confirm this data, RT-PCR was used to determine 
CCR5 and CCR7 gene expression in monocytes, OC pre and post antigen loading 
and matDC. In addition, parallel CCR5 expression was gauged. 
Dendritic cells were generated from ND monocytes with GM/11-4 and X4. At each 
stage of production process, 5xI 05 cells were stored at -800C as a concentrated 
cell pellet. RNA was isolated from cells and used to synthesise cDNA. The relative 
expression of chemokine mRNA was then analysed using a single set of primers, 
within a single PCR reaction. The products of the PCR reaction were analysed by 
conventional gel electrophoresis and visualised by UV light. 
The PCR gel shown in Figure 6-12 shows that in keeping with the cytokine uptake 
assay, there was expression of CCR7 in monocytes collected at the time of stem 
cell mobilisation, as well as in OC pre and post antigen loading. Although the PCR 
that was performed was not quantitative, this expression seemed to up regulate in 
mature DC. The monocytes used in this experiment were >93% pure, so it is 
possible that the CCR7 mRNA detected was due to T cell contamination. 
However, expression was maintained in iDC, which were in culture for 4 or 5 days 
in the absence of any cytokine that would maintain T cell viability. Alongside the 
Bio-CCL19uptake data, these experiments suggest CCR7 expression by 
monocytes. 
Dr Simon J Harrison, 2005 
cj: +. I-- I. - LO W) IX Ir IX w+ 
L) 
A Monocytes 
B iDC 
C OC post AG 
D matDC 
Chapter 6-178 
Figure 6-12 Gel electrophoresis of PCR products for CCRS, CCR7 and D6 
RT-PCR reactions for CCR5, CCR7 and D6 were performed, with and without 
reverse transcriptase (RT), on monocytes harvested at the time of stem cell 
mobilisation (Gel A), OC produced by culture in DC medium supplemented with 
GM/lL-4 (Gel B), DC post antigen loading with U266 tumour cell lysate (Gel C) 
and matDC following the X4 maturation cocktail (Gel D). 
The expression of CCR5 appeared highest in monocytes and iDC, with apparent 
down regulation in OC following antigen loading, and matDC. These findings need 
to be interpreted in light of the contamination in the CCR5 -RT control lane. This 
could be due to contamination of the sample with DNA that has not been 
completely destroyed by the DNAse neutralisation step. This emphasises the 
importance of -RT controls, which are often omitted by others. Finally, there was 
no evidence of D6 expression in any of the test cells in this experiment. Thus the 
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Bio-CCL3 uptake observed in the experiments discussed in 6.1.4 is unlikely to be 
mediated by the D6 decoy receptor. 
6.1.6 CCR8 expression during MoDC production meafured by 
surface marking with blotinylated CCL1 
There is recent evidence that CCR8, as well as CCR7, has a role in the migratign 
of CD40 licensed matDC from peripheral tissues to lymph nodes. The CCL1 (I- 
309) Fluorokine kit, (R and D systems) was used to examine the expression of 
CCR8 on monocytes and DC during MoDC production. CCL1 is the main ligand 
for CCR8. The molecules employed in this method had been biotinylated after 
production. As a result, each CCL1 molecule has multiple biotin sites, and they 
form large complexes when streptavidin-bound fluorochromes are added. This 
prevents this type of molecule from being pre-labelled with streptavidin-bound 
fluorochromes and so they are not suitable reagents to measure ligand 
internal isation. However, it does allow sensitive and specific surface quantification 
of the cell surface receptor expression. 
Aliquots of cells were suspended in cold PBS, and labelled with Bio-CCL1 or 
negative control. The samples were incubated for 1 hour at 40C, the Strep-FITC 
was then added and the samples incubated for a further 30mins, in the dark, at 
40C. Samples were then washed twice and analysed immediately by flow 
cytometry. The specificity of the staining was tested by pre-blocking Bio-CCL1 with 
anti-human CCLI antibody, and performing a competitive binding assay by pre- 
incubating test cells with a ten times excess of non-biotinylated CCL1 for 1 hour. 
The assays were then completed as normal (Figure 6-13). All assays were 
performed in triplicate. 
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Figure 6-13 CCR 8 surface marking with Bio-CCLI is blocked by anti-human 
CCL1 antibody, and partially inhibited by competition with un- 
biotinylated CCLI 
Normal monocytes were prepared by density gradient centrifugation and CD14 
selection. Samples were analysed for CCR8 expression by CCLII surface staining 
(plot B) and compared with negative control samples (A). Blocking with an 
antihuman CCL1 anti-body (C) and pre-stimulation with x1O excess of un- 
biotinylated CCL1 (D) determined specificity of marking. Samples were analysed 
by flow cytometry. The M1 contains 99% of the negative control cells and M2 is 
the positive gate. 
Monocytes were positive for CCR8 (mean 95% + 1.14%) and this was completely 
blocked by anti-human CCL1 antibodies. Pre-stimulation with un-biotinylated 
CCL1 reduced the MFI by a mean of 50% + 2%. This suggested that the Bio-CCL1 
surface staining was both a sensitive and specific method for detecting CCR8 on 
the surface of primary human cells (Figure 6-13). 
We went on to examine the CCR8 levels on monocytes, DC and matDC 
generated from normal donors (n=6) and MM patients (n=6), who were undergoing 
stem cell collection. Monocytes from normal donors had a lower MFI (mean 28.34 
10.80) and percentage of CCR8 positive cells (mean 43.17 + 5.80%) compared 
to MM monocytes (mean 124.69 + 54.0, p<0.001) and (mean 64.79 + 13.90%, 
p<0.03) (Figure 6-14). There was no statistical difference between CCR8 levels 
on normal donor or MM patient iDC. However, the expression of CCR8 on MM 
matDC (163.0 + 18.5) was statistically higher than on ND matDC (163.0 + 18.5, p 
0.01). 
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Figure 6-14 CCR8 levels on normal and MM monocytes, MC and matDC 
CCR 8 levels were assessed using the Bio-CCL1 surface-marking assay. 
Monocytes were isolated from normal donors and MM patients undergoing stem 
cell collection. Immature DC were produced by culture in DC medium 
supplemented with GM/IL4 or GM/IL13. Maturation was induced using the MIMIC 
or X4 maturation cocktails. Plot A shows the MFI data and plot B shows the 
percentage of cells that were CCR8 positive. Samples were analysed from 6 ND 
(n=12) and 6 MM patients (n=6). 
The difference in the level of CCR8 expression on cells from MM patients and ND 
may be constitutive, or due to the differing stem cell mobilisation regimes. This 
may be the case for monocytes, but it is much less likely to be the explanation for 
the different levels of expression seen on matDC. Thus it is more likely that cells 
from MM patients have an inherently higher expression of CCR8. This may be 
further clarified by measuring CCR8 levels on cells from ND and MM patients 
obtained under steady state conditions. 
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6.1.7 Discussion 
Chemokines and their receptors are crucial for the efficient function of the immune 
system. They provide a homeostatic mechanism by which cells such and DC and 
T cells can migrate from the bone marrow to the periphery and then on to 
lymphoid tissues. Chemokines also play a role in the regulation of the 
inflammatory response, by recruiting cells through the up regulation of inducible 
chemokines and then facilitating APC antigen priming of na*fve T cells, through 
their co-localisation in lymph nodes, mediated by CCR7 expression. Unfortunatqly 
turnours can use the chemokine system to down regulate the immune system 
either directly or by recruiting regulatory cells into the tumour site. 
We have shown that the fluorescent biokine uptake assay is a sensitive and 
specific method of detecting chemokine receptor activity on immune cells such as 
monocytes and DC from normal donors and patients with malignant disease, such 
as MM. 
The uptake of Bio-CCL-3 was mediated via CCR1 or CCR5, and uptake generally 
decreased as cells differentiated into matDC. This is consistent with the reported 
reduction of pro-inflammatory chemokine receptors reported as DC mature. 
Interestingly, the level of Bio-CCL-3 uptake activity was lower on MM monocytes 
as compared to ND. This could be simply due to the fact that MM patients have 
stem cells mobilised following chemotherapy, rather than growth factor alone as in 
ND. However, there may be an underlying effect due to the malignant disease, 
and it may be possible to differentiate between the two by analysing monocyte 
expression of CCRII and CCR5 on cells from MM patients or ND collected under 
steady state conditions. It is known that CCL3 levels are elevated in the serum and 
BM supernatants of MM patients. These levels also correlated with the severity of 
MM bone disease and prognosis, and increase with as the disease progresses 
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(Abe, et a/ 2002, Choi, et at 2000, Hashimoto, et at 2004, Magrangeas, et a/ 2003, 
Terpos, et a/ 2003)We postulate that these elevated levels of CCL3 may directly 
induce the down regulation of pro-inflammatory chemokine receptors by 
desensitisation, preventing efficient monocyte recruitment to sites of inflammatiqn. 
Strangely, the level of Bio-CCL3 uptake was dramatically increased by co- 
stimulation with CCL4. This observation is in keeping with a number of recent 
reports that have shown that some chemokines, such as CCL21 and CXCI-13, and 
CXCLB and CXCL6, may produce synergistic effects on target cell migration 
(Paoletti, et al 2005, Struyf, et al 2005). In addition Paoletti et al have suggested 
that these effects may be mediated by the formation of chemokine heterodimers. It 
is already known that CCL3 and CCL4 are secreted in the form of heterodimers by 
monocytes (Guan, et al 2001), and we postulate that these two mechanisms may 
be responsible for the increase in Bio-CCL3 uptake observed by co-stimulation 
with CCL4. These observations are of interest to those who are designing 
immune-based therapies, as it is clear that receptor-ligand interactions alone are 
not enough to trigger functions such as migration (Randolph, et a/ 2005). Dendritic 
cell migration also requires cells to be primed with a balance of other stimuli, such 
as PgE2 and CD40L, in order for migration and not cytokine production to be 
tfiggered. 
Interestingly, this assay showed some CCR7 activity on monocytes collected 
during stem cell mobilisation, which was similar in cells collected from MM patients 
and ND. This expression was confirmed on PCR analysis. To my knowledge, 
CCR7 expression has not been previously reported on monocytes. It is possible 
that this receptor expression may allow limited monocyte access to lymphoid 
tissue, where they could differentiate into macrophages or DC, known to be 
present in these organs. The biokine assay was also used to track the up 
regulation of CCR7 activity through DC development. 
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It is not surprising that that the chemokine receptor profile of MoDC may be 
influenced by the cytokines used to generate them. Immature DC from MM 
patients generated using GMIIL-13 had a lower expression of CCR 7 compared to 
those generated by GM/IL-4. The maturation cocktail also influenced the level of 
CCR7 expression. Normal donor DC matured with X4 had higher level of CCR7 
expression compared with normal donor cells matured with MIMIC and MM DC 
matured with X4, again suggesting an inherent difference between MM and ND 
dedved cells. 
CCR8 expression could be measured using the Bio-CCL1 surface-marking assay, 
and this expression was shown to up-regulate during MoDC production. 
Monocytes and matDC from MM patients were shown to have a significantly 
higher expression of CCR8 as compared to normal donors. This observation 
suggests that cells from MM patients may be more sensitive to the potential 
immunosuppressive effects of CCL1 reported recently (Batten, et a/ 2005) . Batten 
et al showed that mesenchymal stem cells (MSC) directly inhibited T cell 
proliferafive responses to allo PBMCs, and failed to induce the proliferation of 
primary and primed T cells, through the production of CCL1. Furthermore, MSCs 
also induced T cell production of Th2 cytokines and chemokines (IL-3, IL-5, IL-10, 
IL-15 and CCU), accompanied by down regulation of Thl cytokines (IL-1 a, IL-P, 
IFNy and TNFa). 
A greater understanding of how malignant diseases and their therapies interact 
with the chemokine system is required if the DC system is to be used to produce 
effective immune therapies for patients. The changes in the MoDC system 
detected in cells from MM patients suggest that monocytes are unable to home to 
sites of inflammation, matDC have impaired ability to home to LN and 
immunosuppressive chemokines, such as CCL1, may have increased potency on 
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MM monocytes and DC. The correlation between the expression of CCPs on MM 
patient cells With the level of chemokines in the plasma and bone marrqw may 
provide further insights into these processes. 
Observations such as these may help to explain why DC used in immunotherapy 
trials have failed to home effectively to lymph nodes, or have any major impact qf 
the course of malignant diseases, such as MM. 
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7. Discussion and Conclusions 
The field of tumour immunotherapy is still in its infancy. It is becoming clear that 
the human immune response is the result of highly complex, continuously evolving 
interactions between cells of the adaptive and innate arms of the immune system, 
the internal and external environments, and normal and abnormal cells (i. e. 
malignant or virally infected cells). Despite the considerable advances in our 
knowledge over the past 30 years, we still seem to have only scratched the 
surface of the complexities of the immune system and it's interaction with 
malignant disease. It is therefore not surprising that the results from 
immunotherapy trials have so far been disappointing. Although we and others are 
able to generate immune effector cells in the laboratory that are capable of killing 
tumour cells in-vitro, with the notable exception of PTLD (Bollard, et a/ 2003), this 
has not translated into improved outcomes for patients with malignant disease who 
have participated in clinical trials of tumour specific immunotherapy. There are a 
number of factors that are likely to contribute to this situation: 
1. As with most new therapies, the majority of immunotherapy trials have been 
conducted in patients who have advanced malignant disease. Given that 
patients who undergo allo HSCT have improved survival when transplanted 
early in the disease course (Gratwohl, et a/ 1998), and respond best to DLI 
when it is given for relapse at the molecular level (van Rhee, et a/ 1998) the 
poor results so far in the immunotherapy trials are hardly surprising. It 
remains unclear whether the negative impact of disease burden is the result 
of disease suppression of the immune system or if the increased amount of 
treatment that these patients will have received also contributes to their 
poor outcomes. Clearly it will be advantageous to use immunotherapy 
treatments earlier in the disease course, preferably at a time when the 
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tumour burden is at its lowest (Hsu, et al 1997), such as following 
autologous HSCT. 
2. Thus far it has been difficult to identify tumour specific, immunogenic 
antigens with which we can direct the immune system against the malignant 
clone. The success of immunotherapy in the treatment of PTLD is largely 
attributable to the fact that the immune therapy is direct against a few well 
characterised, highly immunogenic viral (i. e. EBV) Ags. In the majority of 
other malignancies in which immunotherapy is being explored, the potential 
target antigens that have been employed so far are normal, often early 
developmental antigens, that are expressed in an aberrant location and to a 
much higher degree than normal (i. e. wrong place, wrong time and wrong 
amount), such as MUC-1, NY-ESO-1 and Id protein (Barratt-Boyes 1996, 
Timmerman, et al 2002, van Rhee, et al 2005a). Many groups, including our 
own, have opted for a simpler approach. Rather than trying to identify 
tumour specific antigens with which to prime the immune system, whole 
tumour cell preparations can be used, such as freeze thaw tumour cell 
lysates and apoptotic tumour cells (Hayashi, et al 2003, Kotera, et al 2001), 
leaving the APC and immune effector cells to identify the most 
immunogenic epitopes. While this method runs the risk of potentially useful 
antigens being ignored by the immune system because of the antigen 
immuno-dominance phenomenon (Berkower, et al 1982, Gapin, et al 1998, 
Milazzo, et a/ 2003), it is less likely that a broad based approach such as 
this will allow the tumour to escape immune based therapies by simple 
down-regulation or deletion of a single target antigen. This approach does 
not get around the theoretical problem of the potential anti-tumour Ags 
being only weakly immunogenic, due to the fact that the host may have 
developed tolerance to them at some stage during development. However, 
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in Figure 5-9, it was shown that this type of antigen preparation is capable 
of producing tumour cell kill at relatively low effector target ratios in-vitro. It 
remains to be seen whether this success can be replicated in-vivo. 
In diseases such as MM, which induce a hostile environment in which to 
attempt to generate an immune response (Brown, et a/ 2001, Cook, et a/ 
1999), it is unclear when and how the cells that are to be used to generate 
APC should be collected. Furthennore, there is still debate about which 
cells should be used i. e. circulating blood DC, MoDC or indeed whether the 
whole of this process can be conducted in-vivo via antigen vaccination with 
the addition of adjuvants to attract APC to the vaccination site and then 
promote maturation, migration and immunogenic antigen presentation to 
immune effectors (Adams, et a/ 2005). In order to reduce the negative 
impact of the tumour on the immune based therapy, it would again seem 
logical to collect the cells and/or vaccinate at a time when the tumour 
burden is at Ws lowest (Hsu, et a/ 1996). In the treatment of the majority of 
patients with myeloma this would be after the patients had recovered from 
autologous HSCT (Attal and Harousseau 1999). 
4. In order to generate a cytotoxic immune response, vaccinated DC need to 
migrate from the vaccination site, i. e. the skin, to secondary lymphoid 
tissues such as draining lymph nodes. There is evidence that matDC used 
in clinical studies fail to migrate in significant numbers (Blocklet, et al 2003) 
despite seemingly adequate expression of chemokine receptors that are 
thought to mediate DC migration to LN, such as CCR7. Recent evidence 
suggests that the factors governing DC migration are not as straight forward 
as originally thought. Other chemokine receptors , such as CCR8, and the 
context in which they are expressed may also be important in DC migration 
Dr Simon J Harrison, 2005 Chapter 7-189 
to LN (Qu, et a/ 2004, Randolph, et a/ 2005). Some groups have tried to 
circumvent this process by direct intranodal injection of DC (Yi, et al 2003). 
However, these approaches have thus far not produced significant 
improvements in the potency of the anti tumour effect in the treatment of 
patients with MM. A greater understanding of how the chemokine system 
controls DC and effector cell migration, and how the hostile tumour induced 
environment may inhibit this process is required if we are to translate the 
encouraging in-vitro anti-tumour effects demonstrated in Figure 5-11 into 
effective therapies for MM patients. Tools such as the fluorescent 
chemokine uptake and staining assays described in Chapter 6 will prove 
useful in this process. They provide a rapid, straight forward, direct 
functional measure of chemokine receptor activity on target cells. Thus it is 
no longer necessary to rely upon phenotypic data alone or undertake 
complex migration experiments in order to assess chemokine receptor 
expression and activity. 
5. Immune effector cells are also suppressed in malignant diseases such as 
MM (Campbell, eta/ 2001, Cook, eta/ 1999). Data from studies such as 
those described in Chapter 5 and the XcellerateTm trial (Vij, et a/ 2003) 
should help us decide whether it is possible to improve/boost any inherent 
anti-tumour immune response (as shown in Figure 5-8), or reverse any 
turnour induced suppression of effector cells in order to improve the efficacy 
of immune base therapies (as suggested by Figure 5-9). It would also 
seem sensible to collect immune effectors for use in immune therapies at a 
time when the disease burden is at its lowest. Given that this cytotoxicity 
data showed the best tumour cell kill was achieved using MM T cells 
collected after cyclophosphamide and G-CSF, it would be reasonable to 
use this type of protocol, rather than mobilising with G-CSF alone. This is in 
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keeping with published data, which suggest that G-CSF alone is associated 
with a greater proportion of DC2 as compared with chemotherapy and G- 
CSF mobilisation (Bolwell, et a/ 2003), and G-CSF mobilised cells contain 
an increase propotion of TRgs (Vela-Ojeda, et a/ 2005). It is not known 
whether the improved cytotoxicity data was as the result of altering the 
proportions of T cell subsets that were collected, i. e. suppressing TRegs. It 
remains to be seen whether this method is preferable to collecting cells 
under steady state conditions, without any formal mobilisation. These 
questions warrant further investigation, as the cellular composition of the 
starting material with which an immunotherapy is built may have a dramatic 
impact on the end results. There is good experimental evidence to suggest 
that depleting subjects of TRgs prior to vaccination with DC based 
immunotherapy may improve the effectiveness of these approaches 
(Ghiringhelli, et al 2005, Sakaguchi, et a/ 2001). Whether this can be 
achieved using a simple in-vivo T cell suppressive therapy such as 
cyclophosphamide (Rosenberg, et a/ 1994a), or requires a more specific 
approach using an anti-CD25 monoclonal antibody, such as denileukin 
diftitox (Ontak) (Olsen, et al 2001), to specifically deplete the subject of 
CD25+ cells remains to be seen. 
When designing immune therapies for use in patients, it is important to consider 
that the building blocks of the treatment, i. e. the cells of the immune system, may 
be numerically and functionally abnormal. The blood DC system in MM and MGUS 
patients is compromised at diagnosis (Brown, et a/ 2001, Ratta, et a/ 2002) and 
Figure 3-6. However, following autologous HSCT or thalidomide therapy for the 
treatment of relapse, there is an improvement in the numbers of circulating blood 
DC, albeit short lived (Figure 3-8 and 3-9). This would suggest that the best time 
for collecting cells for use in immune based therapies is following high dose 
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chemotherapy and stem cell rescue. This is in keeping With other published data, 
which suggest that the best time to use immune base therapies is a time when the 
disease burden is at its lowest (Hsu, et a/ 1997, Stevenson, et a/ 2004). The 
immune system in MM patients follovving these types of therapies does not return 
to non-nal, in that the B cell and pDC numbers remained suppressed (Data not 
shown and Figure 3-8). Along with the data from other groups which has shown 
that the blood DC do not mature normally (Brown, et al 2001, Ratta, et al 2002), it 
is becoming clear that blood DC are not ideal for use as immune therapies for MM. 
Generating DC from monocytes is a more encouraging prospect. Monocytes are 
more readily available than blood DC, and the use of CD34* cells is more 
technically demanding, with respect to the collection and purification of CD34" 
cells in sufficient quantity, and Ag loading of CD34* derived DC. However, even 
when monocytes were collected following a course of anti-MM induction therapy 
and stem cell mobilisation, MoDC generated from MM patients were still found to 
be phenotypically and functionally abnormal at all stages of development (Figure 
4-2,4-4,4-6 and 4-8). Cells that were matured with the X4 cytokine combination 
were found to be superior to those cells matured with the MIMIC combination, in 
that a higher proportion of X4 matured cells expressed CD83 (Table 4-2) and had 
greater CCR7 activity (Figure 6-10). It is also likely that prior to being used as 
therapy, MoDC would need to be matured for 48 hours in order to fully up regulate 
chemokine receptors, such as CCR7, and efficiently migrate to lymph nodes in 
order to interact with T cells (Figure 4-10). It is currently unclear whether the 
increase in CCR8 expression on MM matDC has a negative or a positive impact 
on MoDC migration following vaccination (Figure 6-14). Overall, these findings 
suggest that it may be crucial to optimise MoDC production for each disease state 
in which they are to be used, in order to maximise the chances of inducing an 
effective anti-tumour response. The functional activity of chemokine receptors may 
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best be studied using a combination of ligand uptake, surface antibody staining 
and in-vWtn-vivo migration assays to determine the optimal timing of MoDC Ag 
loading, maturation and administration. 
Despite the limitations imposed by using functionally abnormal cells, MM patient 
MoDC can be used to generate anti-MM cytotoxic T cells in-vitro. The cytotoxic 
activity of unprimed MM patient T cells was better than that observed with ND 
cells, and this may be related to the fact that the MM cells were collected after 
cyclophosphamide and G-CSF, while the ND cells were collected following G-CSF 
alone (Figure 5-8) and the potential differences in the T cell populations in the 
respective collections, as discussed above. The proliferative response to IL-2 + 
matDC and the cytotoxic activity of MM T cells was boosted by pre-stimulating with 
T cell activating beads and IL-2, prior to antigen presentation (Figure 5-2 and 
Figure 5-9). This was despite the fact that this process seemed to render the T 
cells IL-2 dependant, in that they did not proliferate or secrete cytokines in the 
presence of DC alone (Figure 5-2 and 5-5). It remains to be seen whether these 
effects can be transferred in-vitro given the difficulties that surround the use of IL-2 
in patients (Escudier, et a/ 1994, Farag, et at 2002). 
The observations described above could form the basis for a novel clinical 
immunotherapy trial in MM patients, using both autologous moDC, pre-stimulated 
T cells and followed by low dose IL-2 as consolidation immunotherapy following 
inducUon chemotherapy and autologous HSCT (Figure 7-1). Monocytes and T 
cells could be collected by formal cyclophosphamide and G-CSF mobilisation, 
following autologous HSCT, at a time when the disease burden is at its nadir. 
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Collecting immune cells after induction chemotherapy and auto HSCT should 
reduce the tumour burden to its lowest level, reducing any immunosuppressive 
effects on the immune system and the therapeutic cells when given back to the 
pabent. Monocyte derived DC generated with GIVI-CSF and IL-4, loaded with 
autologous tumour cell antigen and matured with X4 could then be given in 2 
weekly aliquots by intra-dermal injection. T cells collected during the same 
procedure, marked to allow tracking studies, pre-stimulated with activating beads 
and IL-2 would be administered simultaneously by IN. infusion. This should 
enable the antigen loaded matDC and pre-stimulated T cell to migrate to lymph 
nodes in the same time frame. IL-2 would be administered by SCI the next day 
and daily for the next 2 weeks to provide cytokine growth support to the pre- 
stimulated cells. 
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The aim of collecting cells at such a late time point in the treatment of MM is to 
minimise any disease related immunosuppressive effects on the collected 
monocytes and T cells. A secondary effect of collecting T cells at this point may be 
a relative depletion of memory and regulatory T cells, whilst enriching for nawe T 
cells as the immune system repopulates itself folloWng autologous HSCT. These 
hypotheses foffn the rational basis for the use of autologous HSCT for the 
treatment of autoimmune diseases such as rheumatoid arthritis and Immune 
thrombocytopaenic purpura (Huhn, et a/ 2003, Snowden, et a/ 2004). Monocytes 
would be cultured with IL-4 and GM-CSF, primed with an autologous tumour cell 
preparation (i. e. tumour cell lysate) collected at the time of diagnosis, and matured 
with the X4 cytokine combination. At the same time T cells could be pre-stimulated 
with anti-CD2,3 and 28 coated beads and IL-2, in order to reverse T cell anergy 
and regain T cell responsiveness to IL-2. Both cell types could be administered on 
the same day, DC by ID and T cells by IV injection, in order to promote rapid co- 
localisation in lymph nodes. Subcutaneous low dose IL-2 would be given the 
following day to maintain T cell viability, increase the T cell proliferation stimulus 
and stimulate the adaptive and innate immune systems (Aladdin, et a/ 2000, 
Dudley, et a/ 2002, Gonzalez-Barca, et a/ 1999). 
In a similar vein, although MM is susceptible to the GVL effect, and patients who 
have relapsed following allo HSCT do respond to DLI. However, it is far less 
potent strategy for patients with MM when compared to other diseases, such as 
CIVIL (Verdonck, et a/ 1998). This may be in part due to the timing of 
administration, as it is known that patients with molecular relapses from CIVIL 
respond better to DLI as compared to patients with haernatological relapse. Up 
until now it has been difficult to monitor MM with this level of sensitivity, but the 
use of techniques such as serum free light chain quantification, high sensitivity 
chimerism assays and rapid PCR MRD monitoring may improve this situation 
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(Rasmussen, et al 2004). As previously discussed, it is also likely that the donor 
lymphocytes are being infused into a hostile immunosuppressive environment 
induced by the MM tumour cell. Pre-stimulation of donor lymphocytes may render 
the cells less sensitive to the effects of the MM turnour cells. When given in 
combination with IL-2 to provide cytokine support to these pre-stimulated cells, 
there may also be more generalised immuno-stimulatory effects on the 
transplanted immune system, which may promote an increase in the GVL effect 
(Kiss, et al 2003, Slaviin, et a/ 1996). This combination may warrant further 
investigation, and could form the basis of a more potent treatment for MM relapse 
following allo HSCT. 
We are about to enter an exciting phase in the development of immune based 
therapies for malignant diseases such as MM when we can build on the results of 
the phase I studies and the advances in basic immunology. A greater 
understanding of how the adaptive and innate arms of the immune system interact 
and regulate each other may be crucial in this process and form the basis of some 
of the next generation of clinical immunotherapy studies (Ritchie D, personal 
communication). It may also be possible to engineer our cellular therapies so that 
a number of different cell types are administered in the correct state of maturation, 
allowing them to rapidly co-localise in lymph nodes and interact efficiently, whilst 
being resistant to the suppressive effects of the tumour. 
Ultimately, it may be possible to avoid having to process cells in-vitro by using 
cytokines and chemokines to manipulated cells of the immune system in-vivo. In 
theory, it should be possible precondition an area of skin so as to attract or 
generate APC ready to receive tumour specific antigen delivered by simple 
vaccination. The addition of adjuvant compounds would then promote efficient 
APC maturation and migration to lymph nodes where they would present antigen 
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to immune effector cells, such as naive T cells. A CD8 cytotoxic T cell response 
could be promoted by further administration of cytokines, such as IL-2. Mowever, 
while we are developing and testing the next generation of immunotherapies we 
should remember that even if the disease burden is reduced to a very low level, it 
may still have a disproportionate suppressive effect on the host immune system. 
Thus these in-vivo approaches would seem to be a very long way off for the 
treatment of diseases such as MM. 
In summary, the results described in this thesis have confirmed that the DC 
system is highly abnormal in MM patients, but does recover to some degree 
following autologous HSCT. Although the mature MoDC produced from MM 
patients seem to be of poorer quality than those from ND, when combined in-vitro 
with pre-stimulated autologous T cells, the resultant cytotoxic T cells had superior 
killing ability compared to ND and un-stimulated T cells. However, the CCR7 and 8 
chemokine activity of mature MoDC when measured using the fluorescent ligand 
uptake and staining assays was abnormal, suggesting that when administered in- 
vivo, MM matDC may not migrate as efficiently to lymph nodes and be more 
susceptible to immunosuppressive chemokines as compared to normal DC. These 
results should help in the development of effective immune based therapies for the 
treatment of MM and other malignant diseases. 
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